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Summary  
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and 
adolescents. Paediatric RMS is classified into two histologically and molecularly distinct 
subtypes: embryonal RMS (eRMS) and alveolar RMS (aRMS). The more common eRMS 
subtype is present in 60-70% of all cases and is associated with a 5-year overall survival rate 
of over 60%, whereas aRMS, occurring in 20-30% of all cases, has a dismal 5-year overall 
survival rate of 22%. Furthermore, the prognosis for eRMS and aRMS patients presenting with 
metastatic disease is particularly poor. Multimodal therapy plans encompass chemotherapy, 
surgery and radiotherapy and often lead to acute and chronic morbidities. Hence, novel, 
complementing treatment options have to be established in order to improve treatment 
outcome and reduce the risk of short and long term side effects.  
In this project, we identified and characterised the proprotein convertase (PC) furin as 
important regulator of RMS maintenance and progression. In an initial study we analysed the 
expression pattern of PCs in paediatric RMS, Ewing sarcoma and osteosarcoma cell lines and 
found that their expression was particularly high in RMS cells, whereby furin showed the most 
consistent expression throughout all investigated cell lines. 
To investigate the role of furin in important cellular processes in vitro and in vivo we 
employed different approaches to modulate furin activity. RMS cell lines with enhanced furin 
activity were generated through stable ectopic expression of furin. To reduce furin activity on 
the other hand, we used different means: 1) application of decanoyl-RVKR-
chloromethylketone (CMK), a pan-PC inhibitor; 2) stable expression of the pan-PC inhibitor 
PDX; 3) RNA interference through transfection of siRNA or tetracycline-inducible expression of 
shRNA.  
Analysis of Rh30 (aRMS) and RD (eRMS) cells with stable modulation of furin activity 
showed that reduced furin activity delays RMS tumour growth in vivo, most likely through 
impaired vessel formation in the initial tumour growth phase. Furthermore, we found evidence 
that furin plays a role in metastatic processes, as a decrease of furin activity resulted in 
reduced migratory and invasive behaviour of RMS cells in vitro. To elucidate the underlying 
mechanisms, we assessed the processing of known furin substrates that have been previously 
associated with RMS progression and metastasis and observed impaired IGF1R, VEGF-C, 
PDGF-BB and MT1-MMP maturation upon application of the inhibitor CMK. Additionally, we 
could confirm that the proteolytic activation of IGF1R through furin is necessary in order to 
elicit IGF1R signalling in RMS cells upon stimulation with IGF-1.  
Many of the known furin substrates are associated with proliferation and survival of 
cancer cells. IGF signalling, for instance, plays an important role in RMS maintenance.
  Summary 
 
 
 
9 
 Therefore, we sought to further characterise the implication of furin activity in 
proliferation and survival of RMS cells. For this purpose, we established various aRMS cell 
lines with tetracycline-inducible furin shRNA expression to study the immediate effects of furin 
silencing, in a way mimicking the effect of a very specific and effective inhibitor. We found that 
silencing of furin impaired cell viability and proliferation in all investigated aRMS cell lines, but 
had no effect in the fibroblast cell line MRC5. Furthermore, half of the aRMS cell lines 
investigated, including Rh3 and Rh4 cells, seemed to be more sensitive to furin depletion, as 
loss of furin activity further elicited induction of apoptosis. Subsequent analysis of apoptosis 
showed that the process is dependent on caspase activity and most likely involves pore 
formation in mitochondria, as a double knock-out of BAX and BAK abolished furin silencing 
induced cell death. A similar pattern of sensitivity could also be confirmed in vivo, as furin 
silencing in the sensitive Rh4 cells led to complete regression of tumours, while reduced furin 
activity in Rh30 xenografts resulted in delayed tumour growth. Apoptosis upon depletion of 
furin in Rh4 xenografts was confirmed by the presence of cleaved caspases and PARP as 
analysed by immunoblot and immunohistochemistry.  
In addition, we assessed the expression pattern of furin protein in a total of 89 eRMS 
and aRMS biopsies on a tissue microarray and could confirm furin expression in 86% of the 
tumours. In conclusion, our findings identify and validate furin as an important factor for RMS 
progression, survival and metastasis and we therefore propose furin as a novel therapeutic 
target for treatment of paediatric RMS. Thus, furin-specific inhibitors could be developed as 
their use, possibly in combination with inhibitors targeting other key signalling molecules like 
IGF1R, represents a promising approach for complementing established chemotherapeutic 
regimens. Furthermore, as we could show previously, furin is a homing receptor for RMS-
specific peptides and might accordingly be exploited for targeted delivery of 
chemotherapeutics, thereby reducing some of the side effects of conventional chemotherapy.
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 Zusammenfassung 
Rhabdomyosarkome (RMS) sind die am häufigsten vorkommenden Weichteilsarkome 
bei Kindern und Jugendlichen. Zwei molekulare Haupttypen pädiatrischer RMS werden 
voneinander unterschieden: embryonale RMS (eRMS) und alveoläre RMS (aRMS). 60-70% 
aller RMS-Fälle gehen auf den häufiger auftretenden Subtyp eRMS zurück, der mit einer 5-
Jahresüberlebensrate von über 60% assoziiert ist. aRMS hingegen kommt seltener vor und 
entspricht 20-30% aller Fälle. Im Gegensatz zu eRMS ist die Prognose für aRMS relativ 
schlecht: die 5-Jahresüberlebensrate beträgt lediglich 22%. Die geringste Überlebenschance 
haben Patienten mit metastasierenden eRMS und aRMS Primärtumoren. Multimodale 
Therapieansätze umfassen Chemo- und Strahlentherapie sowie, soweit möglich, eine 
chirurgische Entfernung des Tumors. Leider führen eben diese Therapien in vielen Fällen zu 
sekundären Erkrankungen. Daher könnten neue, komplementierende Therapiemöglichkeiten 
nicht nur Behandlungserfolge verbessern, sondern gleichzeitig auch das Risiko für 
Nebenwirkungen und Spätfolgen verringern. 
In dieser Arbeit wurde die Proproteinkonvertase Furin als wichtiger Faktor zur 
Erhaltung und Progression von RMS-Zellen identifiziert und in vitro und in vivo charakterisiert. 
Zunächst haben wir das Expressionsmuster von allen Proproteinkonvertasen in pädiatrischen 
Sarkom-Zelllinien analysiert und festgestellt, dass diese besonders stark in RMS-Zelllinien, 
nicht aber in Ewingsarkom- und Osteosarkom-Zelllinien exprimiert werden. Furin war dabei die 
Proproteinkonvertase mit den gleichmässig höchsten Levels.  
  Zur Untersuchung der Rolle von Furin in RMS kamen unterschiedliche Ansätze zur 
Modulierung der Furinaktivität zum Einsatz. Stabil erhöhte Furinaktivität wurde durch 
ektopische Furin-Expression erzielt und unterschiedliche Ansätze konnten etabliert werden um 
die Furinaktivität zu reduzieren: 1) Verwendung des pan-Proprotein Konvertase Inhibitors 
Dekanoyl-RVRK-Chloromethylketon (CMK); 2) Stabile Expression des pan-Proprotein 
Konvertase Inhibitors PDX; 3) RNA-Interferenz durch Transfektion von siRNA oder durch 
Tetracyclin-induzierbare Expression von shRNA. 
Durch den Einsatz stabiler Zelllinien mit modulierter Furinaktivität fanden wir heraus, 
dass eine niedrige Furinaktivität den Wachstum von RMS-Tumoren in vivo verzögert, was mit 
hoher Wahrscheinlichkeit auf unzureichende Blutgefässbildung in frühen Stadien des 
Tumorwachstums zurückzuführen ist. Des Weiteren spielt Furin eine Rolle für die 
Metastasierung von RMS-Zellen: eine geringere Furinaktivität beeinträchtigt das migratorische 
und invasive Verhalten von Rh30 (aRMS) und RD (eRMS) Zellen in vitro. Um die 
zugrundeliegenden Mechanismen aufzuklären haben wir die proteolytische Prozessierung von 
bekannten Furin-Substraten untersucht. Eine Inhibierung von Proproteinkonvertasen durch 
  Zusammenfassung 
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den Inhibitor CMK führt zu einer stark verringerten Prozessierung und Aktivierung der Furin-
Substrate IGF1R, VEGF-C, PDGF-BB und MT1-MMP. Zusätzlich konnten wir zeigen, dass die 
proteolytische Aktivierung von IGF1R notwendig ist zur Stimulierung der in RMS-Zellen 
wichtigen IGF-Signalkaskade. 
Viele der bekannten Furin-Substrate sind mit dem Überleben und der Proliferation von 
Krebszellen assoziiert worden. Der IGF-Signalweg zum Beispiel spielt eine zentrale Rolle für 
den Erhalt von RMS-Zellen. Aus diesem Grund haben wir die Bedeutung von Furin für die 
Proliferation und das Überleben von RMS-Zellen genauer untersucht. Hierfür wurden 
unterschiedliche aRMS Zelllinien mit Tetracyclin-induzierbarer Furin shRNA generiert um die 
unmittelbaren Effekte einer Furin-Eliminierung, wie es beim Einsatz eines sehr spezifischen 
und potenten Inhibitors der Fall wäre, zu analysieren. Ein Verlust der Furinaktivität 
beeinträchtigte stark die Proliferation aller untersuchter aRMS Zelllinien, hatte jedoch keinen 
Einfluss auf die Wachstumsrate von MRC5 Fibroblasten. In der Hälfte aller aRMS Zelllinien, 
einschliesslich Rh3 und Rh4, führte ein Verlust von Furin zum Zelltod durch Apoptose. 
Anschliessende detaillierte Experimente zeigten, dass der Prozess im Zusammenhang mit 
Caspase-Aktivität und BAX/BAK-abhängiger mitochondrialer Porenbildung steht. Der 
Unterschied zwischen den Zelllinien zeigte sich auch in vivo, wo reduzierte Furinaktivität zur 
kompletten Tumorregression der sehr sensitiven Rh4-Zellen führte, wohingegen Rh30-Tumore 
lediglich langsamer wuchsen. Apoptose nach Verlust von Furinaktivität in Rh4-Tumoren wurde 
durch Anwesenheit von geschnittenen Caspasen und PARP per Westernblot und 
Immunhistochemie nachgewiesen. 
Darüber hinausgehend konnten wir anhand eines Tumor-Microarrays der 89 Biopsien 
umfasst die Expression von Furin-Protein in 86% der RMS-Tumore bestätigen. Somit 
validieren unsere Studien Furin als wichtigen Faktor für den Erhalt, das Überleben und die 
Metastasierung von RMS-Zellen und zeigen die Möglichkeit einer Furin-spezifischen neuen 
Behandlungsmöglichkeit von RMS auf. Aufbauend auf dieser Studie könnten zukünftig Furin-
spezifische Inhibitoren zum Einsatz kommen, möglicherweise in Kombination mit Inhibitoren 
für weitere validierte Signalmoleküle wie IGF1R. Alternativ kann Furin, wie wir in früheren 
Studien zeigen konnten, als Zielrezeptor für RMS-spezifische Peptide dienen um 
Chemotherapeutika gezielter in den Tumor zu transportieren. Dadurch können die Belastung 
für den Patienten und das Risiko für Chemotherapeutika-assoziierte Nebenwirkungen 
potentiell gesenkt werden.  
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1.   Cancer in adults and children 
Cancer represents one of the leading causes of mortality worldwide with an estimated 
8.2 million cancer related deaths in 2012 (Stewart and Wild 2014). Cancers may appear 
anywhere in the body and the World Health Organisation (WHO) estimated that over 100 
individual cancer types exist, however cancers in the lung, the liver, the stomach, the breast 
and colorectal cancers are the most common and account together for more than half of all 
deaths (Stewart and Wild 2014). The development of a normal cell into a tumour cell is a 
multistage process, involving several transformation steps and thus the incidence for most 
cancer types rises immensely with age. Besides genetic predisposition, several external 
factors have been described to increase the risk of cancer development; these include 
tobacco and alcohol use, unhealthy diet and physical inactivity as well as viral infections such 
as infection with hepatitis B and C viruses or human papilloma virus (WHO 2015).     
Paediatric cancers are cancers that occur in children under the age of 14, however, 
depending on the definition, cancers in adolescents (age 14-19) are often included. It is 
estimated that over 175’000 children develop cancer every year and despite their rarity 
childhood cancers represent the leading cause of death in developed countries with more than 
96’000 deaths in 2008 (American Cancer Society 2011). Nevertheless, mortality rates have 
clearly decreased in developed countries since the 1970s, most likely due to widely improved 
treatment modalities (Yang, Fujimoto et al. 2009; Bosetti, Bertuccio et al. 2010). The overall 
incidence rate of paediatric cancer has risen slightly over the last decades, for instance from 
11.5 per 100’000 in 1975 to 14.3 per 100’000 in 2007 in the US, which might in part be 
attributed to improved diagnosis and reporting procedures, but true increases in incidence 
have been observed for some types such as leukaemias and soft tissue sarcomas (Kaatsch, 
Steliarova-Foucher et al. 2006; Shah and Coleman 2007). In general, trends for incidence and 
mortality of childhood cancers are more complicated to analyse in third world countries for 
example due to incomplete documentation of cases (Howard, Metzger et al. 2008). The most 
common cancer types observed in children are leukaemias at 34%, brain tumours at 23% and 
lymphomas at 12% (reviewed in (Kaatsch 2010).  
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2.   Sarcomas  
The term sarcoma is derived from the greek word σάρξ sarx, which means “flesh”. This 
type of cancer originates from cells of mesenchymal origin and may therefore develop in any 
kind of connective tissue. Sarcomas are grouped according to the cell type they are derived 
from and include, among others, fibrosarcomas (fibroblasts), osteosarcoma (osteoblasts), 
liposarcoma (adipocytes), angiosarcoma (precursor endothelial cells) and rhabdomyosarcoma 
(myoblasts) (Weinberg 2007).  
The overall incidence for sarcomas across all age groups in Europe is 5.6 per 100’000 
per year, accounting for roughly 28’000 new cases. 84% of all sarcomas are soft tissue 
sarcomas and 14% are sarcomas arising in the bone (Stiller, Trama et al. 2013). Whereas 
sarcomas are rather rare in adults, representing only about 1% of all cases, they are more 
common in children and adolescents and account for approximately 10% of all registered 
cancer cases (source: German Childhood Cancer Registry (GCCR); reviewed in (Kaatsch 
2010)). The incidence rate of paediatric soft tissue sarcomas, as classified by the International 
Classification of Childhood Cancer (ICCC) diagnostic groups, is 9.1 per million children per 
year (source: European Automated Childhood Cancer Information System (ACCIS); reviewed 
in (Kaatsch 2010)). With the advent of chemotherapeutic modalities in the 1970s, prognosis 
for children diagnosed with sarcomas improved dramatically. Thus, the 5-year overall survival 
for paediatric soft tissue sarcomas reached 65% in Europe (source: ACCIS, 1988-1997 
(Sankila, Martos Jimenez et al. 2006)) and 73% in the US (source: SEER (Surveillance, 
Epidemiology, and End Results program), 1985-1999 (Howlader, Noone et al. 2014)).     
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3.   Rhabdomyosarcoma 
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and 
adolescents and represents 55% of all registered soft tissue sarcomas and around 3% of all 
childhood malignancies (source: German Childhood Cancer registry; reviewed in (Kaatsch 
2010)). The age-standardised incidence rate of paediatric RMS in Europe was 5.4 per million 
children in the 1993-1997 period (source: ACCIS (Pastore, Peris-Bonet et al. 2006)). Based on 
histology, childhood RMS can be grouped into two main subgroups: embryonal RMS (eRMS) 
and alveolar RMS (aRMS). eRMS is the most common subtype and represents around 66% of 
all cases. aRMS and botryoid RMS are less common, accounting for 22% and 11% of all 
cases, respectively (Van Gaal, Van Der Graaf et al. 2012).  
The current 5-year overall survival rate of children with RMS, regardless of the 
subclassification, is estimated to be 70-80% (Crist, Anderson et al. 2001; Stevens, Rey et al. 
2005; Dantonello, Int-Veen et al. 2009). Overall survival rates for botryoid, embryonal and 
alveolar RMS are around 78%, 64% and 22%, respectively (Figure 1A; (Van Gaal, Van Der 
Graaf et al. 2012)). Besides the histological subtype, presence of metastasis is one of the 
most important factors influencing prognosis of RMS patients. Thus, 5-year overall survival of 
patients presenting with non-metastatic eRMS or aRMS is 69% and 34%, respectively, 
whereas patients with metastasised disease have a very dismal prognosis of less than 12% 
(Figure 1B (Van Gaal, Van Der Graaf et al. 2012)). Adults suffering from RMS have an even 
worse prognosis than children, as the corresponding 5-year overall survival rate is as low as 
27% (Sultan, Qaddoumi et al. 2009). 
Risk stratification is based on a combination of the classical TNM staging system and 
the surgical/pathologic clinical grouping system as introduced by the Intergroup 
Rhabdomyosarcoma Study Group (IRSG) and includes various key factors (reviewed in 
(Malempati and Hawkins 2012)). These factors include, among others, adequacy of excision, 
subtype, age, stage of disease, primary site and presence of metastasis at time of diagnosis. 
For instance, it was observed that children ≥ 10 years as well as infants fared worse, the latter 
at least partly due to higher occurrence of local failure (Ferrari, Casanova et al. 2003; Joshi, 
Anderson et al. 2004; Malempati, Rodeberg et al. 2011).  
One central point of diagnosis of RMS is the characterisation of embryogenic 
myogenesis. Such identification is mostly based on histologic assessment, ultrastructural 
examinations or immunohistochemical investigation of myogenic markers, including desmin, 
myosin, myoglobin, MyoD and myogenin (reviewed in (Parham and Barr 2013)). However, in 
order to distinguish RMS from other potentially myogenic neoplasms such as Wilms tumours, 
further histologic patterns characteristic for the distinct subtypes of RMS were defined on the 
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basis of the Horn-Enterline system, which was introduced in the late 1950s (Horn and 
Enterline 1958). Additionally, aRMS are most often characterised by the presence of non-
random chromosomal translocations, giving rise to aberrant transcription factors, as will be 
discussed in section 3.1.  
 
Figure 1 Overall survival of patients diagnosed with rhabdomyosarcoma.  
Kaplan-Meier overall survival (OS) curves for patients with rhabdomyosarcoma (RMS) 
by histological subtype (A), botryoid RMS: N=15 patients, embryonal RMS: N=102 
patients, and alveolar RMS: N=51 patients; and according to presence of metastasis at 
time of diagnosis in embryonal and alveolar RMS (B), non-metastatic embryonal RMS: 
N=90 patients, non-metastatic alveolar RMS: N=27 patients, metastatic embryonal and 
alveolar RMS: N=35 patients. ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal 
rhabdomyosarcoma.  
Adapted from. (Van Gaal, Van Der Graaf et al. 2012).  
 
Furthermore, RMS, as other soft tissue sarcomas, appears to be more frequent in boys 
with a male to female ratio of 1.3-1.4 (Pastore, Peris-Bonet et al. 2006; Kaatsch 2010). 
However, this male predominance seems to be more prevalent in eRMS with a male to femal 
ratio of 1.51 (Ognjanovic, Linabery et al. 2009). 
RMS may arise at many different sites throughout the body, whereby tumours appear 
most frequently in the head and neck region, in the genitourinary region, in the pelvis, in the 
trunk or in extremities (reviewed in (Pastore, Peris-Bonet et al. 2006)). 
3.1. Embryonal and alveolar rhabdomyosarcoma 
Embryonal RMS (eRMS) and alveolar RMS (aRMS) constitute the two most common 
paediatric RMS subtypes, but differ in many aspects, most importantly in their genetic 
background and key proteins that drive tumourigenesis and tumour progression.  
eRMS occurs much more frequently in children than aRMS with an age-standardised 
incidence rate of 3.6 per million children, as compared to 0.8 per million children for aRMS 
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(source: ACCIS (Pastore, Peris-Bonet et al. 2006)). Furthermore, patients with eRMS fare 
better than aRMS patients (see Figure 1).  
Both subtypes are characterised by distinct histological patterns, that were originally 
described in detail by Horn and Enterline based on their examinations of 39 different RMS 
tumours (Horn and Enterline 1958). eRMS often resemble immature skeletal muscle with long, 
spindle-like cells and round cells embedded in a myxoid matrix (Figure 2A), whereas the 
histology of aRMS is vaguely similar to foetal alveoli (Figure 2B) (Parham and Barr 2013). In 
the early to mid 1990s, documentation of a solid variant of aRMS led to the revision of the 
international classification system, encouraging the classification of aRMS based on the 
presence of any amount of alveolar pattern for further risk stratification (Tsokos, Webber et al. 
1992; Newton, Gehan et al. 1995). 
  
Figure 2 Histological patterns of embryonal and alveolar rhabdomyosarcoma.  
(A) Embryonal rhabdomyosarcoma (eRMS) mostly contain spindle cells with regions of 
dense and loose cellularity. (B) Alveolar RMS (aRMS) are characterised by round cells 
clustered into nests, thus resembling lung alveoli. Adapted from (Parham and Barr 
2013). 
 
Loss of heterozygosity (LOH) analysis revealed that 94% of RMS contain at least one 
15 Mb region with LOH, whereby the levels of fractional allelic loss (FAL) appear to be much 
higher in eRMS than in other RMS subtypes (Davicioni, Anderson et al. 2009). Predominant 
regions of LOH were found in both arms of chromosome 11 (70% of analysed tumours) and 
additional affected chromosomal regions were described for 8q, 10q, 10p, 6q and 4q 
(Davicioni, Anderson et al. 2009). A hotspot of allelic imbalance in fusion-negative RMS is 
situated in the chromosome region 11p15 (Davicioni, Anderson et al. 2009), which will be 
discussed in the context of genetic aberrations in eRMS tumours further below.  
In contrast to other tumours, mutations in the tumour suppressor gene TP53 might be 
a rather rare event (Taylor, Shu et al. 2000; Ognjanovic, Martel et al. 2012), although previous 
studies reported that four out of six eRMS and one out of four aRMS contained TP53 
mutations (Felix, Kappel et al. 1992).  
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Embryonal rhabdomyosarcoma 
eRMS very often appears in the head and neck  and genitourinary regions, whereby 
the trunk and the genitourinary region represent the most favourable primary sites both with a 
5-year overall survival rate of around 83%  (source: ACCIS (Pastore, Peris-Bonet et al. 2006)). 
eRMS shows a bimodal age distribution, with highest incidence rates in children between 0-5 
years of age and in adolescent males (Ognjanovic, Linabery et al. 2009).  
In contrast to most aRMS, eRMS are devoid of chromosomal translocations that drive 
oncogenesis. Nevertheless, several common aberrant genetic features have been described 
in eRMS tumours. In general, eRMS tumours share a complex karyotype, characterised by 
severe genetic and chromosomal instability (Helman and Meltzer 2003). A recurrent attribute 
of eRMS tumours is the LOH in 11p15.5, which is also observed in Wilm’s tumours (Scrable, 
Cavenee et al. 1989; Besnard-Guerin, Newsham et al. 1996). LOH in this region occurs in 72-
77% of eRMS (Visser, Sijmons et al. 1997; Davicioni, Anderson et al. 2009) and was proposed 
to result from isodisomy of paternal origin (Scrable, Cavenee et al. 1989). This uniparental 
isodisomy affects several imprinted genes, resulting in potential loss of tumour suppressor 
H19 and p57KIP2 gene expression due to their natural paternal imprinting status and 
overexpression of the IGF2 gene, as the maternal imprinted allele is replaced by a second 
active paternal allele (reviewed in (Merlino and Helman 1999; Smith, Choufani et al. 2007)). 
Over the recent years, evidence accumulated that eRMS tumours are hierarchically 
organised (Sana, Zambo et al. 2011; Walter, Satheesha et al. 2011; Ignatius, Chen et al. 
2012). Furthermore, self-renewal capacity of a stem-like cancer cell subpopulation of eRMS 
was proposed to be controlled by hedgehog signalling (Pressey, Anderson et al. 2011), 
whereby expression of the downstream gene GLI1 and the stem cell gene NANOG had 
prognostic significance (Satheesha, Manzella et al. 2015). Thus, eRMS treatment might be 
improved in future through therapies targeted against the cancer stem cell compartment.  
 
Alveolar rhabdomyosarcoma 
In contrast to eRMS, incidence rates of aRMS in children and adolescents appear to 
be equally distributed (Ognjanovic, Linabery et al. 2009) and primary sites are most often the 
trunk and extremities. In general, aRMS is the more aggressive subtype and most often 
patients present with metastasis at the time of diagnosis. The most common metastatic sites 
are the lungs, the bone marrow and lymph nodes (Breneman, Lyden et al. 2003).  
Around 70-80% of all aRMS tumours are characterised by specific chromosomal 
translocations that can be detected by cytogenetic or molecular analyses (Sorensen, Lynch et 
al. 2002). The translocation t(2;13)(q35;q14) occurs in approximately 60-70% of aRMS, 
whereas in around 10% an alternative translocation t(1;13)(p36;q14) is detected (Galili, Davis 
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et al. 1993; Davis, D'Cruz et al. 1994). These chromosomal translocations fuse either the 
PAX3 or the PAX7 gene to the FOXO1 gene, thereby giving rise to chimeric transcription 
factors named PAX3/7-FOXO1. These aberrant transcription factors contain a PAX-derived 
paired domain and homeodomain, the latter mediating DNA binding, at their N-terminus and a 
FOXO1-derived C-terminal transactivation domain (Davis, Bennicelli et al. 1995). PAX3/7-
FOXO-1 positive aRMS tumours share a common gene expression profile that is distinct from 
that of eRMS or fusion-negative aRMS (Wachtel, Dettling et al. 2004; Davicioni, Finckenstein 
et al. 2006) and thus a dominant role of these fusion proteins as oncogenic driver has been 
suggested (Sorensen, Lynch et al. 2002; Shern, Chen et al. 2014). Furthermore, confirmation 
of PAX3/7-FOXO1 occurrence is an important factor for risk stratification, allowing for 
classification of aRMS patients into low, intermediate and high risk subgroups. Presence of 
PAX3-FOXO1 characterises high risk patients, as survival rates are very poor in contrast to 
PAX7-FOXO1 associated low risk patients, with 4-year overall survival rates of 8% and 75%, 
respectively (Sorensen, Lynch et al. 2002). Dismal prognosis for PAX3-FOXO1 patients 
correlates with a higher probability of bone marrow metastases (Sorensen, Lynch et al. 2002). 
Besides the very common PAX3/7-FOXO1 translocations, alternative translocations have 
been described in aRMS tumours; t(2;2)(q35;p23) and t(2;8)(q35;q13) give rise to PAX3-
NCOA1 or PAX3-NCOA2 fusion proteins, which have similar transactivation properties as 
PAX3-FOXO1 (Wachtel, Dettling et al. 2004; Sumegi, Streblow et al. 2010). Additionally, 
fusion-negative aRMS have been reported (Barr, Qualman et al. 2002) that appear to be 
clinically and molecularly indistinguishable from eRMS, suggesting that the presence of fusion 
proteins is more crucial than the histological phenotype for classification and risk stratification 
(Davicioni, Anderson et al. 2009; Williamson, Missiaglia et al. 2010). 
3.2. Inherited conditions 
A variety of genetic disorders are known to predispose children to sarcomas, most 
often associated with defects in genes responsible for prevention of DNA damage (reviewed in 
(Parham, Alaggio et al. 2012)). For instance, germline mutations in the tumour suppressor 
gene TP53 are associated with Li-Fraumeni syndrome (Srivastava, Zou et al. 1990). Patients 
suffering from this condition are often affected by occurrence of several tumours, especially 
sarcomas like rhabdomyosarcoma, throughout their life (Khayat and Johnston 2004). Other 
genetic disorders that have been associated with RMS are, among others, the Beckwith-
Weidemann syndrome, neurofibromatosis 1, hereditary retinoblastoma and Costello syndrome 
(reviewed in (Slater and Shipley 2007; Parham, Alaggio et al. 2012)).   
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3.3. Aberrant signalling pathways 
One central signalling pathway involved in RMS tumourigenesis and progression is the 
insulin-like growth factor (IGF) pathway. Around ten years ago it was reported that elevated 
activity of this signalling pathway is associated with unfavourable prognosis (Blandford, Barr et 
al. 2006). The main receptor tyrosine kinase involved, the insulin-like growth factor 1 receptor 
(IGF1R) is a transcriptional target of PAX3/7-FOXO1 (Ayalon, Glaser et al. 2001) and was 
also shown to be expressed on eRMS cells (El-badry, Kohn et al. 1990). Its ligand IGF2 is 
abundantly expressed in most RMS tumours (Scott, Cowell et al. 1985; Gray, Tam et al. 
1987), where it was shown to act as an autocrine mitogen (El-badry, Kohn et al. 1990). 
Overexpression of IGF2 in eRMS is mostly due to LOH in the chromosomal region 11p15.5 
(see section 3.1), whereas a loss of imprinting (LOI) in the same region, leading to biallelic 
expression, is primarily associated with IGF2 overexpression in aRMS (Zhan, Shapiro et al. 
1994). Therefore, increased IGF2 and IGF1R levels are key to a strong mitogenic signalling 
loop that promotes sustained proliferation as well as survival of RMS cells. 
Several other receptor tyrosine kinase receptors besides IGF1R play a role in RMS 
progression (reviewed in (Crose and Linardic 2011) and, like IGF1R, some of them are also 
direct transcriptional targets of the PAX3/7-FOXO1 fusion protein, including MET, the platelet 
derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor 1 
(VEGFR1) and fibroblast growth factor receptor 4 (FGFR4) (Epstein, Shapiro et al. 1996; 
Epstein, Song et al. 1998; Barber, Barber et al. 2002; Cao, Yu et al. 2010). Their involvement 
in RMS progression has been confirmed by numerous studies (reviewed in (Crose and 
Linardic 2011). For instance, MET in combination with its ligand, the hepatocyte growth factor 
(HGF), not only regulates migration and metastasis of RMS, but MET/HGF signalling might 
also play a role in promoting proliferation, as a MET knockdown led to decreased cell 
proliferation and tumour burden (Taulli, Scuoppo et al. 2006; Lukasiewicz, Miekus et al. 2009).  
One of the more recently identified receptor tyrosine kinases of importance in RMS 
tumour growth and metastasis is FGFR4. Elevated mRNA levels of FGFR4 have been found 
in all aRMS cases (Wachtel, Dettling et al. 2004; Davicioni, Finckenstein et al. 2006) where it 
could be shown that FGFR4 is a direct target of PAX3-FOXO1 (Cao, Yu et al. 2010). Further 
investigations reported activating mutations in FGFR4 in up to 20% of RMS (Taylor, Cheuk et 
al. 2009; Paulson, Chandler et al. 2011) and amplifications of the FGFR4 gene in around 20% 
of eRMS (Paulson, Chandler et al. 2011). The study of Taylor et al. further demonstrated the 
oncogenic role of mutationally active FGFR4 in RMS cell lines (Taylor, Cheuk et al. 2009). 
Wachtel et al. identified subgroups of aRMS cells in which stimulation of FGFR4 signalling, 
through application of basic fibroblast growth factor (bFGF), rescues from IGF1R-PI3K-mTOR 
inhibition induced apoptosis (Wachtel, Rakic et al. 2014). These cells mediated proapototic 
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stimuli via the BH3-only proteins Bim and Bad, whereas apoptosis induction in non-rescue 
cells was Bmf-dependent. These data suggest that a subset of FGFR4-sensitive aRMS, 
characterised through low levels of the PAX3-FOXO1 target gene AP2β, will very likely benefit 
from FGFR4 inhibition for improvement of current RMS treatment modalities (Wachtel, Rakic 
et al. 2014).  
3.4. Treatment of rhabdomyosarcoma 
During the last 50 years, therapy plans for treatment of RMS have evolved 
significantly. Nowadays all patients receive intensive, multi-agent chemotherapy, which is 
most often accompanied by radiotherapy and in some cases by surgical resection of the 
tumour. One of the most common chemotherapeutic regimen is referred to as VAC and 
combines the three drugs vincristine, actinomycin-d and cyclophosphamide. Other drugs that 
are sometimes included are irinotecan or topotecan, ifosfamide, etoposide and doxorubicin. 
The general VAC regimen dates back to the early seventies, however constant efforts are 
being made to improve treatment plans, e.g. by testing different drug combinations or 
optimising dosages of employed drugs (review of recent trials (Hawkins, Gupta et al. 2014)). 
Furthermore, better risk stratification helps to tailor treatment strategies to individual patients 
(Parham and Barr 2013; Hawkins, Gupta et al. 2014). However, survival rates stagnated or 
barely improved over the last years and are still particularly low for metastatic RMS 
(Ognjanovic, Linabery et al. 2009; Van Gaal, Van Der Graaf et al. 2012). Additionally, chemo- 
and radiotherapy might lead to long term side effects in children, including deafness and 
secondary malignancies (Robison and Hudson 2014). Therefore, novel therapies, e.g. 
involving recently identified targets (see section 3.3), are required to complement current 
treatment options. 
In order to improve existing therapy modalities, many targeted agents currently 
undergo clinical testing in paediatric sarcomas (reviewed in (Anderson, Denny et al. 2012). As 
direct targeting of transcription factors like PAX3/7-FOXO1 remains a very challenging task, 
the focus of targeted therapies for treatment of RMS has been put on specific signalling 
pathways that promote RMS progression in vitro and in vivo (see section 3.3). For instance, 
targeting the IGF pathway represents a promising approach to treat RMS tumours. Different 
ways to disrupt IGF1R signalling in RMS cells have been explored, including IGF1R anti-
sense RNA (Shapiro, Jones et al. 1994), IGF1R blocking antibodies (Kalebic, Tsokos et al. 
1994) and the application of the selective inhibitor NVP-AEW451 (Scotlandi, Manara et al. 
2005). Blocking IGF1R signalling causes cell cycle arrest in G1 and apoptosis in highly 
sensitive cells (Scotlandi, Manara et al. 2005), whereby sensitivity to inhibition correlates with 
levels of IGF1R in RMS cells (Cao, Yu et al. 2008). Thus, Cao et al. showed that Rh4 and 
Introduction 
 
 
 
25 
CTR were the most sensitive RMS cell lines, while RD, Rh30 and RMS13 were moderately 
sensitive to treatment with an anti-IGF1R antibody (Cao, Yu et al. 2008). Combined use of 
IGF1R and mTOR inhibitors proved to suppress a rapamycin treatment-induced Akt feedback 
loop and was therefore proposed to be of benefit for the treatment of RMS and other IGF-
driven tumours (Wan, Harkavy et al. 2007; Cao, Yu et al. 2008; Kurmasheva, Dudkin et al. 
2009). Currently, several phase I and II clinical trials investigating the use of monoclonal 
IGF1R antibodies for therapy of RMS are being conducted, with a focus on the compound 
cixutumumab (clinicaltrials.gov, search term “IGF1R AND rhabdomyosarcoma”) (McKian and 
Haluska 2009).  
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4.   Proprotein convertases 
Most proteins are modified during or after protein biosynthesis. These post-
translational modifications increase the diversity of proteins encoded by the genome of an 
organism. Over 200 posttranslational modifications are currently known, including serine, 
threonine or tyrosine phosphorylation; cholesterol attachment; cysteine palmitoylation; lysine 
methylation and ubiquitination; protein oxidation or sumoylation; and asparagine and 
serine/threonine glycosylation. Many of these processes are carried out by specific enzymes. 
A frequent irreversible posttranslational modification is the limited proteolysis of precursor 
proteins. It has been estimated that the human degradome comprises over 550 distinct 
proteases that can be classified into five major classes: aspartic, metallo-, cysteine, serine and 
threonine proteases (reviewed in (Puente, Sanchez et al. 2003)). Among these enzymes 
serine proteases seem to be the most abundant as over 200 serine proteases in humans have 
been identified, representing ~1% of all proteins (Puente, Sanchez et al. 2003; Long and 
Cravatt 2011). Serine proteases can be divided into two main families depending on their 
relation to either trypsin/chymotrypsin or bacterial subtilisin. The latter are often referred to as 
subtilases and can be further subdivided into the prokaryotic subfamily S8A and the eukaryotic 
subfamily S8B, comprising the archetype yeast kexin and the proprotein convertases (PCs) 
(Siezen and Leunissen 1997; Rawlings, Barrett et al. 2012). The family of PCs can be further 
subdivided into the seven basic amino acid-specific members: PC1/3, PC2, furin, PC4, PC5, 
PACE4 (paired amino acid cleaving enzyme 4) and PC7; and two members, SKI-1 (subtilisin 
kexin isozyme 1; also known as S1P) and PCSK9 (proprotein convertase subtilisin kexin 9), 
that have no preference for basic amino acid motifs for cleavage.    
4.1. Discovery  
The first cornerstone for the identification of PCs was laid in 1984 with the discovery of 
the yeast convertase kexin that cleaves the precursor of pro-K1 killer toxin and pro-α-factor of 
the yeast Saccharomyces cerevisiae C-terminally of ArgArg↓ and LysArg↓ basic residue pairs 
(Julius, Brake et al. 1984; Fuller, Sterne et al. 1988). Shortly thereafter, the product of the fur 
gene, furin, was proposed to be a mammalian homologue of kexin, mainly based on their 
striking similarity (van de Ven, Voorberg et al. 1990). Simultaneously, two other PCs, PC1/3 
and PC2, were discovered (Seidah, Gaspar et al. 1990; Smeekens and Steiner 1990; 
Smeekens, Avruch et al. 1991). Within the following five years four more PCs were 
discovered: PC4 (Nakayama, Hosaka et al. 1991; Seidah, Day et al. 1992), PC5 (Lusson, 
Vieau et al. 1993; Nakagawa, Murakami et al. 1993), PACE4 (Kiefer, Tucker et al. 1991) and 
PC7 (Meerabux, Yaspo et al. 1996; Seidah, Hamelin et al. 1996). These seven PCs with a 
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cleavage preference for basic amino acid residues are known as furin-like PCs and represent 
the core members of the PC family. Two more subtilisin-related proteases have been 
described: the pyrolysin-like SKI-1 (Espenshade, Cheng et al. 1999; Seidah, Mowla et al. 
1999); and the proteinase K-like PCSK9 (Seidah, Benjannet et al. 2003). Thus, the family of 
PCs contains nine subtilisin-like secretory serine proteases and their respective genes are 
called PCSK1-PCSK7, whereby the gene encoding furin (PCSK3) is officially named FURIN. 
4.2. Structure & biochemistry 
Structural features 
All PCs share a high structural homology. Their N-terminal part is the most conserved 
region and consists of common domains that serve discrete biochemical functions, whereas 
the C-terminal displays more variability among PCs (Figure 3).  
The N-terminal part encompasses three to four important domains: the signal peptide, 
the prodomain, the catalytic domain and, in the case of the furin-like PCs, the P domain. The 
signal peptide at the very N-terminus directs translocation into the endoplasmatic reticulum 
(ER) and is subsequently cleaved and released by signal peptidases. The signal peptide is 
followed by a prosegment that essentially acts as a molecular chaperone and inhibitor of PCs. 
Its role in the zymogen activation mechanism will be discussed in detail below. The most 
conserved domain is the catalytic domain, sharing 54-70% sequence identity across all PCs 
as compared to furin (Siezen and Leunissen 1997; Thomas 2002). A catalytic triad consisting 
of the amino acids Asp, His and Ser is required for enzymatic activity, as is the presence of an 
Asn residue, or Asp in the case of PC2, providing the oxyanion hole during the hydrolyses 
reaction. The active site will be discussed in detail further below. The P domain is located C-
terminally from the catalytic domain in all basic amino acid-specific PCs and plays an 
important role in ensuring proper folding of the proteins and in maintaining stability and 
activity. Another function of the P domain is the regulation of pH and calcium dependence 
(Zhou, Martin et al. 1998). Furthermore, all PCs but PC7 contain an RGD motif within the P 
domain. Despite first investigations revealing that mutations in the RGD motif of PC1/3 lead to 
a loss of function and intracellular relocation (Lusson, Benjannet et al. 1997), the exact 
function of this conserved motif is still poorly understood. 
In contrast to the well conserved N-terminus, the C-terminal part is more specific to 
individual PCs and regulates their intracellular localisation and trafficking. The C-terminal part 
of furin, PC5 and PACE4 for instance includes a Cys-rich domain (CRD). For PC5 and PACE4 
it has been shown that this region allows cell surface anchoring via binding of heparan 
sulphate proteoglycans (HSPGs) or tissue inhibitors of metalloproteases (TIMPs), thus 
favouring the proteolytic processing of their cognate surface-tethered substrates (Nour, Mort et 
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al. 2005; Mayer, Hamelin et al. 2008). The three transmembrane PCs furin, PC5B and PC7 
present a unique transmembrane domain that directs localisation to the membrane and sorting 
to cellular compartments. PCSK9 harbours a unique Cys-His-rich domain (CHRD) that is 
necessary to target the extracellular low density lipoprotein receptor (LDLR) for degradation 
(Saavedra, Day et al. 2012).        
 
Figure 3 Schematic representation of the primary structures of human proprotein 
convertases. 
The different domains, positions of N-glycosylations and primary (green arrows), as well 
as secondary autocatalytic cleavage sites (black arrows) are depicted. PC4, PC7 and 
PCSK9 contain only a primary site. All PCs contain a signal peptide, a prosegment and 
a catalytic domain, whereby presence of a β-barrel P domain is limited to the kexin-like 
PCs. The catalytic triad residues Asp, His and Ser and the oxyanion hole residue Asn 
(Asp for PC2) are indicated within the catalytic domain. The distinct C-terminal domains 
contain unique sequences regulating localisation and trafficking of the individual PCs. 
PC5A and PC5B represent the two validated alternative splice variants of PC5. Modified 
from (Seidah and Prat 2012) 
 
Activation of proprotein convertases 
All PCs undergo a well-orchestrated zymogen activation mechanism consisting of up to 
two autocatalytic cleavage steps and other posttranslational modifications (Figure 4). This 
multi-step mechanism has been first described for the activation of furin (Anderson, VanSlyke 
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et al. 1997). All PCs but PC2 are co-translationally modified in the ER, where a signal 
peptidase cleaves and releases the signal peptide and N-glycosylations are introduced at 
various sites. The N-terminal prosegment acts as a chaperone and inhibitor and guides proper 
folding of the proprotein convertases into an active conformation within the ER lumen. Hence, 
the primary cleavage site becomes accessible, allowing intramolecular autocatalytic cleavage 
of the prosegment. The prosegment remains attached to the mature protease, keeping it in an 
inactive state. Initial cleavage of the prosegment is required for release of the complex from 
the ER (Creemers, Vey et al. 1995). Different than for the other PCs, primary cleavage within 
the prosegment of SKI-1 occurs at two internal sites, called B and B’ (Espenshade, Cheng et 
al. 1999; Elagoz, Benjannet et al. 2002). With the exception of PC4 and PC7 a secondary 
autocatalytic cleavage step within the prosegment is required to release the inhibitory segment 
(Anderson, Molloy et al. 2002). PCs requiring this secondary cleavage step display distinct pH 
and calcium optima for this last cleavage step, ensuring that activation takes place in selected 
intracellular compartments (Seidah, Mayer et al. 2008). Thus, PC1/3 and PC2 are generally 
activated in immature secretory granules of the regulated secretory pathway. Furin is primarily 
activated in the trans-Golgi network (TGN), whereby PACE4 and PC5 may be activated both 
in the TGN and on the cell surface. SKI-1 is fully activated in the cis- and medial-Golgi. 
 
Figure 4 Schematic representation of the autocatalytic activation mechanism of 
proprotein convertases. 
Proprotein convertases (PCs) are translated as inactive zymogens that undergo a 
multi-step activation process involving one or two autocatalytic cleavage steps. In the 
endoplasmatic reticulum (ER), pro-PCs are subject to folding events and removal of 
the signal peptide. Subsequently, the catalytic domain (red) cleaves the prosegment 
(green) (1). The prosegment remains attached, keeping the PC in an inactive state (2). 
Upon shuttling to the TGN a secondary autocatalytic cleavage within the prosegment 
takes place (3), leading to the release of this inhibitory chaperone molecule and 
subsequent activation of the mature PC (4). PC4, PC7 and PCSK9 do not require this 
second step for activation.  
 
Similar to PC4 and PC7, PCSK9 undergoes only one autocatalytic cleavage step, 
however, other than in all other PCs, the protein remains bound to the prosegment (Seidah, 
Benjannet et al. 2003; Benjannet, Rhainds et al. 2004). Association to its prosegment keeps 
PCSK9 in an enzymatically inactive state (Cunningham, Danley et al. 2007). As PCSK9’s 
Introduction 
 
 
 
30 
chaperone function on LDLR is independent of its catalytic activity, PCSK9 itself represents its 
only known enzymatic target (McNutt, Lagace et al. 2007).    
PC2 does not follow the aforementioned autocatalytic cleavage mechanism. proPC2 is 
bound to its ~30 kDa binding protein 7B2 and the complex is transported to acidic immature 
secretory granules. The protein 7B2 was first described in 1982 (Hsi, Seidah et al. 1982) and 
has been reported to act as a chaperone for proPC2 maturation and activity (Braks and 
Martens 1994). Thus, it facilitates intracellular transport of PC2 and additionally inhibits PC2 
whilst being bound. Autocatalytic cleavage of the prodomain of proPC2 and subsequent 
dissociation of the prodomain and 7B2 occur in the acidic environment of the secretory 
granules.  
 
The consensus cleavage sequence of proprotein convertases 
Due to their similarity to furin, the seven basic amino acid-specific PCs are often 
referred to as “furin-like PCs”. These seven core members exclusively process motifs that 
require the presence of basic flanking arginine (R) or lysine (K) residues and thus the most 
common consensus cleavage site is R/K-Xn-R/K↓, whereby X represents any amino acid but 
cysteine and rarely proline, n represents the numbers 0, 2, 4 or 6, and the arrow stands for the 
cleavage site. The sequence of the recognition site is based on analysis of various substrates 
and was first described in the early 1990’s, among others for furin-mediated cleavage of 
anthrax protective antigen (Molloy, Bresnahan et al. 1992). Despite the similarities in 
sequence preference, certain differences exist. For instance, furin seems to favour the 
presence of arginine at position P4 and arginine or lysine at position P2, thus preferentially 
recognizes a site represented by R-X-R/K-R (Hosaka, Nagahama et al. 1991). The 
preferences of furin for arginine in P1 as well as for basic amino acids at P2 and P4 are 
explained by the structure of its catalytic domain, which was solved in 2003 by Henrich et al. 
(Henrich, Cameron et al. 2003) and will be discussed in detail in section 5.1. Since less 
favourable residues at P1 and P4 may be compensated for by favourable residues at P2 and 
P6 and some amino acids are better tolerated than others at P1’ and P2’, the use of a neural 
network instead of a strict consensus sequence for prediction of PC substrates has been 
proposed (Duckert, Brunak et al. 2004). Such furin- or PC-specific networks trained with 
extensive datasets of known substrates would allow identifying substrates that do not harbour 
the stringent consensus cleavage site.  
The remaining two PCs, SKI-1 and PCSK9, do not cleave after basic amino acid 
residues. SKI-1 cleaves its substrates after non-basic residues carboxyterminally of the 
recognition sequence R-X-(L/V/I)-X↓ (Seidah, Mowla et al. 1999; Toure, Munzer et al. 2000). 
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PCSK9 on the other hand processes itself at its internal sequence VFAQ↓ (Naureckiene, Ma 
et al. 2003).  
 
4.3. Subcellular localisation and tissue distribution 
All PCs display distinct tissue expression and subcellular localisation (Table 1), a 
feature that determines their selectivity towards distinct substrates.  
Furin, PC7 and PC5B can cleave their substrates within the constitutive secretory 
pathway. They are widely expressed and can cycle from the TGN to the cell surface and back 
through endosomes (Molloy, Anderson et al. 1999; Xiang, Molloy et al. 2000; Rousselet, 
Benjannet et al. 2011). Nevertheless, these three PCs display distinct intramolecular sorting 
motifs and/or additional trafficking routes. For instance, while the majority of mature PC7 
cycles to the cell surface within the constitutive secretory pathway, a fraction of PC7 reaches 
the cell surface through an unconventional secretory pathway that is brefeldin A- and COPII-
independent (Rousselet, Benjannet et al. 2011). Recycling of PC7 from the cell surface via 
clathrin-coated vesicles seems to be dependent on the cytoplasmic region between Ala713 and 
Cys726 (Declercq, Meulemans et al. 2012). Trafficking of furin will be discussed in detail in the 
section 5.1. In contrast to the membrane-bound PC5B, the alternative splice variant PC5A is 
secreted into the extracellular milieu (Lusson, Vieau et al. 1993). 
PC1/3 and PC2 are exclusively expressed in neuroendocrine cells. Processing of 
PC1/3 and PC2 prohormone substrates takes place within immature and dense-core secretory 
granules as part of the acidic regulated secretory pathway. Due to their requirement for a low 
pH, optimal pH range for PC1/3 and PC2 lies around 5.5-6.5 and 5.5-6.0, respectively, 
processing of substrates outside the cell is highly unlikely (Jean, Basak et al. 1993; Shennan, 
Taylor et al. 1995).   
The tissue expression of PACE4 is widespread and abundant amounts of this enzyme 
can be found in the anterior pituitary, the heart, the liver, the kidney, the digestive system, the 
placenta and the brain (Seidah, Chretien et al. 1994; Tsuji, Sakurai et al. 2003). Like PC5A, 
PACE4 can be transported from the TGN to the cell surface and be retained at the cell surface 
and/or extracellular matrix (ECM) through binding to HSPGs or TIMPs (Tsuji, Sakurai et al. 
2003; Mayer, Hamelin et al. 2008).  
PC4 seems to be exclusively expressed in germ cells. Thus, its expression was 
confirmed in testicular germ cells in males (Seidah, Day et al. 1992; Gyamera-Acheampong, 
Tantibhedhyangkul et al. 2006) and in the placenta and ovary in females (Gyamera-
Acheampong and Mbikay 2009). Its exact intracellular localisation remains elusive.  
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The pyrolysin-like PC SKI-1 is ubiquitously expressed (Seidah, Mowla et al. 1999). It is 
mostly localised in the cis- and medial-Golgi and generally does not reach the cell surface. 
Furthermore, SKI-1 can be sorted to endosomal/lysosomal compartments for degradation 
(Pullikotil, Benjannet et al. 2007). 
Expression of PCSK9 is mostly found in adult liver, small intestine and kidney (Seidah, 
Benjannet et al. 2003; Zaid, Roubtsova et al. 2008). PCSK9 is secreted into the extracellular 
milieu, whereby hepatocytes in the liver represent the main source of circulating PCSK9 (Zaid, 
Roubtsova et al. 2008). Upon binding to LDLR at the cell surface, the complex is internalised 
into endosomes and forwarded to lysosomes for degradation (Maxwell, Fisher et al. 2005; 
Nassoury, Blasiole et al. 2007). 
  
Table 1 Expression and subcellular localisation of proprotein convertases.  
ECM, extracellular matrix; PACE4, paired basic amino acid cleaving enzyme 4; PC1/3, 
proprotein convertase 1/3; PCSK9, proprotein convertase subtilisin kexin 9; SKI-1, subtilisin 
kexin isozyme 1; TGN, trans-Golgi network. Modified from (Seidah and Prat 2012). 
 
4.4. Proprotein convertases in health and disease 
Proprotein convertases cleave a huge variety of proproteins. Cleavage redundancy 
towards substrates might occur because of overlapping cleavage motif preferences, tissue 
expression and subcellular localisation. Redundancy in substrate processing was observed  in 
in vitro and in vivo studies, especially between furin, PC5 and PACE4 and to a lesser extent 
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for PC7 (reviewed in (Seidah, Mayer et al. 2008)). Nevertheless, time and spatial resolution, 
i.e. localisation of a PC and a substrate at a given time, are key determinants that have to be 
assessed in vivo. A collection of the various PC substrates can be found in the MEROPS 
Peptidase Database (https://merops.sanger.ac.uk/ (Rawlings, Barrett et al. 2012)). A choice of 
key substrates is presented in Table 2.  
Table 2 Substrates of proprotein convertases. 
α-MSH, α-melanocyte-stimulating hormone; ACTH, adrenocorticotropic hormone; ADAM-TS4, a 
disintegrin and metalloprotease with thrombospondin motif 4; ATF6, activating transcription 
factor 6; CCHF Gn, Crimean–Congo haemorrhagic fever virus glycoprotein Gn; CREB, cyclic 
AMP-responsive element binding protein; GDF11, growth differentiation factor 11; GHRH, growth 
hormone-releasing hormone; GlcNAc, N-acetylglucosamine; GLP1, glucagon-like peptide 1; 
gp160, envelope glycoprotein 160; IGF1/2, insulin-like growth factor 1/2; IGF1R, insulin-like 
growth factor 1 receptor; L1CAM, L1 cell adhesion molecule; LDLR, low-density lipoprotein 
receptor; LRP8, LDLR-related protein 8; MCH, melanin concentrating hormone; MT1-MMP, 
membrane-type 1 matrix metalloprotease; pa83, protective antigen 83; PACAP, pituitary adenylyl 
cyclase-activating peptide; PACE4, paired basic amino acid cleaving enzyme 4; PC1/3, 
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proprotein convertase 1/3; PCSK9, proprotein convertase subtilisin kexin 9; PTPRM, protein 
tyrosine phosphatase receptor type M; RGMA, repulsive guidance molecule A; SKI-1, subtilisin 
kexin isozyme 1; SREBP, sterol regulatory element-binding protein; TGFβ, transforming growth 
factor-β; TRH, thyrotropin releasing hormone; VLDLR, very-low-density lipoprotein receptor. 
Modified from.(Seidah and Prat 2012). 
Based on their involvement in the activation and expression of a vast number of 
substrates, the function of PCs has been implied in the development and progression of many 
pathological disorders and infectious diseases (reviewed in (Artenstein and Opal 2011)). The 
role of PCs in cancer will be discussed in section 4.5. 
 
Deciphering the roles of PCs: use of knockout mice 
In order to decipher the role of distinct PCs in tissues and organs, knockout mice have 
been generated resulting in in vivo defects that have been studied in detail (reviewed in 
(Scamuffa, Calvo et al. 2006)). From these studies it emerged that PCs have an important 
function in embryogenesis and organ development. Decreased expression or lack of 
expression of PCs can affect several programmes of organogenesis. Particularly furin, PC5 
and SKI-1 null mice show an increased rate of embryonic mortality (Roebroek, Umans et al. 
1998; Yang, Goldstein et al. 2001; Essalmani, Hamelin et al. 2006). Knockout of PC1/3 or PC2 
results in metabolic or endocrine disorders and developmental defects or growth retardation 
(Furuta, Yano et al. 1997; Zhu, Zhou et al. 2002). PACE4 null mice have a high viability rate of 
75%, but are often born with craniofacial abnormalities (Constam and Robertson 2000). The 
knockout of PC4 decreases fertility of the mice (Mbikay, Tadros et al. 1997), while absence of 
PC7 does not have any apparent consequences. The insights gained from partial or complete 
knockouts of furin will be discussed in more depth in section 5.1.  
 
Hormones and endocrinopathies 
Mice that are deficient in PC1/3 or PC2 are viable but display complex endocrinologic 
disturbances. They show irregular processing of hormones in the pro-opiomelanocortin 
(POMC) pathway, abnormalities concerning neuroendocrine function and impaired maturation 
of pro-glucagon and pro-insulin, leading to glucose homeostasis defects (Furuta, Yano et al. 
1997; Zhu, Zhou et al. 2002). Several congenital cases of PC1 deficiency have been 
described in humans. They recapitulate some of the phenotypical features observed in PC1/3 
knockout mice, such as abnormal glucose homeostasis or impaired prohormone processing, 
but in contrast to mice, the affected subjects had a normal growth and suffered from early-
onset obesity (O'Rahilly, Gray et al. 1995; Jackson, Creemers et al. 1997; Jackson, Creemers 
et al. 2003; Farooqi, Volders et al. 2007). In the first case ever described, the female patient 
harboured two mutations in both PC1/3 alleles: a heterozygous missense mutation of 
Gly593Arg, leading to improper processing of PC1/3 and retention in the ER, and a 
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heterozygous AÆC transversion at the +4 donor splice site of intron 5, causing exon skipping, 
a frameshift and generation of a premature stop codon (Jackson, Creemers et al. 1997). In a 
different case, a homozygous missense mutation Ser307Leu was described resulting in 
impaired autocatalytic activity of PC1/3 (Farooqi, Volders et al. 2007). Furthermore, several 
studies have shown that mutations in the PCSK1 gene can be the cause of monogenic obesity 
(Benzinou, Creemers et al. 2008; Corpeleijn, Petersen et al. 2010). Being a carrier of a 
heterozygous mutation in PCSK1 that (partially) disables the function of the PC1/3 enzyme 
increases the risk of obesity by 8.7 fold compared to wild type carriers (Creemers, Choquet et 
al. 2012).         
 
Alzheimer’s disease 
The WHO estimates that 60-70% of the 47.5 million dementia cases worldwide can be 
attributed to Alzheimer’s (WHO 2015). Alzheimer’s disease is a neurodegenerative disease 
leading to deterioration of cognitive functions. The first symptoms often manifest in people 
over age 65, nevertheless, 4-5% of the patients present with early-onset Alzheimer’s disease 
(reviewed in (Mendez 2012)). It has been shown that furin and/or furin-like PCs are the 
proteases responsible for the conversion of pro-BACE (β-site amyloid precursor protein 
cleaving enzyme)  and have thus been directly linked with amyloid plaque formation in 
Alzheimer’s disease (Bennett, Denis et al. 2000). Amyloid plaques, as well as neurofibrillary 
tangles represent the two pathological core hallmarks of Alzheimer’s disease (reviewed in 
(Ballard, Gauthier et al. 2011)). Neurofibrillary tangles are formed by aggregates of the 
microtubule-associated protein tau, leading to disruption of microtubules inside nerve cell 
bodies. Pathological or toxic tau is thought to arise from hyperphosphorylation of normal tau, 
however underlying mechanism are still poorly understood (reviewed in (Iqbal, Alonso Adel et 
al. 2005)). Around 25 years ago another hypothesis emerged postulating that the deposition of 
extracellular amyloid beta (Aβ) might be the main cause of Alzheimer’s disease (Hardy and 
Allsop 1991). Cleavage of amyloid precursor protein (APP) into the Aβ peptides Aβ40 and Aβ42 
is catalysed by the secretase enzymes BACE and γ-secretase (reviewed in (Vassar, Kovacs 
et al. 2009)). An increased ratio in favour of Aβ42 is thought to trigger formation of amyloid 
plaques, as Aβ42 aggregates more readily (Jarrett, Berger et al. 1993). As mentioned above, 
the APP cleaving enzyme BACE in turn requires PC mediated proteolytic removal of its 
prodomain to form the mature enzyme. Interestingly, alternative cleavage of APP resulting in a 
secreted APPα fragment was suggested to be catalysed either by furin or by PC7 (Lopez-
Perez, Seidah et al. 1999; Hwang, Kim et al. 2006), pointing at opposing roles of PCs in 
amyloid plaque formation as increased APPα fractions are considered to lower potentially 
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harmful Aβ fractions. Nevertheless, the exact contribution of PC activity to the onset of 
Alzheimer’s disease still remains elusive. 
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Infectious diseases 
The action of PCs has been implied in the activation of many bacterial and viral 
pathogens. For instance, three distinct forms of bacterial toxins are known to require 
processing of furin or furin-like PCs for their activation. Single-chain toxins, which are 
composed of a toxic subunit and a binding subunit, are cleaved within endosomes. Prominent 
examples are the furin-catalysed conversion of pseudomonas exotoxin A (Gu, Gordon et al. 
1996), diphtheria toxin (Tsuneoka, Nakayama et al. 1993) and Shiga toxins  (Lea, Lord et al. 
1999). The second group of bacterial toxins that are cleaved by PCs is called binary toxins 
and is represented by the anthrax toxin protective antigen (PA) (reviewed in (Young and 
Collier 2007)). Upon binding of PA83 to receptors on the cell surface, an N-terminal 20 kDa 
fragment, PA20, is removed proteolytically by furin to generate the active PA63 moiety (Klimpel, 
Molloy et al. 1992; Molloy, Bresnahan et al. 1992). PA63 is then able to self-associate to form 
the prepore and to form complexes with up to three moieties of lethal factor (LF) and/or edema 
factor (EF), leading to endocytosis of the complex. Ultimately, this results in the release of LF 
and EF into the cytosol where these two enzymes act on cytosolic substrates. Even though 
furin seems to be the main activator of PA83, PACE4 was proposed as an alternative cleaving 
enzyme (Gordon, Rehemtulla et al. 1997). In the case of the soluble bacterial toxin aerolysin, 
secreted by Aeromonas hydrophila, it could be shown that proteolytic cleavage of soluble 
proaerolysin through furin, PACE4 or PC5A on the cell surface is required for subsequent pore 
formation and entry into host cells (Abrami, Fivaz et al. 1998).  
Many envelop glycoproteins of viral pathogens also require proteolytic cleavage before 
their mature forms can fuse with the host cell membrane. Many viruses utilise furin or other 
host PCs for this purpose. For instance, the conversion of the human immunodeficiency virus 
(HIV) 1 glycoprotein 160 (gp160) into gp120 and the fusiogenic gp41 is promoted by PCs 
(reviewed in (Moulard and Decroly 2000)). Furin was thought to be the central endoprotease in 
this process (Hallenberger, Bosch et al. 1992), however gp160 can be efficiently cleaved in 
the furin-deficient LoVo cell line (Ohnishi, Shioda et al. 1994), suggesting the presence of 
alternative gp160 cleaving enzymes. In the case of influenza A viruses the haemagglutinin 
glycoprotein undergoes proteolytic activation. It has been shown that the virulence of influenza 
virus directly correlates with the presence of a PC cleavage motif (Decha, Rungrotmongkol et 
al. 2008). Other examples of (potentially) deadly viruses that rely on PC activity are measles 
(Watanabe, Hirano et al. 1995) and the two highly pathogenic filoviruses Marburg (Volchkov, 
Volchkova et al. 2000) and Ebola (Volchkov, Feldmann et al. 1998). Similar to influenza 
viruses the absence of a PC cleavage site, as in the Ebola Reston subtype, conveys reduced 
pathogenicity in humans (Volchkov, Feldmann et al. 1998).     
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Lipid disorders and atherosclerosis  
PCSK9 has a unique role in protein degradation of the hepatic low density lipoprotein 
receptor (LDLR). Independent of its intrinsic enzymatic activity, it binds tightly to cell surface 
LDLR, thereby mediating internalisation and subsequent lysosomal degradation (McNutt, 
Lagace et al. 2007; Zhang, Garuti et al. 2008). As low density lipoprotein (LDL) cholesterol is 
primarily cleared by binding to LDLR and subsequent receptor-mediated endocytosis, removal 
of cell surface LDLR leads to elevated levels of circulating LDL cholesterol (Maxwell and 
Breslow 2004). Accordingly, mutations in PCSK9 that increase its affinity for LDLR have been 
associated with autosomal dominant hypercholesterolaemia (ADH) (Abifadel, Varret et al. 
2003; Allard, Amsellem et al. 2005). The approaches and the potential of inhibiting the function 
of PCSK9 in order to treat hypercholesterolaemia will be discussed in section 4.6. In contrast 
to PCSK9’s function in hypercholesterolaemia, frequent loss-of-function mutations leading to 
hypocholesterolaemia have equally been described. The two nonsense mutations Y142X and 
C679X, found in 2% of African Americans, were associated with 40% lower LDL cholesterol 
plasma levels and it was hypothesised that carriers of such mutations exhibit substantially 
lower risk for coronary heart disease (Cohen, Pertsemlidis et al. 2005; Kotowski, Pertsemlidis 
et al. 2006).  
4.5. Proprotein convertases and cancer 
Over the last 20 years evidence accumulated linking the activity of PCs to the genesis 
and progression of multiple proliferative disorders, including cancer. Initial hypotheses were 
based on their role in processing and activation of proteins directly involved in the formation of 
neoplasias. Later, these were expanded by direct investigations of PC expression and loss- or 
gain-of-function studies in different human cancer models and tumour cell lines (reviewed in 
(Khatib, Siegfried et al. 2002; Bassi, Fu et al. 2005)). Their expression inside a tumour can be 
assessed either at the protein level by immunohistochemical staining and immunoblotting, or 
at the mRNA level by quantitative reverse transcriptase polymerase chain reaction (qRT-
PCR), Northern blot and in situ hybridisation. However, examination of enzymatic activity of a 
distinct PC within tumour samples has not been reported yet. Nevertheless, increased 
expression of PCs has been reported in various cancer types and was often found to correlate 
with aggressiveness of the malignancy. 
Furthermore, based on the numerous substrates that are cleaved and activated by 
PCs, they may directly or indirectly influence the malignant phenotype and the potential for 
metastasis of cancer cells. Thus, they may modulate central processes like proliferation, 
survival, invasion and migration. Amongst the critical substrates involved in neoplasia 
formation and progression are growth factors and their receptors, matrix metalloproteases 
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(MMPs) and adhesion molecules. Examples of substrates will be discussed below; however 
the implication of furin activity in the formation and progression of different cancer types will be 
discussed in detail in section 5.2. 
 
Proprotein convertases are highly expressed in certain cancers 
The two neuroendocrine PCs, PC1/3 and PC2, were shown to be expressed in 
cancers composed of neural and/or endocrine cells (Jin, Kulig et al. 1999; Kajiwara, Itoh et al. 
1999). For instance, high PC1/3 and PC2 expression was found in pheochromocytoma, 
neuroendocrine tumours of the medulla or adrenal glands, but was absent in normal adrenal 
tissue (Konoshita, Gasc et al. 1994). Furthermore, their expression pattern was correlated with 
the expression of their substrate proenkephalin (Breslin, Lindberg et al. 1993), suggesting 
function of PC1/3 and PC2 activity in tumours of the endocrine glands.  
Aberrant PACE4 expression has been reported in breast cancer (Cheng, Watson et al. 
1997). Furthermore, D’Anjou et al. found high expression of PACE4 in prostate cancers of all 
different clinical stages and showed, in functional studies, that decreased PACE levels in 
prostate cancer cell lines leads to reduced proliferation and clonogenic potential, and 
abrogates tumour growth in athymic nude mice (D'Anjou, Routhier et al. 2011). They further 
developed peptide-based inhibitors against PACE4 for treatment of prostate cancer, as 
discussed in section 4.6.  
Studies examining PC5 and PC7 expression in different cancer entities are rather rare 
and the prognostic value of their expression is still elusive. Nevertheless, PC5 is expressed in 
colon cancer cell lines (Rovere, Barbero et al. 1998) and considerable PC7 expression was 
found in the majority of investigated breast cancer cell lines and tissues (Cheng, Watson et al. 
1997). 
 
Processing of growth factors and their receptors 
Many cancer types are known to depend on growth factor signalling pathways for 
maintaining certain malignant characteristics such as unrestricted proliferation and high 
invasive potential. Various growth factors and their receptors involved in these processes 
require proteolytic activation by PCs to be converted into their mature forms. For instance 
IGF1R as well as its ligand IGF1 are processed by furin-like PCs (Duguay, Milewski et al. 
1997; Khatib, Siegfried et al. 2001). Likewise, the activity of furin, PC5B or PACE4 seems to 
be necessary to process the precursor of the neurotrophin nerve growth factor (NGF) 
(Bresnahan, Leduc et al. 1990; Seidah, Benjannet et al. 1996). PCs also activate other growth 
factors whose functions have been linked to cancer progression, e.g. endothelin (Denault, 
Claing et al. 1995), parathyroid hormone (PTH) (Hendy, Bennett et al. 1995) and transforming 
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growth factor β1 (TGFβ1) (Dubois, Laprise et al. 1995). Siegfried et al. further characterised 
the catalytic events leading to activation of the platelet-derived growth factors (PDGF) A and 
B, a prerequisite for the role of these growth factors in tumourigenesis (Siegfried, Khatib et al. 
2003; Siegfried, Basak et al. 2005). Additionally, PCs have been shown to be responsible for 
processing of the vascular endothelial growth factors (VEGF) C and D, growth factors that 
promote angiogenesis and lymphangiogenesis, thereby facilitating tumour growth and 
metastatic spread (Siegfried, Basak et al. 2003; McColl, Paavonen et al. 2007). In addition to 
IGF1R, other receptor tyrosine kinases are equally processed by PCs. Thus, the insulin 
receptor was reported to require PC-mediated processing in order to exert its function in 
glucose homeostasis (Robertson, Moehring et al. 1993; Hwang, Hernandez et al. 2000). In 
contrast, endoproteolytic cleavage of HGF by furin appears to be dispensable for its function 
(Komada, Hatsuzawa et al. 1993).  
 
Matrix metalloproteases - destructors of the extracellular matrix 
In order to successfully form metastasis a tumour cell proceeds through four essential 
steps: detachment, migration, invasion and adhesion. Thus, a metastasising cell has to be 
able to destruct the basement membrane and the surrounding ECM to escape the primary 
tumour. The ECM consists of various components, including collagen, gelatin, proteoglycans, 
laminin, fibronectin and vitronectin. Degradation of these components is mediated by 
proteases that are secreted by the malignant cells, but also by stroma cells. One of the main 
groups of ECM-degrading proteases is the family of matrix metalloproteases (MMPs). Under 
physiological conditions these enzymes with endopeptidase activity are tightly regulated and 
their expression is generally induced during wound healing or inflammation (reviewed in 
(Chakraborti, Mandal et al. 2003)). Nevertheless, high expression and activity of MMPs has 
been reported for various types of cancer and has been correlated with poor prognosis 
(reviewed in (Basset, Okada et al. 1997; Brown and Murray 2015)). Many MMPs and 
membrane-type MMPs (MT-MMPs) contain potential PC cleavage sites, however only a few of 
them have been shown experimentally to be PC substrates. One well studied example is MT1-
MMP, also called MMP14, the best known member of the membrane-type subfamily of MMPs. 
The MT1-MMP zymogen may be cleaved by furin or PC5 (Maquoi, Noel et al. 1998; Yana and 
Weiss 2000). Active MT1-MMP in turn can directly cleave ECM components like collagen 1, 
but equally activates pro-MMP2 (Sato, Takino et al. 1994; Ohuchi, Imai et al. 1997). Other 
ECM-degrading metalloproteases processed by PCs include stromelysin-3 (Pei and Weiss 
1995; Santavicca, Noel et al. 1996), the adamalysin metalloproteases (also a disintegrin and 
metalloprotease; ADAMs) (Loechel, Gilpin et al. 1998) and the adamalysin metalloproteases 
with thrombospondin motif (ADAM-TS) (Kuno, Terashima et al. 1999). Accordingly, application 
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of PC inhibitors was found to significantly lower the invasive potential of various tumour cells 
due to altered processing and activation of MMPs (reviewed in (Bassi, Fu et al. 2005)).  
 
Cell adhesion molecules - important factors in metastasis  
Cell adhesion molecules (CAMs) are proteins that are present on the cell surface and 
mediate cell-cell or cell-matrix interactions. Furthermore, they are involved in the activation of 
cell survival and proliferation mechanisms through the action of integrins. In the context of 
metastasis formation they play a pivotal role in migration and invasion of a tumour cell through 
lymphatic or angiogenic vessels as well as in arrest and extravasation of the cell at a distal 
site. Cell adhesion molecules can be grouped into three main families: immunoglobulins, 
integrins and selectins.  
In the case of immunoglobulins, the implication of PCs is rather indirect as none of 
them seem to be direct substrates of PC processing. However, some of the cytokines and 
growth factors, like IGF1 or endothelins, which promote ICAM-1 or VCAM-1 expression in 
endothelial cells, are known PC substrates (Denault, Claing et al. 1995; Duguay, Lai-Zhang et 
al. 1995; Balaram, Agrawal et al. 1999; Ishizuka, Takamizawa-Matsumoto et al. 1999).  
The importance of integrins in tumour progression and metastasis has been well 
established. Besides their role in adhesion of a cell to the ECM, integrins can control MMPs on 
the cell surface, interact with the cytoskeleton for alterations of cell shape and motility or 
transmit growth and survival signals (reviewed in (Seguin, Desgrosellier et al. 2015)). Integrins 
are heterodimeric receptors composed of an α- and a β-subunit. To date 18 α-subunits and 
eight β-subunits are known that form at least 24 different functional integrin receptors. This 
flexibility in formation of functional integrin receptors allows recognition of and adaptation to 
distinct environments. Half of the known α-subunits contain potential PC processing sites and 
α3, α4, α5, α6 and αv have been shown to be cleaved by furin, PC5 and to a lesser extent by 
PACE4 (Lehmann, Rigot et al. 1996; Lissitzky, Luis et al. 2000).  
Selectins bind fucosylated carbohydrates, like sialyl-LewisX and sialyl-Lewisa, and are 
comprised of the three family members E-selectin (endothelium), P-selectin (platelets) and L-
selectin (lymphocytes), named after the cell type on which they were originally identified. They 
mediate adhesive interactions of leukocytes and platelets with the endothelium within the 
blood circulation, therefore similarities to dissemination of circulating tumour cells during 
metastasis have been hypothesised (Kannagi 1997; Krause and Turner 1999). Furthermore, 
as most cancer cells express increased levels of selectin ligands, which is associated with a 
poor prognosis, cell-cell interaction with selectins on leukocytes, platelets and endothelial cells 
was proposed to be required for metastatic progression (reviewed in (Laubli and Borsig 
2010)). For instance, E-selectin appears to be a main homing receptor of breast and colon 
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cancer cells on activated endothelial cells (Tözeren, Kleinman et al. 1995) and adhesion of 
colon cancer cells to endothelial cell surface E-selectin seemed to be dependent on the 
amount of tumour cell-bound sialyl-LewisX, one of the E-selectin ligands (Izumi, Taniuchi et al. 
1995). Additionally, tumour cells that enter the hepatic circulation seem to be able to trigger E-
selectin expression on endothelial cells, thereby favouring extravasation to liver tissue (Khatib, 
Kontogiannea et al. 1999). E-selectin expression was shown to be induced by various 
cytokines, like IL-1 and TNFα, as well as by several growth factors including VEGF and IGF-1 
(Kim, Moon et al. 2001; Che, Lerner-Marmarosh et al. 2002; Simiantonaki, Jayasinghe et al. 
2002). Thus, although PCs do not directly process selectins, processing of cytokines and 
growth factors that might induce selectin expression indirectly favours formation of 
metastases. 
4.6. Inhibitors of proprotein convertases 
The involvement of PCs in many physiological and pathological processes has resulted 
in the development of many inhibitors. However, designing specific and efficient inhibitors 
remains a challenge, particularly for inhibition of the seven core members of this enzyme 
family.  
One central issue is the lack of specificity of most PC antagonists caused by the 
common recognition site shared between furin-like PCs. Thus, many efforts have been made 
in order to determine the cleavage preference of distinct PCs. For instance, Remacle et al. 
used over 100 decapeptide sequences representing the R-X-(R/K/X)-R↓ motif from human, 
bacterial and viral proteins and evaluated the relative cleavage efficiency of furin, PC2, PC4, 
PC5, PACE4 and PC7 (Remacle, Shiryaev et al. 2008). Alas, they limited their analyses to 
known PC substrates and did not comment on the usefulness of their data for future inhibitor 
design. The work of others has been more concentrated on developing a tool to predict 
cleavage sites in potential PC substrates. Hence, Duckert et al. constructed artificial neural 
networks implementing furin- or PC-specific datasets in order to predict potential substrates 
(Duckert, Brunak et al. 2004). Despite these efforts, the information on cleavage preferences 
of distinct PCs are still sparse and design of specific inhibitors remains challenging. 
Nevertheless, the first furin specific inhibitors in the form of camelide antibodies, called 
nanobodies, have been recently described (Zhu, Declercq et al. 2012) and will be discussed in 
section 5.3.  
Another important aspect that will be of concern for the clinical use of wide range PC 
inhibitors is the potential interference with the physiological function of these proteases. 
Nevertheless, it can be speculated that the redundancy in PC functionality that arises from 
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overlapping substrate preferences and intracellular or tissue expression might counteract most 
side effects.  
     
Naturally occurring inhibitors of the neuroendocrine proprotein convertases 
Among the endogenous inhibitors of PCs are 7B2 and ProSaas as well as the 
prosegments of the PCs, which will be discussed further below. As mentioned in the section 
about PC activation, 7B2 acts as a chaperone for proPC2 maturation and activity (Braks and 
Martens 1994). Within the ER, pro7B2 forms a complex with proPC2 and can be cleaved by 
PCs in the less alkaline, high calcium environment of the TGN. The released C-terminal part of 
processed 7B2 acts as an inhibitor of PC2. Once proPC2 is autocatalytically activated in the 
acidic environment of the secretory granules, mature PC2 as well as carboypeptidase E 
rapidly degrade 7B2 and the prosegment of PC2 (reviewed in (Khatib 2013)). In 1998, 
Apletalina et al. performed a positional scanning of a synthetic peptide combinatorial library to 
evaluate the inhibitory efficiency of hexapeptides on PC1/3 and PC2 (Apletalina, Appel et al. 
1998). The hexapeptide LLRVKR proved to be the most potent inhibitor for both 
neuroendocrine PCs. This sequence represents the inhibitory sequence of proSAAS, a protein 
that is primarily found in the brain and other neuroendocrine tissue and that is generally 
cleaved by carboxypeptidase E (Fricker, McKinzie et al. 2000). Other than the hexapeptide 
alone proSAAS appears to be a specific inhibitor of PC1/3. ProSAAS and 7B2 exhibit some 
structural and functional homology: for instance both molecules contain a proline-rich 
sequence and a C-terminal peptide that can be cleaved by furin to exert the described 
inhibitory function (Cameron, Fortenberry et al. 2000). Thus, Cameron et al. proposed that 
proSAAS and 7B2 may belong to a new group of functionally homologous convertase 
inhibitors (Cameron, Fortenberry et al. 2000). 
 
Prosegments of the proprotein convertases 
Beside their chaperone function in guiding correct folding and intracellular trafficking, 
the prosegments of PCs also act as endogenous inhibitors of PCs. Interestingly, the inhibitory 
potency of furin-like PC prosegments was found to go beyond activity inhibition of the parent 
enzyme and various studies have demonstrated that all prosegments of furin-like PCs can act 
on various PCs (reviewed in (Khatib 2013)). Zhong et al. were the first to report the inhibitory 
potential of ex vivo expressed furin and PC7 prosegments on the processing of selected PC 
substrates including NGF (Zhong, Munzer et al. 1999). Soon thereafter, others confirmed the 
potent inhibitory function of the prosegments (Fugere, Limperis et al. 2002; Nour, Basak et al. 
2003). Simultaneously, the potency of shorter peptides derived from the original prosegments 
was evaluated. Generally, complete prosegments seem to be more potent than shorter 
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peptides, whereby both display only limited specificity towards their cognate enzymes (Fugere, 
Limperis et al. 2002; Nour, Basak et al. 2003). Nevertheless, Bhattacharjya et al. identified a 
24 amino acid long peptide derived from the C-terminal end of the PC7 prosegment that 
showed comparable inhibition of PC7 as compared to the full length fragment (Bhattacharjya, 
Xu et al. 2000). Consequently, expression of PC prosegments has often been used as a tool 
to demonstrate the involvement of PC activity in the processing of suspected substrates, e.g. 
VEGF-C, PDGF-A and PDGF-B (Siegfried, Basak et al. 2003; Siegfried, Khatib et al. 2003; 
Siegfried, Basak et al. 2005). 
 
Small molecule- and peptide-based inhibitors 
Expression of the pan-PC inhibitor α1-antitrypsine Portland, mostly referred to as α1-
PDX, is one of the most common tools of research to investigate the effect of furin-like PC 
inhibition on the behaviour of cells. The serine protease inhibitor (serpin) was derived from 
serial mutations of α1-antitrypsine which shifted the specificity of inhibition from the neutrophil 
elastase, to PCs (Owen, Brennan et al. 1983; Anderson, Thomas et al. 1993; Wright 1996). Its 
potential of inhibiting PCs was shown by Anderson et al. and Benjannet et al. (Anderson, 
Thomas et al. 1993; Benjannet, Savaria et al. 1997). Further modifications led to two variants, 
RRRRSA and AVNR, that appear to be highly selective for PACE4 and PC5 or furin, 
respectively (Tsuji, Kanie et al. 2007; Hada, Isshiki et al. 2013). Like other serpins, α1-PDX is 
an inhibitor that undergoes conformational changes upon cleavage leading to the formation of 
a stable enzyme-inhibitor complex (Wright 1996; Tsuji, Kanie et al. 2007). Experimentally α1-
PDX is mostly introduced into cells by expression of recombinant protein; however purified 
recombinant α1-PDX became commercially available very recently and has been used for 
instance on osteosarcoma cell lines (Liu, Li et al. 2014).  
Other small-molecule inhibitors are cell-permeable and act mostly in a competitive 
manner, e.g. dicoumarol derivates (Komiyama, Coppola et al. 2009), 2,5-dideoxystreptamine 
derivates (Jiao, Cregar et al. 2006) and decarboxylated P1 arginine peptide mimetics (Becker, 
Sielaff et al. 2010). Incorporation of peptide motifs consisting of patterns of basic amino acid 
residues has been explored by many groups, resulting, among others, in the description of a 
nona-D-arginine peptide (Kacprzak, Peinado et al. 2004). Similarly, the compound decanoyl-
RVKR-chloromethylketone, mostly referred to as dec-CMK or CMK, has been often used as 
an irreversible pan-PC inhibitor in experimental setups (Garten, Stieneke et al. 1989; Denault, 
Claing et al. 1995; de Cicco, Bassi et al. 2007). 
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PCSK9 inhibitors  
The most promising PC inhibitors to date are the ones that target active PCSK9 to treat 
hypercholesterolaemia and prevent coronary artery disease due to PCSK9’s unique role in 
protein degradation of the low density lipoprotein receptor (LDLR) (Seidah, Benjannet et al. 
2003; Chan, Piper et al. 2009; Seidah and Prat 2012). Several approaches have been 
investigated to decrease the amounts of circulating PCSK9 or levels of PCSK9 mRNA in 
hepatocytes, which are the major source of circulating PCSK9. Small-molecule inhibitors could 
be administered orally and either interfere allosterically with the PCSK9-LDLR interaction or 
interrupt the autocatalytic processing of PCSK9 in the ER. The company Serometrix has 
adopted the first approach with their compound SX-PCSK9, whereas two other companies, 
Zydus Cadila group and Shifa Biomedical Corporation, opted for the latter option. 
Nevertheless, information on specific compounds and clinical advances are sparse (reviewed 
in (Seidah 2013)). Furthermore, Bristol-Myers Squibb/Adnexus described fibronectin derived 
adnectins. These around 12 kDa molecules are cheap to produce, but have a rather short 
plasma half life due to quick kidney clearance (discussed in (Seidah 2013)). Application of 
antisense RNAi targeting PCSK9, such as the lipoid nanoparticle formulation ALN-PCS from 
the company Alnylam, aims at reducing PCSK9 mRNA levels in hepatocytes and seems 
promising (company website and (Frank-Kamenetsky, Grefhorst et al. 2008)).  
Several monoclonal antibodies have been developed to interrupt the interaction of 
PCSK9 and LDLR (Chan, Piper et al. 2009; Ni, Di Marco et al. 2011; Liang, Chaparro-Riggers 
et al. 2012). A meta-analysis of phase II and III trials recently compared 24 studies and 
confirmed the potential of PCSK9 antibodies to reduce LDL cholesterol levels and predicted 
safety and efficacy (Navarese, Kolodziejczak et al. 2015). In general, inhibition of PCSK9 is 
hypothesised to be more specific and have fewer side effects than the use of statins, but might 
also be used in combination with statins to counteract their PCSK9 upregulating function that 
attenuates the decrease in LDL cholesterol (Rashid, Curtis et al. 2005; Marais, Blom et al. 
2012; Seidah and Prat 2012). Overall, anti-sense RNA, adnectins and small-molecule 
inhibitors of PCSK9 are mostly in pre-clinical testing phases or entered phase I clinical trials, 
whereas the application of different monoclonal antibodies against PCSK9 is more advanced 
and phase III trials have commenced with >20,000 enrolled individuals (reviewed in (Seidah 
2013)). 
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5.   Furin 
Furin was identified as the first member of the PC family over 25 years ago (van de 
Ven, Voorberg et al. 1990). Due to its ubiquitousness and biological importance, furin is also 
the most studied member of this enzyme family. Some of its most important characteristics are 
summarised in Table 3. 
Table 3 Furin at a glance. 
PACE4, paired basic amino acid cleaving enzyme 4; PC, proprotein convertase; TGN, trans-
Golgi network. Chromosomal locations: National Center for Biotechnology Information (NCBI); 
mouse furin gene ID- 18550; human furin gene ID- 5045. Molecular weight prediction: ExPASy, 
Compute pI/MW tool (Gasteiger, Hoogland et al. 2005) 
 
5.1. The proprotein convertase furin at a glance 
From gene to active enzyme 
The locus of the FURIN gene, also called FUR (fes/fps upstream region) gene, was 
first described by Roebroek et al. in 1986 (Roebroek, Schalken et al. 1986; Roebroek, 
Schalken et al. 1986a). It lays in the upstream region of the c-fes/fps proto-oncogene, a gene 
that encodes the protein tyrosine kinase c-Fes which is involved in myeloid cell development 
(reviewed in (Kim, Ogata et al. 2004) and has been associated, among others, with prostate 
cancer recurrence (Miyata, Watanabe et al. 2012). The FURIN gene is located on 
chromosome 15 in position q26.1 (NCBI, gene ID: 5045). Interestingly, PCSK6, the gene of 
PACE4, is located at 15q26.3 (NCBI, gene ID: 5046) and is thus situated in close proximity to 
the FURIN gene, suggesting that both evolved from a common ancestor (Kiefer, Tucker et al. 
1991). The loci of the other human PCSK genes are spread throughout the genome.    
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A few years after the identification of the FURIN gene, Fuller et al. and van de Ven et 
al. characterised the associated protein furin as the mammalian homologue to the prohormone 
processing yeast kexin (Fuller, Brake et al. 1989; van de Ven, Voorberg et al. 1990). Furin is 
translated as a 794 aa zymogen that undergoes several posttranslational modifications to give 
rise to the active type-1 transmembrane protein (reviewed in (Thomas 2002)). Firstly, the 
signal peptide that directs localisation to the ER is removed through signal peptidase-mediated 
cleavage. As discussed in section 4.2., furin undergoes a two-step, compartment-specific 
autocatalytic cleavage of its 83 aa prosegment. The first cleavage step is rather fast with a half 
life of t1/2=10 min and occurs at Arg107 in the ER. Once the prosegment-furin complex trafficked 
to the mildly acidic environment of the TGN/endosomal system, the prosegment is cleaved a 
second time. This cleavage is pH sensitive, rather slow with a half life of t1/2<2h and processes 
the prosegment at Arg75, leading to the liberation of the inhibitory prosegment. However, furin 
requires a specific calcium concentration and pH for optimal activity, which will be discussed 
further below. Another reported posttranslational modification is the phosphorylation of the 
cytoplasmic tail through casein kinase 2, regulating intracellular localisation of furin (Jones, 
Thomas et al. 1995). Three potential N-linked glycosylation sites, Asn387, Asn440 and Asn553, 
have been identified; however, reports on their importance in maintaining furin activity are 
conflicting (Creemers, Vey et al. 1995; McCulloch, Wylie et al. 2010). 
 
Subcellular localisation and tissue distribution 
Furin orthologues are found in all vertebrates and many invertebrates including model 
organisms such as mouse, rat or Drosophila melanogaster (Seidah, Day et al. 1998). As PC7, 
furin appears to be ubiquitously expressed, whereby expression levels between different 
tissues may vary. Higher quantities of furin are found in the human liver and kidney (Seidah, 
Day et al. 1998). Similarly, furin, as well as PC7 expression have been confirmed in all 
investigated cell lines (The Human Protein Atlas: Furin, CAB009499).  
Furin cleaves its substrates within the constitutive secretory pathway. Accordingly, 
mature furin can be found in the TGN, on the cell surface, as well as in endosomes where it 
may cleave its substrates (reviewed in (Molloy, Anderson et al. 1999)). The majority of furin 
appears to be located in the TGN (Bosshart, Humphrey et al. 1994), from where it cycles to 
endosomes, the cell surface and back. From the TGN, furin is sorted to endosomes via 
clathrin coated vesicles, a process that is dependent on the recruitment of AP-1 (adaptor 
protein 1) (Teuchert, Schäfer et al. 1999). Furin tethering to the cell surface, on the other 
hand, seems to be mediated through interaction with filamin ABP-280 (Liu, Thomas et al. 
1997). Endocytosis of cell surface furin is initiated through binding of furin to the µ2 subunit of 
plasma membrane-specific AP-2 (Teuchert, Berghöfer et al. 1999). Whether endosomal furin 
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is then recycled back to the cell surface or redirect to the TGN appears to be, at least in part, 
dependent on the phosphorylation of its cytoplasmic tail through casein kinase 2. Interestingly, 
phosphorylation of the acidic cluster and interaction with the sorting protein PACS-1 
(phosphofurin acidic cluster sorting protein-1) favour recycling to the cell surface, but are 
equally required for retrieval of furin from endosomes to the TGN (Wan, Molloy et al. 1998; 
Crump, Xiang et al. 2001). Thus, dephosphorylation of the cytoplasmic tail by specific isoforms 
of protein phosphatase 2A (PP2A), which was proposed to occur prior to the transit to late 
endosomes, liberates furin from the phosphorylation-dependent local cycling loop between 
early endosomes and the cell surface, thereby enabling sorting to the TGN (Molloy, Thomas et 
al. 1998). Degradation of furin occurs in lysosomes with a proposed half life of t1/2=2-4h 
(Bosshart, Humphrey et al. 1994). Aggregation of furin in the TGN is likely mediated via its 
cytoplasmic domain and might trigger delivery to lysosomal compartments for subsequent 
degradation (Wolins, Bosshart et al. 1997). 
 
 
Figure 5 Compartments of furin substrate processing within the trans-Golgi 
network/endosomal system.  
At steady state, furin (represented by scissors) is predominantly localised to the trans-
Golgi network (TGN), from where it cycles to the cell surface, endosomes and back. In 
the TGN/biosynthetic pathway, furin processes many secreted prohormones like pro-β-
nerve growth factor (pro-β-NGF) or pro-bone morphogenic protein-4 (pro-BMP-4). Cell 
surface furin mainly cleaves extracellular substrates such as anthrax toxin protective 
antigen (PA). Other bacterial toxins, e.g. diphtheria toxin and shiga toxin, are 
preferably cleaved in mildly acidic early endosomes within the endocytic pathway. 
Modified from (Thomas 2002). 
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Domain structure of furin 
The general domain structure of furin follows that of the other furin-like PCs (Figure 3 
and Figure 6). The N-terminal part comprises four important domains: 1) signal peptide 
directing translocation to the ER during translation, 2) prosegment with chaperone function, 3) 
highly conserved catalytic domain and 4) P domain. The latter regulates the stability, calcium 
and pH dependence of furin (Zhou, Martin et al. 1998). The P domain also contains a 
conserved RGD motif, whose function is not well understood. The more individual C-terminal 
part of furin contains a Cys-rich domain, a transmembrane domain and a short cytoplasmic 
tail. The cytoplasmic tail was shown to be both necessary and sufficient to direct TGN 
localisation of mature furin (Bosshart, Humphrey et al. 1994; Chapman and Munro 1994; 
Molloy, Thomas et al. 1994). More precisely, TGN localisation was found to depend on the 
presence of an acidic amino acid cluster, CPSDSEEDEG783, and phosphorylation of serine 
residues by casein kinase 2 (Jones, Thomas et al. 1995; Schäfer, Stroh et al. 1995; Voorhees, 
Deignan et al. 1995). Recruitment of AP-1 and interaction with its µ1 subunit, a prerequisite for 
vesicle formation upon budding from the TGN, is mediated by a tyrosine tetrapeptide motif 
YKGL765 and to a lesser extent by a leucine-isoleucine signal LI760 (Teuchert, Schäfer et al. 
1999). Furthermore, YKGL765, LI760 as well as F790 constitute important motifs for recycling of 
cell surface furin by mediating sorting or tethering to early endosomes (Jones, Thomas et al. 
1995; Voorhees, Deignan et al. 1995; Teuchert, Berghöfer et al. 1999).   
Figure 6 The furin sorting motifs of the cytoplasmic domain. 
Shown is the primary structure of human furin with a focus on its cytoplasmic domain 
and its contained intracellular sorting motifs. AP, adaptor protein; PACS-1, 
phosphofurin acidic cluster sorting protein-1; PP2A, protein phosphatase 2A; TGN, 
trans-Golgi network. Modified from (Thomas 2002). 
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Cleavage preference and active site 
Many efforts have been made to elucidate the stringent cleavage preference of furin-
like PCs for basic amino acid motifs and to uncover possible differences between the PCs in 
order to design specific inhibitors. An important step was done in 2003 when Henrich et al. 
described the first crystal structure of the mouse furin ectodomain, amino acids 108-582 
(Henrich, Cameron et al. 2003). This 2.6 Ǻ crystal structure comprises the catalytic domain, 
bound to the pan-PC inhibitor CMK, as well as the P domain (Figure 7A). The obtained 
crystals contained eight molecules per asymmetric unit, each consisting of two separate 
domains, the spherical catalytic domain (amino acids 110-445) and the barrel-like P domain 
(amino acids 446-573). The core of the catalytic domain basically consists of a twisted β-sheet 
and in total seven flanking α-helices connected by two β-hairpin loops. Some extended 
surface loops were shown to mediate interactions with the P domain or shape the active site 
cleft. Furthermore, two internal disulfide bridges and two calcium binding sites were identified. 
The glycosylation state of the three potential N-linked glycosylation sites could be determined, 
whereby Asn387 seemed to be monoglycosylated and Asn440 bound up to eleven sugars. The P 
domain on the other hand is organised as an eight-stranded β-sandwich similar to a jelly-roll β-
barrel. The remaining C-terminus of furin, including the transmembrane domain, was predicted 
to consist of unstructured regions. Based on the interactions of the catalytic domain and the P 
domain, the latter was proposed to exert a stabilising function by shielding the catalytic domain 
from the bulk solvent, potentially preventing aggregation.  
The active site of furin resembles a crevice with the catalytic triad Ser368-His194-Asp153 
arranged in its centre (Figure 7B). The preference for the stringent consensus cleavage 
sequence R-X-K/R-R↓ of furin was elucidated on the basis of the covalently bound inhibitor 
CMK that harbours the tetrapeptide RVKR. The P1-Arg side chain spreads into the S1 pocket 
that would fit any other side chain, including that of lysine, less well due to its specific 
structure. The charges and the geometry of the S2 pocket on the other hand benefit a P2-Lys 
side chain, but would also allow an Arg side chain. The P3-Val side chain points into the bulk 
solvent, thus explaining the relative lack of amino acid preference. The cleft that 
accommodates the P4 residue favours an Arg or to a lesser extent a Lys side chain, but is not 
exclusive for those two residues. Therefore, a short P4 residue can be compensated for by a 
favourable P6 residue whose side chain might extend into the S4 pocket, as it is the case with 
the second autocatalytic cleavage site RGVTKR75↓ within the prosegment. 
In conclusion, this report confirms previous hypotheses and explains the preference for 
multiple basic residues in the cleavage sequence based on electrostatic interactions between 
the negatively charged catalytic domain and the substrate (van de Ven, Voorberg et al. 1990; 
Siezen, Creemers et al. 1994). Further structural investigations comparing the crystal 
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structures of mouse furin (Henrich, Cameron et al. 2003) and Kex2, both bound to covalent 
inhibitors, showed the similarities of the catalytic domains, both in overall fold and topology. 
These comparisons further explained, based on structural differences, the stronger basic 
amino acid preferences in P2 and P4 for Kex2 and furin, respectively (Holyoak, Kettner et al. 
2004; Rockwell and Thorner 2004). Crystallisation of human furin in complex with noncovalent 
inhibitors highlighted the high overall structural similarities of the mouse and human catalytic 
and P domains, and supports previously reported amino acid preferences (Dahms, Hardes et 
al. 2014). 
 
Figure 7 Three dimensional structure of the CMK-inhibited mouse furin 
ectodomain. 
A) Stereo ribbon plot of soluble furin. The spherical catalytic domain (amino acids 110-
445) contains two calcium ion binding sites (Ca1 and Ca2) and has a CMK molecule 
bound in its active site. The P domain (amino acids 446-573) is of barrel-like shape. B) 
Detailed view of the active site. The inhibitor CMK (blue stick model) is covalently 
bound via its hemiketal methyl group to the Oγ of Ser368. The three residues of the 
catalytic triad, Ser368, His194 and Asp153, are depicted in green.  
PDB entry: 1P8J, pictures prepared with the programme PyMOL (Schrodinger 2015).  
 
Calcium and pH dependence  
The calcium ion dependence of furin for furin substrate processing has been shown in 
vitro (Bresnahan, Leduc et al. 1990; Molloy, Bresnahan et al. 1992; Stieneke-Grober, Vey et 
al. 1992). Furthermore, autocatalytic activation of furin is dependent on the presence of 
calcium ions, whereby maximal activity appears to require a millimolar range calcium 
concentration (Vey, Schafer et al. 1994). This calcium dependence was explained by the 
crystal structure of mouse furin that showed that the calcium ion in the second binding site, 
Ca2, seems to stabilise the S1 pocket, thereby determining the preference for Arg in P1 
(Henrich, Cameron et al. 2003). Further structural studies confirmed Ca2 to be essential for P1 
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specificity and pointed out that furin contains no K+ binding sites (Than, Henrich et al. 2005). 
Crystallisation of the catalytic and P domains of human furin indicated the presence of a third 
calcium binding site, as well as a sodium binding site, however functional studies are elusive 
so far (Dahms, Hardes et al. 2014). 
The pH dependence of furin has been described mostly for the two consecutive 
cleavage steps and removal of the furin prosegment. Anderson et al. were the first to 
investigate in more detail the second cleavage at RGVTKR75↓ that occurs in the mildly acidic 
and calcium containing environment of the TGN (Anderson, VanSlyke et al. 1997). They 
determined the pH optimum to be 6.0 and hypothesised that binding of two calcium ions in the 
proposed pockets is required for secondary cleavage of the prosegment. Nuclear magnetic 
resonance (NMR) studies a few years later showed that the pH most likely influences the 
conformational stability of the prosegment, thus the prosegment unfolds under acidic 
conditions leading to exposure of the secondary cleavage site (Bhattacharjya, Xu et al. 2001). 
Conserved His69, which directly precedes the second internal cleavage site in the prosegment, 
was finally described to be an internal pH sensor (Feliciangeli, Thomas et al. 2006; 
Williamson, Elferich et al. 2013). Unprotonated His69 in the ER stabilises a hydrophobic pocket 
required for primary cleavage at Arg107, whereby protonation of His69 in the TGN leads to 
disruption of this pocket and exposure of the cleavage site at Arg75. Histidine protonation as a 
reason for furin prosegment unfolding was further confirmed by Dillon et al. who compared the 
pH dependence of the prosegments of furin and PC1/3 and attributed the higher pH optimum 
of furin to the 2-fold higher overall histidine content of the prosegment (Dillon, Williamson et al. 
2012). Furthermore, His69 in PC1/3 appears to have an acid-shifted pKa (acid dissociation 
constant) compared to furin, thus explaining the lower pH optimum (pH~5.5) of PC1/3 
(Elferich, Williamson et al. 2015). 
 
Furin knockout models and the role of furin in embryogenesis 
As for most PCs, the physiological role of furin has been deduced from the use of 
knockout mice (reviewed in (Scamuffa, Calvo et al. 2006)). Zheng et al. investigated the 
expression pattern of furin and observed that it changes throughout rat development (Zheng, 
Streck et al. 1994). Between E7 and E10, furin was found to be expressed in the endoderm 
and mesoderm, whereby increased levels were observed in heart and liver primordia around 
E10. At later stages, furin appears to be broadly expressed in the peripheral tissues. The 
complete absence of furin in PC null mice leads to lethality in early embryonic stages, which is 
also seen for the phenotype of PC5 and SKI-1 null mice. Thus, embryos with lack of furin died 
between E10.5 and E11.5, presumably based on haemodynamic insufficiencies, ventral 
closure defects and failed axial rotation (Roebroek, Umans et al. 1998). An endothelial cell 
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specific knockout of furin in mice led to ventricular septal defects and/or valve malformations, 
was associated with disrupted endothelin-1 and bone morphogenetic protein 4 (BMP4) 
maturation in lung endothel cells, resulting in death shortly after birth (Kim, Essalmani et al. 
2012). TGFβ is another furin substrate hypothesised to play a role in the embryonic 
cardiovascular system (Scamuffa, Calvo et al. 2006), as embryos deficient in TGFβ showed a 
similar phenotype to furin deficient embryos (reviewed in (Dunker and Krieglstein 2000). 
 
Visualisation of furin-like activity 
In order to gain a better understanding of the role of furin activity in embryogenesis or 
processes like tumour growth and migration it would be of great advantage to be able to 
visualise furin activity in a non-invasive manner. Furthermore, such methods would create the 
unique opportunity to directly assess efficacy of inhibitory drugs in vivo. One of the few 
reported approaches described the use of bioluminogenic furin probes based on tetrapeptides 
representing optimal furin cleavage motifs coupled to D-aminoluciferin, an analogue of D-
luciferin (Dragulescu-Andrasi, Liang et al. 2009). Removal of the peptide group upon 
processing through furin generates free D-aminoluciferin, leading to bioluminescent signal 
emission in the presence of firefly luciferase. It was shown that these probes are cell 
permeable in vitro, lead to furin activity-dependent bioluminescence in breast cancer cells in 
vitro and could be used to visualise furin activity in breast cancer xenografts in living mice 
(Dragulescu-Andrasi, Liang et al. 2009).  
Another group used the well known Förster resonance energy transfer (FRET) 
phenomenon to create probes that consist of two fluorophores joined by the PC recognition 
motif RQRR (Mesnard and Constam 2010). As cleavage of the non-cell permeable probes 
leads to proportional loss of FRET, they were able to follow the activity pattern of cell surface 
bound PCs during mouse embryo development. In contrast to the above described 
bioluminescence or fluorescence based imaging approaches, which suffer from strong 
scattering of light in deep biological tissues, photoacoustic imaging might provide higher 
sensitivity and simplicity in target validation in deep tissues. Thus, photoacoustic imaging, a 
combination of optical and ultrasound imaging technologies, offers high spatial resolution at a 
depth of several centimetres and is therefore highly suitable for biomedical imaging. In 2012, 
Liang et al. described a furin activity-driven condensation reaction between 1,2-aminothiol and 
2-cyanobenzothiazole resulting in the formation of nanostructures, which was proposed for 
imaging of furin activity in cells (Liang, Ren et al. 2010). Dragulescu-Andrasi et al. redesigned 
the probe in order to generate an oligomerisable probe that accumulates at the target site 
upon furin processing and serves as an exogenous contrast agent for photoacoustic imaging 
(Dragulescu-Andrasi, Kothapalli et al. 2013). 
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Despite their great potential for visualisation of furin overexpressing tumours in 
patients, all described imaging probes appear to be rather furin-like PC specific than 
exclusively furin specific, as they rely on cleavage of tetrapeptide sequences which might be 
recognised by several furin-like PCs.  
5.2. Furin and cancer 
Tumourigenesis requires the activity of numerous proteins that support the malignant 
phenotype by maintaining tumour-related capabilities such as sustained proliferation, evasion 
of apoptosis, angiogenesis or activation of invasive and metastatic processes. Many of those 
cancer-related proteins are overexpressed and have to be proteolytically processed. 
Therefore, high activity levels of involved proteases likely favours cancer progression and 
metastasis. Accordingly, high expression of PCs has been found in various human tumours 
and tumour cell lines (see also section 4.5.).  
 
Furin expression is associated with high aggressiveness in several carcinomas 
High furin expression levels have been found in lung tumours and lung cancer cells. As 
furin expression appears to be elevated in non-small cell lung carcinomas (NSCLCs) it was 
proposed as a marker to discriminate between NSCLCs and small cell lung carcinomas 
(SCLCs)(Schalken, Roebroek et al. 1987). Low levels of furin mRNA in SCLCs were 
confirmed in a study by Mbikay et al. (Mbikay, Sirois et al. 1997). However, both studies are 
limited to expression levels and do not comment on the functional relationship between furin 
expression and the malignancy state of lung cancer types. Nevertheless, a recent study 
employing the inhibitor α1-PDX showed that inhibition of furin-like PCs might reduce 
proliferation and migration of the lung carcinoma cell line A549 (Ma, Fan et al. 2014). 
Apart from lung carcinomas furin expression has also been associated with other 
carcinomas, whereby functional investigations remain elusive in most cases. Thus, furin and 
VEGF-C expression were examined in squamous cell carcinoma and it was proposed that 
furin might be a marker for tumour progression and potentially cleaves VEGF-C, leading to 
higher microvessel density (Lopez de Cicco, Watson et al. 2004). High levels of furin have 
also been found in ovarian cancer specimens and cell lines, whereby furin expression 
appeared to be linked to a poor outcome in patients (Page, Klein-Szanto et al. 2007). 
Furthermore, furin expression was confirmed in a small set of gastric cancer tissues and cell 
lines, where it was proposed to regulate maturation of the parathyroid hormone-related 
peptide (Nakajima, Konda et al. 2002). Overexpression of furin in a gastric cancer cell line 
further suggested a possible role of furin in gastric cancer growth. 
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In other cancer types, furin expression and activity have been studied in more detail. 
Cheng et al. investigated the expression of six PCs in breast cancer samples and stated that 
PC1/3, furin, PACE4 and PC7 mRNA levels are detected in most cases (Cheng, Watson et al. 
1997).  Furthermore, furin expression seemed to be confined to tumour cells as the 
surrounding tissue was furin negative. A follow-up study could further show that exogenous 
overexpression of either PC1/3 or furin not only increases the proliferation rate in the breast 
cancer cell line MCF7, but also conveys a certain level of anti-oestrogen resistance upon 
treatment with tamoxifen (Cheng, Xu et al. 2001). Additionally, Lapierre et al. used exogenous 
expression of furin and PACE4 prosegments to decipher their role in the highly malignant 
MDA-MB-231 breast cancer cell line and found that both PCs seem to exert opposing roles 
(Lapierre, Siegfried et al. 2007). Furin activity positively correlated with the aggressive 
phenotype and inhibition led to reduced cell motility, migration and invasion, whereas PACE4 
inhibition even enhanced these features. This report shows that PCs may exert distinct 
functions in the same cancer or even act in an opposing manner. Thus, it would be of 
importance to assess expression levels of all related PCs upon investigation of a distinct PC in 
a certain tumour type.    
Head and neck tumours represent an additional group of tumours that are associated 
with elevated levels of furin. Thus, increased furin mRNA and protein levels correlate with 
increased levels of maturated MT1-MMP and aggressiveness of head and neck squamous cell 
carcinomas (HNSCCs), as measured by presence of metastases in patients (Bassi, Mahloogi 
et al. 2001). Further investigations showed that inhibition of furin-like PCs through expression 
of α1-PDX reduces TGFβ, MT1-MMP and MMP2 processing and decreases the invasive 
potential of invasive HNSCC cell lines in vitro as well as in vivo. α1-PDX expression also 
clearly reduced tumourigenicity upon subcutaneous inoculation of modified cells (Bassi, Lopez 
De Cicco et al. 2001). Accordingly, overexpression of furin in HNSCC cell lines with moderate 
invasive potential increased MT1-MMP processing led to earlier tumour growth and enhanced 
invasiveness in vitro and in vivo (Bassi, Mahloogi et al. 2003). Hence, high furin activity in 
HNSCC cells favours metastatic and invasive potential most likely by mediating sustained 
processing and high activity of matrix degrading proteases like MT1-MMP and indirectly 
MMP2.  
 
Furin substrates are implied in tumour progression and metastasis 
Many of the proteins that were described to require processing by furin or furin-like 
PCs are involved in tumour progression and/or metastasis. As most of them have already 
been described in section 4.5, this section will focus on a few selected furin substrates and 
their implication in tumour formation and aggressiveness (Figure 8). 
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Many growth factors that have been implicated in sustained proliferation of tumour 
cells are activated by furin processing. These include PDGF-A and -B as well as TGFβ 
(Dubois, Laprise et al. 1995; Siegfried, Khatib et al. 2003; Siegfried, Basak et al. 2005). 
Furthermore, furin activity is required for active IGF signalling, as it matures the receptor 
tyrosine kinase IGF1R as well as its natural ligands IGF1 and 2 (Duguay, Lai-Zhang et al. 
1995; Duguay, Jin et al. 1998; Khatib, Siegfried et al. 2001). Besides supporting proliferation, 
aberrant IGF signalling also favours anti-apoptotic effects, mediated by MAPK or PI3 kinase 
pathways, respectively (Gooch, Van Den Berg et al. 1999).  
Furthermore, efficient tumour growth requires sufficient supply of oxygen and nutrients, 
highlighting the importance of adequate vascularisation. It could be shown that VEGF-C as 
well as VEGF-D have to be fully processed by furin or related PCs to stimulate VEGF 
signalling and induce angiogenesis and lymphangiogenesis (Millauer, Wizigmann-Voos et al. 
1993; Joukov, Sorsa et al. 1997; McColl, Paavonen et al. 2007). Additionally, only mature 
VEGF-C appears to be able to initiate tumourigenesis in mice (Siegfried, Basak et al. 2003). 
 
Figure 8 Substrates of furin and their involvement in tumour progression. 
Schematic representation of some cancer-related proteins that are cleaved by furin 
and furin-like PCs and their relevance in important cancer-related processes. ADAM, a 
disintegrin and metalloprotease; IGF1R, insulin-like growth factor 1 receptor; MT1-
MMP, membrane type 1 matrix metalloprotease; PDGF, platelet derived growth factor; 
TGFβ, transforming growth factor β; VEGF-C, vascular endothelial growth factor C. 
Modified from (Bassi, Fu et al. 2005). 
 
 . Some of the described substrates exert very diverse functions related to cancer 
progression. For instance, PDGF signalling is not only a potent mitogen, autocrine PDGF 
signalling equally promotes metastatic potential of breast cancer and pancreatic cancer cells, 
(Jechlinger, Sommer et al. 2006; Weissmueller, Manchado et al. 2014). In addition, PDGF-BB 
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appears to induce endothelial cell proliferation, migration and sprouting through paracrine 
stimulation of its receptor PDGFR-β, thereby favouring tumour angiogenesis (Xue, Lim et al. 
2012).  
Several other furin substrates could be shown to play a central role in dissemination, 
motility and metastasis formation of cancer cells. As mentioned previously, furin catalytically 
activates MT1-MMP (Maquoi, Noel et al. 1998; Yana and Weiss 2000; Remacle, Rozanov et 
al. 2006), which has been linked to progression of head and neck squamous cell carcinomas 
(Bassi, Lopez De Cicco et al. 2001; Bassi, Mahloogi et al. 2001). MT1-MMP in turn is the main 
enzyme to process pro-MMP2 on the cell surface (Sato, Takino et al. 1994; Ohuchi, Imai et al. 
1997), resulting in an intermediate 64 kDa form that requires further intermolecular 
autocleavage to yield fully active 62 kDa MMP2, which is also called gelatinase A, a major 
mediator of basement membrane degradation (Atkinson, Crabbe et al. 1995; Strongin, Collier 
et al. 1995). Besides the well studied cell surface activation of MMP2, intracellular cleavage of 
the precursor protein has been reported (Lee, Akers et al. 1997) and further investigations 
suggested that intracellular processing of pro-MMP2 occurs within the TGN, most likely by 
furin (Cao, Rehemtulla et al. 2005). However, generated MMP2 appears to be cleaved only 
once, resulting in secretion of inactive MMP2. Cao et al. hypothesised that this negative 
regulation of pro-MMP2 activity by furin might provide a paradoxical regulatory mechanism to 
control MT1-MMP-mediated activation of pro-MMP2 (Cao, Rehemtulla et al. 2005). As around 
40% of all MMPs contain a conserved RXKR motif including the membrane type MMPs MT5-
MMP and MT2-MMP (Takino, Sato et al. 1995; Pei 1999), it is not surprising that furin activity 
appears to mediate cleavage of MT3-MMP within the TGN (Kang, Nagase et al. 2002) and 
shedding of MT5-MMP (Wang and Pei 2001).  
Further metalloproteases involved in ECM degradation are synthesised as inactive 
zymogens and appear to require cleavage through furin or furin-like PCs in order to gain their 
full activity. These comprise for example the adamalysin metalloproteases ADAM12 and 
ADAM17, which is also known as tumour necrosis factor α convertase (TACE) (Loechel, Gilpin 
et al. 1998; Schlöndorff, Becherer et al. 2000), and the secreted ADAMTS-1 (Kuno, Terashima 
et al. 1999). 
5.3. Inhibitors of furin 
Due to the implication of furin substrates in many pathological conditions such as 
Alzheimer’s disease, cancer or bacterial and viral infections (see sections 4.4 and 5.2.), the 
development of specific furin inhibitors would be of potential benefit for treatment of patients. 
Despite the variety of reported furin inhibitors only a handful of strategies or compounds 
appear to be furin specific. Hence, most inhibitors like α1-PDX, CMK or peptides based on 
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poly-basic amino acid motifs (see section 4.6.) act to varying degrees on all furin-like PCs and 
have to be classified as pan-PC inhibitors.  
 
Prosegment of furin 
The prosegment of furin represents the most important endogenous inhibitor of this 
enzyme. However, as it also inhibits other furin-like PCs to a certain degree, its specificity 
appears to be limited (see also section 4.6.). Nevertheless, ectopic expression of the 
prosegment has been used in experimental setups to determine the role of furin in cancer 
progression. For instance, López de Cicco et al. could show that ectopic expression of furin’s 
prosegment in HNSCC cell lines reduces substrate processing, proliferation and the invasive 
capability of the cells (Lopez de Cicco, Bassi et al. 2005). Furthermore, introduction of the 
prosegment of furin in breast cancer and colon cancer cell lines efficiently diminished PDGF-A 
and IGF1R processing, decreasing cell survival in vitro and inhibited tumour growth in vivo 
(Scamuffa, Sfaxi et al. 2014).  
 
Endogenous inhibitors of furin 
In addition to the prosegment, other endogenous inhibitors have been reported. The 
albumin-type serpin proteinase inhibitor 8 was the first naturally occurring furin inhibitor 
described.  It forms a stable complex with soluble furin and direct interaction was shown in 
platelets by co-immunoprecipitation (Dahlen, Jean et al. 1998; Leblond, Laprise et al. 2006). 
Another endogenous serpin that blocks furin activity is the inter-α-inhibitor protein, whose 
application appears to exert a certain protective function against anthrax infection in mice 
(Opal, Artenstein et al. 2005). Direct interaction of the serpin nexin-1 and furin in endothelial 
cells blocks ADAM17-mediated shedding of endothelial protein C receptor (Boulaftali, Francois 
et al. 2013). Furthermore, plasminogen activator inhibitor 1 seems to inhibit intra-Golgi furin 
activity by forming a stable complex, thus preventing furin-mediated maturation of the insulin 
receptor and ADAM17 (Bernot, Stalin et al. 2011). Nevertheless, none of the studies 
commented on the specificity of the proposed furin inhibitors, thus requiring follow up 
investigations to examine the inhibitory efficacy on other furin-like PCs.  
 
Furin specific nanobodies  
In 2012, Zhu et al. proposed the use of furin-specific nanobodies for the therapeutic 
intervention in pathological conditions that are dependent on furin activity (Declercq, 
Meulemans et al. 2012). These camelide antibodies were raised against catalytically active 
furin and appear to inhibit furin but not other PCs in a non-competitive manner. The 
nanobodies inhibited cleavage of the known furin substrates TGFβ, glypican 3 and diphtheria 
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toxin, and protected HEK293 cells from cytotoxicity caused by diphtheria toxin. Thus, 
nanobodies represent the first generation of highly specific inhibitors of furin.  
5.4. Furin and rhabdomyosarcoma 
The role of furin activity in RMS tumourigenesis and progression has not been 
investigated in detail, yet. Earlier studies in our laboratory indicated that furin represents the 
target receptor of the RMS homing peptide RMS-P3 with the minimal binding motif RTRR 
(Hajdin, D'Alessandro et al. 2010). Furthermore, microarray profiles of PCs in RMS suggested 
that furin, in contrast to PC1/3, PC2, PACE4 and PC6, has a consistently high expression in 
RMS cell lines and biopsies. Despite the lack of a direct link between furin activity and RMS, 
many known furin substrates are overexpressed in RMS and have been associated with RMS 
progression. 
Some of the most prominent examples of furin substrates involved in RMS are 
components of the IGF signalling pathway. Thus, IGF1R and its ligand IGF1 are not only both 
processed by furin-like PCs (Duguay, Lai-Zhang et al. 1995; Duguay, Milewski et al. 1997; 
Khatib, Siegfried et al. 2001), elevated levels of IGF1R have also been correlated with poorer 
outcome in RMS patients (Blandford, Barr et al. 2006). Similarly, increased levels of the PDGF 
receptor were associated with a decreased survival rate of patients (Blandford, Barr et al. 
2006), indicating a potential importance of furin-mediated PDGF-A and PDGF-B processing 
(Siegfried, Khatib et al. 2003; Siegfried, Basak et al. 2005). Additionally, TGFβ1 expression 
appears to be higher in RMS compared to normal skeletal muscle cells and silencing of 
TGFβ1 resulted in differentiation of RMS cells (Wang, Guo et al. 2010). Hence, cleavage and 
activation of TGFβ1 through furin (Dubois, Laprise et al. 1995) might favour sustained 
proliferation of RMS cells. RMS cells were also shown to express various matrix 
metalloproteases such as MT1-MMP and MMP2, which are implied in dissemination and 
metastasis (Onisto, Slongo et al. 2005). Furthermore, autocrine VEGF signalling was 
hypothesised to favour RMS growth (Gee, Tsuchida et al. 2005). 
Thus, the broad implication of furin activity in processing and activation of proteins 
related to RMS progression encouraged us to study in detail the biological role of furin in RMS.    
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6.   Subject of investigation 
Rhabdomyosarcoma is the most common paediatric soft tissue sarcoma. Despite 
advances in risk stratification and therapy options, 5-year overall survival rates are still in need 
of improvement, particularly for patients with metastatic disease. Furthermore, conventional 
multimodal treatment strategies often result in acute and long term side effects. Hence, 
identification and characterisation of novel targets is key to the establishment of 
complementing treatment options. 
Therefore, the main aim of this thesis was to investigate the role of the proprotein 
convertase furin in RMS maintenance and progression. Since furin proteolytically activates 
many proteins implicated in RMS-associated signalling pathways, we hypothesised that furin 
activity is important for proliferation, survival and metastasis of RMS cells.  
Firstly, we examined the impact of furin silencing or inhibition on furin substrate 
processing, migration and invasion in RMS cells in vitro and studied RMS tumour growth upon 
modulation of furin activity in vivo. 
Secondly, we established a RMS cell model of inducible furin silencing that we further 
employed to investigate cell viability and apoptosis induction in aRMS cells in vitro and tumour 
growth of Rh30 and Rh4 xenografts in vivo. We further analysed furin protein expression in 
aRMS and eRMS biopsies on a tissue microarray.  
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1. Introduction 
Vast varieties of proteins are synthesized as inactive precursor proteins and require 
limited proteolysis to be converted into bioactive proteins and peptides. Proproteins are 
usually cleaved at the general consensus motif R/K-Xn-R/K↓, where n=0, 2, 4 or 6 and X rarely 
Cys or Pro (Molloy, Bresnahan et al. 1992). Seven mammalian proprotein convertases (PCs) 
cleaving substrates at dibasic motifs have been described: PC1/3, PC2, furin, PC4, PC5, 
PACE4 and PC7. In the secretory pathway, PCs mediate the tissue-specific endoproteolytic 
activation of precursor proteins, including hormones, neuropeptides, growth factors and their 
receptors, adhesion molecules, bacterial toxins and viral glycoproteins (Seidah and Prat 
2012). Consequently, deregulated activity of PCs has been associated with pathological 
conditions like Alzheimer’s disease (Bennett, Denis et al. 2000), endocrinopathies (Jackson, 
Creemers et al. 1997) or cancer (Khatib, Siegfried et al. 2002; Bassi, Fu et al. 2005). 
Increased PC activity correlates with higher aggressiveness of diverse cancer types like 
prostate cancer, colon carcinoma or small cell lung carcinoma (Creemers, Roebroek et al. 
1992; Khatib, Siegfried et al. 2001; D'Anjou, Routhier et al. 2011).  
Furin was the first described PC and is active within the constitutive secretory pathway 
(Molloy, Thomas et al. 1994). This calcium-dependent protease cleaves different proteins 
implicated in cancer progression and metastasis such as the insulin-like growth factor receptor 
1 (IGF1R) (Khatib, Siegfried et al. 2001), the growth factors vascular endothelial growth factor 
C (VEGF-C)  and platelet derived growth factor (PDGF) (Siegfried, Basak et al. 2005) and 
membrane-type 1 matrix metalloprotease 1 (MT1-MMP) (Yana and Weiss 2000; Remacle, 
Rozanov et al. 2006). Furthermore, elevated levels of furin are found in head and neck cancer, 
breast, lung and colon cancers (Schalken, Roebroek et al. 1987; Cheng, Watson et al. 1997; 
Bassi, Mahloogi et al. 2001; Scamuffa, Siegfried et al. 2008).  
In a previous study, we identified cell surface furin as a potential receptor for peptides that 
specifically homed to rhabdomyosarcoma (RMS) cells in vitro and in vivo (Hajdin, 
D'Alessandro et al. 2010). RMS represents with around 55% of all cases the most common 
soft tissue sarcoma in children and adolescents (Kaatsch 2010). Based on histology, 
paediatric RMS are grouped into two main subtypes: embryonal RMS (eRMS) and alveolar 
RMS (aRMS). eRMS occurs in around 60-70% of all patients and is associated with a rather 
good prognosis, whereas 20% of the patients present with aRMS, having a 5-year overall 
survival of only 20-30%  (Van Gaal, Van Der Graaf et al. 2012). Prognosis for patients with 
metastasis at time of diagnosis is particularly poor with a 5-year overall survival rate of less 
than 12% (Van Gaal, Van Der Graaf et al. 2012). Complementing or improved treatment 
strategies are urgently needed and thus many recent efforts have been concentrated on the 
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identification of key pathways that drive RMS progression. In 80% of aRMS, tumour formation 
is driven by expression of the chimeric transcription factor PAX3/7-FOXO1 (Sorensen, Lynch 
et al. 2002; Chen, Stewart et al. 2013; Shern, Chen et al. 2014), which induces expression of 
a specific gene expression signature (Wachtel, Dettling et al. 2004; Davicioni, Finckenstein et 
al. 2006; Williamson, Missiaglia et al. 2010). Many receptor tyrosine kinases are direct targets 
of PAX3/7-FOXO1, including IGF1R, VEGFR and PDGFR (Epstein, Song et al. 1998; Cao, Yu 
et al. 2010), and RMS progression is characterised by aberrant activation of growth factor 
signalling pathways (Crose and Linardic 2011). As furin is involved in the maturation and 
activation of many components of these pathways, we hypothesized that furin activity is 
important for maintenance of the malignant phenotype of RMS cells. Therefore, we assessed 
the expression levels of furin and other PCs in paediatric sarcoma cell lines and generated 
RMS cell lines with modulated furin activity. We subsequently used these cell lines to examine 
tumour growth in vivo and to assess processing of furin substrates, migration, and invasion in 
vitro. Our investigations showed that furin promotes tumour growth as well as migration and 
invasion abilities in RMS by cleaving key proteins involved in RMS cell growth, tumour 
vascularisation, and cell motility and invasiveness. Therefore, we propose the PC furin as new 
therapeutic target for treatment of RMS.  
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2. Material and methods 
Ethics Statement 
All animal experiments were approved and monitored by the veterinary office of the 
Canton of Zurich according to the Swiss Federal Law.  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Data are expressed as mean 
± standard deviation (SD). Statistical significance was tested with unpaired two-tailed 
Student’s t-tests, or for multiple comparison analysis of variance (ANOVA). The differences 
were considered to be significant if p<0.05.  
 
Cell lines and cell culture 
Osteosarcoma cell lines SAOS, LM5, HOS, 143B, MG63, M8, HU09 and M132 were 
kindly provided by Roman Muff (University Hospital Balgrist, Zurich, Switzerland). Ewing 
sarcoma cell lines TC71, A673, RD-ES, SK-ES and SKNMC, as well as the RMS cell line 
RUCH-2, were kindly provided by Beat Schäfer (University Children’s Hospital Zurich, Zurich, 
Switzerland). Other RMS cell lines were kindly provided by following sources: Rh3 and Rh5 by 
Susan Ragsdale (St. Jude Children’s Research Hospital, Memphis, TN, USA); RD, Rh36, 
Rh18, Rh4 and Rh41 by Peter Houghton (The Research Institute at Nationwide Children’s 
Hospital, Columbus, OH, USA); TTC442 and Birch by Timothy Triche (Children’s Hospital Los 
Angeles, Los Angeles, CA, USA); NRS-1 (RIKEN Cell Bank); RMS and SCMS-RMZ by Janet 
Shipley (The Institute of Cancer Research, London, UK); Rh28 by Corinne Linardic (Duke 
University School of Medicine, Durham, NC, USA); RMS13 by Roland Kappler (LMU, Munich, 
Germany); CW9019 by Soledad Gallego (Hospital Universitari Vall d’Hebron, Barcelona, 
Spain); KFR by Jindrich Cinatl (Frankfurter Stiftung für krebskranke Kinder, Frankfurt, 
Germany); RC2 by Pier-Luigi Lollini (University of Bologna, Bologna, Italy) and RhJT by Scott 
Diede (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Rh30 cells were 
purchased from ATCC (LGC Promochem, Molsheim Cedex, France). All cells were 
maintained under proliferating conditions in high glucose DMEM medium (Sigma-Aldrich, 
Buchs, Switzerland) supplemented with 10% fetal calf serum (Bioconcept, Switzerland) in 5% 
CO2 at 37 °C.  
 
Plasmids and Transfections 
pcDNA3.1(+) vectors encoding the full length furin (fur) (Bassi, Mahloogi et al. 2003) or 
α1-AT Portland (pdx), were generous gifts of Andres JP Klein-Szanto (Fox Chase Cancer 
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Center, Philadelphia, PA). For stable transfections, 2.5-5x105 RD, Rh4 or Rh30 cells were 
transfected with 2 µg DNA according to the jetPRIME™ short protocol (Polyplus Transfection, 
Illkirch, France). Selection with 1 mg/ml G418 (Promega, Wallisellen, Switzerland) was started 
48h post transfection and was continued for 14 days. RMS cells transfected with empty 
pcDNA3.1(+) vector were used as control in qRT-PCR experiments. 
 
Transient and stable silencing of furin 
To transiently silence furin, 10 nM siRNA (Silencer Select, Ambion, Austin, Texas) were 
reverse transfected into RD cells using the transfection reagent INTERFERin (Polyplus 
Transfection, Illkirch, France) according to manufacturer’s instructions. Following siRNAs were 
used: scrambled (scr, ID: AM4637), siFurin1 and siFurin2 (siFur1, ID: s9987; siFur2, ID: 
s9988). For stable silencing of furin in RD, Rh4 and Rh30 cells, mission shRNA lentiviral 
particles (Sigma-Aldrich) based on a pLKO.1 plasmid backbone were used. Lentiviral particles 
of five clones (SHCLNV-NM 002569 Human, TRCN0000075238-42) targeting different 
sequences of furin RNA or lentiviral particles non-target shRNA (SHC002V) were added at an 
MOI of 5 to RMS cells for 24h. Selection was started on day 5 with 2 µg/ml of puromycin 
(Invitrogen, Basel, Switzerland). Non-target shRNA RMS cells were used as control in qRT-
PCR experiments. 
 
Animal models 
To study in vivo growth, 5x106 RMS cells in 150 μl of PBS were injected s.c. into 
NOD/Scid IL2rg-/- mice (Charles River) at 5-6 weeks of age, under anaesthesia induced by 
intraperitoneal injection of 100 mg/kg ketamine (Ketalar, Parke-Davis, Morris Plains, NJ) and 
16 mg/kg xylazine (Rompun, Bayer HealthCare, Leverkusen, Germany). For measurement of 
the tumour size, both diameters (d) of the spherical tumours were measured with a caliper and 
the tumour volume was calculated using the formula V = (4/3)πr3, whereby r = ((d1+d2)/4). 
Mice were sacrificed when a tumour size of 1000 mm3 was reached. Mice were perfused with 
PBS after terminal anaesthesia with 420 mg/kg pentobarbital (Esconarkon; Streuli Pharma, 
Uznach, Switzerland). Tumours were dissected, fixed for 24 hours in 4% PFA (Thermo 
Scientific, Switzerland) and embedded in paraffin, or stabilised in 30% sucrose (Sigma-Aldrich, 
Basel, Switzerland) and frozen in O.C.T embedding medium (Leica Microsystems, Heerbrugg, 
Switzerland), as indicated.  
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Immunofluorescence  
Immunofluorescence to detect angiogenic blood vessels in RMS xenograft tumours was 
performed on 5 µm fresh frozen section from O.C.T. embedded samples. Sections were 
washed in TBS/0.2% Tween-20 for 15 min and stained with CD31 antibody (550274, BD 
Pharmingen, Allschwil, Switzerland) diluted 1:100 in antibody diluent solution (Zytomed 
Systems GmbH, LabForce, Nunningen, Switzerland). Secondary Alexa Fluor 594-labelled 
goat anti-rat IgG was used for detection (A-11007, Invitrogen). Sections were washed twice 
with PBS and mounted with Vectashield Mounting medium containing DAPI (Reactolab SA, 
Servion, Switzerland). 
 
Immunohistochemistry 
Immunohistochemistry of PFA-fixed tumours was performed by Sophistolab (Muttenz, 
Switzerland) on an automated Leica BondMax system using Bond Polymer Refine Detection 
(DS9800, Leica Microsystems Newcastle, UK) including all buffer-solutions from Leica, 
processed according to the manufacturer’s instructions. Paraffin slides were dewaxed, 
pretreated with ER-Solution 2, and incubated with the following antibodies: polyclonal rabbit 
anti-furin (ab28547, Abcam, Cambridge, UK) used at a dilution of 1:3000 after pretreatment for 
10 min at 95 °C; anti-CD31 (ab28364, Abcam) used at a dilution of 1:100 after antigen 
pretreatment for 20 min at 100 °C. 
 
Quantitative RT-PCR 
Total RNA was extracted from RMS cells or tumour tissue using the RNeasy Kit 
(Qiagen, Hombrechtikon, Switzerland) including a DNase treatment step. 1 μg total RNA was 
reverse-transcribed with random primers using the Omniscript Reverse Transcription Kit 
(Qiagen). qRT-PCR detection of furin, α1-PDX and the house keeping gene GAPDH was 
performed with assay-on-demand Hs00965485_g1, Hs01097800_m1 or Hs99999905_m1, 
respectively (Applied Biosystems, Basel, Switzerland) and normalized to GAPDH.  
 
Immunoblot 
RMS cells were lysed in denaturing buffer (50 mM TrisHCl, 0.1% Triton X-100, 1 mM 
EDTA, 1 mM EGTA, 50 mM NaF, 5 mM Na4P2O7, 10 mM C3H7Na2O6P, 1 mM sodium 
orthovanadate) supplemented with 1 mM PMSF (phenylmethylsulfonyl fluoride) and Roche 
Complete Protease inhibitor (Roche, Rotkreuz, Switzerland). Cell lysates were centrifuged for 
10 min at 10’000 rpm, the supernatant was collected and protein concentrations were 
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determined in a Bradford assay (Bio-Rad laboratories, Reinach, Switzerland). Total cell 
extracts were separated on 4-12% NuPAGE Bis-Tris gels (Invitrogen) and blotted on 
nitrocellulose membranes (0.1 µm; Schleicher & Schuell, Dassel, Germany). Blots were 
blocked with 5% milk in TBS/0.05% Tween-20, incubated with the first antibody overnight at 
4 °C, and with the corresponding HRP-conjugated secondary antibody for 1h at RT. Enhanced 
chemiluminescence detection system SuperSignal West Femto (Pierce, Perbio Science, 
Lausanne, Switzerland) was used for signal detection. The following antibodies were used: 
anti-furin mouse monoclonal MON-152 (ALX-803-017-R100, 1:750, Alexis Corporation, 
Lausen, Switzerland), anti-VEGF-C rabbit polyclonal (sc-25783, 1:200; Santa Cruz, LabForce, 
Switzerland), anti-IGF1Rβ rabbit polyclonal (9750S, 1:1000, Cell Signaling, Bioconcept), anti-
MT1-MMP rabbit polyclonal (NG1726963, 1:750, Millipore), anti-PDGF goat polyclonal (06-
127, 1:500, Millipore), anti-pAkt polyclonal rabbit (9271S, 1:1000, Cell Signaling, Bioconcept) 
and anti-Akt polyclonal rabbit (9272, 1:1000, Cell Signaling, Bioconcept). Mouse anti-β-actin 
(A5316, 1:5000, Sigma-Aldrich) or anti-α-tubulin (T4026, 1:1000, Sigma-Aldrich) were used for 
loading controls. 
 
Furin activity test  
To measure the activity of furin, an immobilised furin assay was performed as described  
previously (Bourne and Grainger 2011). 106 RMS cells were treated with 5x lysis/ reaction 
buffer (500 mM HEPES pH 7.0, 2.5% Triton X-100, 5 mM calcium chloride, 5 mM β-
mercaptoethanol), incubated on ice for 10 min and centrifuged. Black FluoroNunc 96 well 
plates (MaxiSorp surface, Nunc, Thermo Scientific) were coated with goat anti human furin 
antibody (AF1503, R&D Systems) at 10 μg/ml in 50 mM Na2CO3, pH 9.6 (50 μl/ well) for 8h at 
RT, protected from light. After blocking for 1h at RT (0.5% sucrose, 0.5% Tween-20 in PBS), 
cell lysates were plated in triplicates and incubated over night at 4 °C. Wells were washed, 
180 µL 1.1x lysis buffer per well added, and the reaction was started by adding 20 μl/well of 
1 mM furin fluorogenic Boc-RVRR-AMC (ALX-260-040 Alexis, Enzo Life Sciences). 
Fluorescence (ex: 380 nm; em: 460 nm) was measured using a Bio-TEK Multi-Mode 
Microplate Reader (Witec AG, Luzern, Switzerland).  
 
Cell migration  
RMS cells were cultured to 90% confluency in 6-well plates and three separate wounds 
per well were introduced with a 200 μl pipette tip. Six pictures per well were taken at 10x 
magnification at different time points (0, 4, 16, 24 hours), analysed with the program TScratch 
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(Geback, Schulz et al. 2009) and the percentage of closed wound was calculated over the 
time point 0h. 
 
Invadopodia assay 
Invadopodia assays were performed following the manufacturer’s instructions (ECM670, 
Millipore, Zug, Switzerland). For the experiment, 1.2x103 cells were seeded onto FITC-labeled 
gelatin into 8-chamber slides and incubated at 37 °C for 24h or 48h. Cells were fixed with 4% 
formaldehyde for 30 min, washed and stained with a solution of TRITC-phalloidin (2 µg/ml) 
and DAPI (1 µg/ml) in fluorescent staining buffer (PBS with 2% blocking serum and 0.25% 
Triton X-100) for 1h at RT, protected from light. Coverslips were mounted on the slides using 
hard set mounting medium (Reactolab) and pictures were taken at 20x magnification with a 
fluorescence microscope (Axioskop 2 Mot, Zeiss, Feldbach, Switzerland). Image analysis was 
performed using the program ImageJ (Schneider, Rasband et al. 2012). 
 
IGF1 stimulation  
RD cells were transiently transfected with anti-furin siRNA (siFur1 and siFur2) or control 
(scr) siRNA, as described above. After 24h of starvation (DMEM, 0.2% FBS), cells were 
stimulated for 10 min with 50 ng/mL IGF1 (ab73455, Abcam). Cells were washed with ice-cold 
PBS and snap frozen in liquid nitrogen. Whole cell lysates were prepared as described above 
and IGF1Rβ, Akt and phosphorylated Akt were analysed by immunoblotting. 
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3. Results 
Furin is expressed and active in RMS cell lines 
To assess the presence of furin and other PCs in paediatric sarcomas we examined 
the mRNA levels of all nine known PCs in 5 Ewing sarcoma, 8 osteosarcoma and 
20 rhabdomyosarcoma (RMS) cell lines. Overall, RMS cell lines showed higher levels of PCs 
than Ewing sarcoma or osteosarcoma cell lines. Particularly furin, PACE4 and S1P were 
highly expressed, with furin being the PC with the most consistently elevated mRNA level 
(Figure 1A and S1).  
 
 
Figure 1. Furin is highly expressed in rhabdomyosarcoma (RMS) cell lines. A) mRNA 
levels of all nine proprotein convertases (PCs) were determined by qRT-PCR in 5 Ewing 
sarcoma, 8 osteosarcoma and 20 rhabdomyosarcoma (RMS) cell lines. Shown are levels 
relative to GAPDH expression. B) Protein levels of proform and mature furin were assessed by 
immunoblotting in 20 different RMS cell lines. C) Endogenous furin activity of selected RMS cell 
lines: Rh36, RD (eRMS), Rh3, Rh4, Rh30, Rh41 and RMS13 (aRMS). Furin was captured from 
cell lysates on anti-furin antibody coated plates and furin activity was measured by addition of 
the fluorogenic substrate Boc-RVRR-AMC after 6h. Displayed are values normalised to 
background control.  
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Subsequently, we analysed maturation status of furin protein in all RMS cell lines and 
found detectable amounts of mature furin in approximately half of the cell lines tested (Figure 
1B). From those, we chose seven cell lines (two eRMS, five aRMS) and measured activity of 
furin based on a fluorogenic substrate assay. These experiments showed that levels of mature 
furin protein detected by immunoblot correlate with furin activity in vitro, thus indicating that 
immunoblots can be used to predict furin protease activity in vitro (Figure 1C). 
 
Establishment and validation of RMS cells with modulated furin activity 
To investigate the function of furin in RMS, we selected two cell lines, one for each 
RMS subtype, Rh30 (aRMS) and RD (eRMS), and generated stable cell lines with either 
increased furin activity by overexpression of furin (fur), or with decreased furin activity by 
overexpression of the pan-PC inhibitor α1-antitrypsin Portland variant (pdx). In addition, to 
achieve a specific inhibition of furin, we downregulated furin expression with two distinct 
shRNAs targeting furin (shFA and shFE). Furin and pdx overexpression, as well as furin 
silencing by shRNA, were first validated at the mRNA level by qRT-PCR. As expected, RMS 
cells overexpressing furin (RMS fur) showed an increased level of furin expression compared 
to the respective empty vector cells (Figure 2A; Rh30 fur: 5.5-fold, RD fur: 8-fold). De novo 
expression of pdx was confirmed by qRT-PCR (data not shown). Both furin shRNAs, shFA 
and shFE, on the other hand decreased furin expression around 5-fold over control (scr) 
shRNA (Figure 2A).  
Next, furin protein levels were analysed by immunoblotting, confirming overexpression 
of furin in Rh30 fur and RD fur, wild type levels in Rh30 pdx and RD pdx, and decreased 
protein levels for both silenced Rh30 and RD (Figure 2B). In order to verify the correlation 
between the presence of furin protein and its activity, we performed a whole cell lysate specific 
furin activity assay (Bourne and Grainger 2011). Furin overexpression led to a significant 
increase in furin activity (Figure 2C; Rh30 fur: 1.8-fold, RD fur: 2.5-fold). Inhibition of furin 
through pdx expression, or reduction of furin expression by shRNA both efficiently reduced 
furin activity (Figure 2C). In order to exclude possible compensation of lowered furin activity 
through increased expression of related PCs, we analysed mRNA levels of all PC family 
members and did not observe any compensatory increase of other PCs upon loss of functional 
furin (data not shown). Thus, successful modulation of furin activity in the aRMS and eRMS 
cell lines Rh30 and RD could be confirmed at mRNA, protein and activity levels, allowing the 
use of these cell lines for further investigations on the role of furin in RMS progression.  
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Figure 2. Generation and validation of RMS cells with stable modulation of furin. Rh30 
and RD cells were stably transfected with pcDNA3.1(+) full length furin (fur) or α1-AT Portland 
(pdx). shRNA lentiviral particles were employed for stable furin silencing (shFA, shFE). A) Furin 
mRNA levels were quantified by qRT-PCR. Expression levels were normalised to GAPDH and 
to furin expression of the respective control cells (empty vector or scrambled shRNA). B) Levels 
of furin protein in stable Rh30 and RD cell lines were assessed by immunoblotting with 
antibody MON-152. C) Assessment of furin activity in furin modulated cell lines. The results 
were normalised over the respective wt cells on a log10 scale. Data represent three 
independent experiments. Depicted are mean values ± SD. Two-way ANOVA, p<0.05. 
 
Furin activity correlates with tumour growth in vivo 
Having successfully established Rh30 and RD cells with different levels of furin activity, 
we used these cell lines to investigate the impact of furin on RMS tumour growth in vivo. RMS 
tumours were generated from the different RMS cell lines by subcutaneous engraftment in 
NOD/Scid IL2rg-/- mice, and tumour growth was monitored. Wild type aRMS Rh30 cells grew 
faster than wild type eRMS RD cells; Rh30 tumours were followed over a period of 40 days, 
while RD tumours were followed over a period of 20 weeks. No difference in tumour growth 
was observed between Rh30 wt and Rh30 fur, whereas decreased furin activity resulted in a 
clear delay in tumour growth (Figure 3A); Rh30 pdx, Rh30 shFA and Rh30 shFE tumours took 
approximately 1.5-times longer to reach a size of 500 mm3 compared to Rh30 wt (Figure 3A). 
The time period to reach 500 mm3 was 22 days for Rh30 wt and Rh30 fur, 30 days for Rh30 
pdx, and 35 days for Rh30 shFA and Rh30 shFE. The same trend was observed for RD 
tumours, whereby RD tumours with decreased furin activity grew slower than RD wt tumours 
and took almost 30% longer to reach a size of 500 mm3 (Figure 3B; RD wt: 14 weeks, RD pdx: 
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20 weeks). Remarkably, an increase in furin expression led to faster tumour growth in RD 
xenografts; RD fur tumours reached a size of 500 mm3 in 8 weeks compared to 14 weeks 
required by RD wt to reach the same size, which corresponds to a 40% decrease (Figure 3B). 
This acceleration in tumour growth upon furin overexpression was not observed in the more 
aggressive Rh30 tumour model. These results suggest that furin activity supports a rapid 
tumour growth in RMS xenografts. However, in an already very fast growing model, such as 
Rh30, tumour growth cannot be further increased by furin overexpression.  
 
 
Figure 3. Furin activity positively correlates with tumour growth and microvessel 
density. 5 million RMS cells with stable modulation of furin activity were injected s.c. into 
NOD/Scid IL2reg-/- and tumour growth was monitored over time. A) Tumour growth in aRMS 
Rh30 xenografts. Tumours took on average 20-35 days to reach a size of 500 mm3. Each 
group consisted of 6 mice. B) Tumour growth in eRMS RD xenografts. Tumours took on 
average 7-19 weeks to reach a size of 500 mm3. Each group consisted of 10 mice. C) 
Histological analysis of microvessel density in Rh30 xenografts. Tumours were collected when 
they reached a size of 200-400 mm3 and sections were stained for CD31. Microvessel density 
was assessed as vessels per mm2. Right: Representative pictures are shown (magnification: 
10x). Left: The graph shows the quantification averaged per picture. Depicted are mean values 
± SD.  
 
Assessment of furin protein levels by immunoblotting post tumour extraction revealed 
that overexpression of furin in Rh30 fur in vivo could only moderately increase furin levels as 
compared to tumours derived from Rh30 wt cell lines, in contrary to what was observed in vitro 
(Figure 2B and S2). This might be due to an increase of furin protein levels in Rh30 tumours 
grown in vivo. Importantly, immunoblots showed that the silencing of furin in shFA and shFE 
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was maintained in vivo in Rh30 cells derived tumours (Figure S2). Taken together, these 
results support the hypothesis that furin activity contributes to RMS growth in vivo. Moreover, 
furin silencing and inhibition led to delayed tumour onset rather than to a complete tumour 
growth inhibition, hinting at a role of furin in early steps of tumour growth in vivo.        
 
Furin affects microvessel formation in Rh30 xenografts in vivo 
Since we observed a delayed initiation of tumour growth upon reduction of furin 
activity, we were interested to elucidate the involved molecular mechanisms. Therefore, we 
analysed the microvessel density (MVD) on sections from Rh30 tumours by immunostaining 
for CD31. Furin overexpression in Rh30 fur resulted in a slight increase in MVD compared to 
wild type Rh30 (Figure 3C; Rh30 wt: 40 vessels/mm2, Rh30 fur: 50 vessels/mm2). Conversely, 
reduced furin activity in Rh30 cells led to lower MVD (Figure 3C; Rh30 pdx: 25 vessels/mm2, 
Rh30 shFA: 30 vessels/mm2, and Rh30 shFE: and 20 vessels/mm2). These results suggest a 
possible role of furin in the recruitment of new blood vessels at the early stage of RMS tumour 
growth, which, in turn, might account for the differences in tumour growth onset that were 
observed. 
 
Furin activity favours migration and invasion in vitro 
In order to further investigate the contribution of furin to the malignant phenotype of 
RMS cells, we studied migration and invasion abilities of Rh30 and RD cells with distinct furin 
activities in vitro. To investigate cell migration in vitro, we assessed wound closure over a 
timeframe of 24h. Rh30 wt cells migrated in general a little faster than RD wt cells (Figure 4A 
and B). In both cell lines, overexpression of furin led to an accelerated wound closure 
compared to the corresponding wild type cells. This effect was more pronounced in RD fur as 
compared to Rh30 fur. In contrast, inhibition of furin activity through expression of pdx or 
decreased expression by silencing of furin resulted in delayed wound closure for both Rh30 
and RD cells. These results indicate a positive correlation between furin activity and the ability 
of RMS cells to migrate.  
Next, we monitored the effect of furin on the ability of Rh30 and RD cells to invade a 
matrix. This was assessed with an invadopodia assay that allows assessment of cellular 
invasiveness by measuring the degradation of fluorescent gelatin. In addition to the previously 
described stable cell lines with modulated furin, we also used the potent PC inhibitor decanoyl-
RVKR-chloromethylketone (CMK) in this assay. In both RMS cell lines, Rh30 and RD, 
reduction of furin activity, either in stably modified cells (pdx or shRNA) or in wild type cells 
treated with CMK, resulted in diminished matrix degradation (Figure 4C and D). The gain in 
furin activity, on the other hand, led to increased degradation of the matrix in RD fur cells 
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compared to RD wt. Surprisingly, Rh30 fur were less able to degrade gelatin than Rh30 wt, 
although not in a statistically relevant manner. This result is in line with previous in vitro and in 
vivo observations, where we did not observe an impact of furin overexpression in Rh30 on the 
cell phenotype, suggesting that in Rh30 cells furin activity appears to be already at a plateau 
and cannot be further increased. Taken together, these results point at a role of furin activity in 
migration and invasion processes in RMS cells. 
 
 
Figure 4 Migration and invasion of RMS cells is influenced by furin activity. A) Impact of 
furin activity on wound healing. Rh30 and RD cells with stable modulation of furin activity were 
used in a scratch assay. Pictures were taken at 0h, 4h, 16h and 24h, and wound healing was 
assessed over time 0h using the program TScratch. Depicted are mean values ± SD. B) Effect 
of furin activity on RMS cell invasiveness. Rh30 and RD cells (wt, fur, pdx, shFA and shFE) 
were cultured on fluorescently labeled gelatin-coated 8-chamber slides for 24h and 48h, 
respectively. Treatment with 50 µM of the pan-PC inhibitor decanoyl-RVKR-chloromethylketone 
(CMK) was started 16h prior plating of the cells. Immunofluorescent pictures were taken and 
percentage of invasion was calculated based on degradation of fluorescent gelatin using the 
programme ImageJ. Depicted are mean values ± SD. Student t-test, p<0.05 *, p<0.01 **, 
p<0.005 ***.  
 
Furin regulates maturation of substrates important in RMS progression 
To decipher the furin substrates involved in tumour growth, migration and invasion in 
RMS cells, we examined by immunoblotting the maturation status of IGF1Rβ, VEGF-C, 
PDGF-BB and MT1-MMP in Rh30 wt and RD wt cells upon inhibition of furin activity by the PC 
inhibitor CMK (Figure 5A). In the case of IGF1Rβ and PDGF-BB, we observed an 
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accumulation of precursor and decrease in mature proteins upon inhibition of furin with CMK. 
For VEGF-C and MT1-MMP reduced furin activity resulted in lower levels of mature and 
precursor protein, suggesting enhanced degradation of unprocessed protein proforms. Thus, 
in RMS cells PCs seem to be involved in the maturation of all four investigated furin 
substrates. In addition to the use of the inhibitor CMK, we examined the maturation of IGF1Rβ 
in Rh30 and RD cells with stable modulation of furin activity by immunoblotting (Figure 5B). In 
both cell lines, we observed a slight increase in cleaved IGF1Rβ upon overexpression of furin. 
Conversely, a decrease of furin activity, either by expression of the inhibitor pdx or by silencing 
of furin, led to an accumulation of IGF1Rβ precursor and lower levels of mature IGF1Rβ 
(Figure 5B).  
 
 
Figure 5 Maturation of furin substrates and IGF1R signalling are furin activity dependent 
in RMS cells. A) Maturation of furin substrates upon treatment with pan-PC inhibitor CMK. 
Rh30 and RD cells were treated with 50 µM CMK for 16h and maturation status of the furin 
substrates IGF1Rβ, VEGF-C, PDGF-BB and MT1-MMP were examined by immunoblotting. B) 
IGF1Rβ maturation in Rh30 and RD cell lines. Levels of precursor and mature IGF1Rβ were 
analysed in stable Rh30 and RD cell lines (wt, fur, pdx, shFA and shFE) by immunoblotting. C) 
IGF signalling in RD cells upon transient furin silencing. RD cells were transiently transfected 
with control (scr) or anti-furin siRNA (siFur1 and siFur2) and serum starvation was started 24h 
post transfection. Cells were stimulated for 10 min with 50 ng/mL IGF1 48h post transfection 
and maturation status of IGF1Rβ and phosphorylation of Akt (Ser473) were assessed by 
immunoblotting.   
 
In order to examine the impact of furin activity on IGF signalling in RMS cells, and to 
exclude any type of effect arising during cell selection required for shRNA, we transfected RD 
cells with specific siRNA against furin (siFur1 and siFur2) and stimulated the cells with 
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50 ng/mL IGF1, 48h post transfection. As expected, silencing of furin severely impaired 
maturation of IGF1Rβ, leading to a decrease in mature form and accumulation of IGF1Rβ 
proform. Control siRNA transfected RD cells showed a high level of Akt phosphorylation upon 
stimulation with IGF1. In contrast, silencing of furin and subsequent loss of IGF1Rβ maturation 
mostly prevented stimulation of Akt phosphorylation, indicating an inability of RMS cells to 
trigger IGF signalling in the absence of furin activity (Figure 5C). Phosphorylation of Erk1/2 
was generally not stimulated in RD cells upon treatment with IGF1 (data not shown). Taken 
together our data suggest that furin activity is necessary to ensure processing of IGF1Rβ, 
VEGF-C, PDGF-BB and MT1-MMP and that maturation of IGF1Rβ by furin is required to 
maintain IGF signalling. Thus, furin has an important role in promoting the malignant 
phenotype of RMS cells by supporting the maturation and activation of proteins involved in, or 
enabling, cellular abilities such as proliferation or matrix degradation.  
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4. Discussion 
In this study, we show that furin activity plays a crucial role in RMS progression in vitro 
and in vivo. Loss of furin activity, through RNA interference or application of pan-PC inhibitors, 
delayed tumour growth in vivo and decreased migration and invasion in vitro. Furthermore, 
reduced furin activity resulted in diminished processing of important furin substrates and 
abrogation of IGF signalling.  
Upon engraftment of mice with Rh30 and RD cells having stably silenced furin 
expression or with expression of the pan-PC inhibitor α1-PDX/pdx (Anderson, Thomas et al. 
1993) we observed delayed RMS tumour growth and we hypothesise this could be the result 
of reduced growth factor signalling and/or impaired vessel formation. We could show that 
proteolytic activity of furin is required to process the potent mitogen PDGF-BB and the growth 
factor receptor IGF1R in RMS cells, the latter resulting in decreased IGF signalling upon 
stimulation with IGF1. Similarly, furin inhibition in carcinoma cells diminishes PDGF-A and 
IGF1R processing and abolishes stimulation of related signalling pathway (Scamuffa, Sfaxi et 
al. 2014). Our findings suggest that furin plays a role in RMS cell proliferation and thus 
reduced levels of furin likely impair tumour growth in vivo. In order to grow beyond a certain 
size, a tumour has to initiate angiogenesis, a step in tumourigenesis that is known as the 
angiogenic switch (Bergers and Benjamin 2003). Furin activity has been shown to promote 
vascularisation of tumours (Khatib, Siegfried et al. 2001; Lopez de Cicco, Watson et al. 2004; 
Lopez de Cicco, Bassi et al. 2005), whereby stimulation of vessel formation is dependent on 
secretion of different angiogenic growth factors like VEGF-C and VEGF-D, both of which 
require processing through furin or furin-like PCs to stimulate VEGF signalling and 
angiogenesis or lymphangiogenesis (Joukov, Sorsa et al. 1997; McColl, Paavonen et al. 
2007). Accordingly, maturation of VEGF-C was shown to be necessary for subsequent tumour 
formation (Siegfried, Basak et al. 2003). Likewise, secretion of mature PDGF-BB favours 
tumour angiogenesis through paracrine stimulation of PDGFR-β on endothelial cells, leading 
to proliferation, migration and sprouting (Xue, Lim et al. 2012). Hence, decreased VEGF-C 
and PDGF-BB processing, as confirmed in vitro, is likely responsible for reduced microvessel 
density in vivo, and delayed the angiogenic switch. We therefore suggest that the shift in initial 
tumour growth observed in RMS tumours with reduced furin activity can be attributed to 
impaired furin substrate processing, which reduced growth factor signalling and angiogenesis.  
Furthermore, we found that presence of furin is necessary to maintain the migratory 
and invasive behaviour of RMS cells in vitro. Hence, we observed reduced ability of wound 
healing and gelatin degradation, which correlated with decreased processing of the furin 
substrate MT1-MMP. Furin is also responsible for the activation of other matrix 
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metalloproteases including ADAMs (Loechel, Gilpin et al. 1998) and ADAM-TS (Kuno, 
Terashima et al. 1999) and indirectly mediates MMP2/gelatinase A activation, since active 
MT1-MMP is the main enzyme responsible for processing of pro-MMP2 on the cell surface 
(Ohuchi, Imai et al. 1997). Additionally, autocrine PDGF signalling was shown to promote the 
metastatic potential of breast cancer and pancreatic cancer cells (Jechlinger, Sommer et al. 
2006; Weissmueller, Manchado et al. 2014). Therefore, furin-mediated PDGF processing in 
RMS cells might further favour their metastatic behaviour. Thus, several lines of evidence 
support the notion that PCs, and in particular furin, activate metastasis-associated proteins. 
For instance, furin-mediated catalytic activation of MT1-MMP has been linked to progression 
of head and neck squamous cell carcinomas (Bassi, Lopez De Cicco et al. 2001; Bassi, 
Mahloogi et al. 2001). Similar to our studies, others showed that inhibition of furin decreases 
cell motility, migration and invasiveness of breast cancer, lung adenocarcinoma, fibrosarcoma 
and osteosarcoma cells in vitro (Lapierre, Siegfried et al. 2007; Coppola, Bhojani et al. 2008; 
Liu, Li et al. 2014; Ma, Fan et al. 2014) and proposed furin inhibition for prevention of 
metastasis (Scamuffa, Siegfried et al. 2008). 
In conclusion, our study identifies a role of furin activity in RMS progression and 
metastasis, which is mediated via proteolytic activation of key substrates involved in 
proliferation, motility and dissemination of RMS cells. We confirmed furin-dependent 
processing of IGF1R, PDGF-BB, VEGF-C and MT1-MMP in RMS cells; however, it is likely 
that other known furin substrates are involved. Based on our findings and studies from other 
groups, we predict that furin inhibition will be of benefit for treatment of patients with RMS or 
other cancer types, particularly for prevention of metastasis.     
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5. Supplementary figures 
 
 
Figure S1. Furin mRNA levels in RMS cell lines. A) Endogenous furin mRNA levels were 
determined by qRT-PCR in 5 eRMS and 15 aRMS cell lines. Expression levels relative to 
GAPDH are shown. 
 
 
Figure S2. Furin protein levels in Rh30 xenografts. A) 5x106 RMS cells with stable 
modulation of furin activity were s.c. injected in NOD/Scid IL2reg-/- mice and tumour growth 
was monitored over time. Tumours were excised upon a size of 750-1000 mm3 and furin 
protein levels were assessed by immunoblot. 
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1. Introduction 
Rhabdomyosarcoma (RMS) is the most common paediatric soft tissue sarcoma, 
representing 5-8% of all childhood cancers. RMS is subdivided in two main histological 
subgroups, embryonal (eRMS) and alveolar (aRMS) RMS. aRMS is more aggressive and is 
associated with a poorer prognosis with a 5-year survival of 48% (Ognjanovic, Linabery et al. 
2009). Around 80% of aRMS tumours harbour the chimeric transcription factor PAX3/7-
FOXO1 inducing a specific gene expression signature (Wachtel, Dettling et al. 2004; 
Davicioni, Finckenstein et al. 2006). A dominant role of PAX3/7-FOXO1 as oncogenic driver 
has been suggested (Sorensen, Lynch et al. 2002; Shern, Chen et al. 2014). Despite the 
dependence of aRMS tumours on PAX3/7-FOXO1 expression, transcription factors in general 
represent a challenging target.  
Thus, many efforts have been made to characterise key pathways driving RMS 
progression in order to identify targets for novel therapeutic approaches. The insulin-like 
growth factor 1 receptor (IGF1R) is one among them. IGF1R is a transcriptional target of 
PAX3-FOXO1 (Ayalon, Glaser et al. 2001) and increased levels of the receptor correlate with 
poorer outcome in aRMS patients (Blandford, Barr et al. 2006). The ligand of IGF1R, the 
insulin-like growth factor 2 (IGF-2), is overexpressed in RMS (Gray, Tam et al. 1987) and acts 
as an autocrine mitogen (El-Badry, Minniti et al. 1990). Therefore, the IGF1R signalling 
pathway is a promising target to treat aRMS tumours. Different approaches to disrupt IGF1R 
signalling in RMS have been investigated: IGF1R anti-sense RNA (Shapiro, Jones et al. 
1994), IGF1R-specific blocking antibodies (Kalebic, Tsokos et al. 1994) and the selective 
IGF1R inhibitor NVP-AEW541 (Scotlandi, Manara et al. 2005). 
Proteolytic processing of precursor proteins by proprotein convertases (PCs) produces 
a large variety of bioactive proteins, such as growth factors, receptors, enzymes and cell-
adhesion molecules. PCs are calcium-dependent serine proteases and seven of the nine 
family members (PC1, PC2, furin, PC4, PC5, paired basic amino acid cleaving enzyme 4 
(PACE4) and PC7) process proproteins at basic residues. The other two, SK-1 and PCSK9, 
cleave after non-basic residues (Seidah and Prat 2012). Enhanced activity of PCs has been 
associated with pathological conditions like Alzheimer’s disease (Bennett, Denis et al. 2000) 
and correlates with increased malignancy of certain cancer types such as prostate cancer, 
colon carcinoma or small cell lung carcinoma (Creemers, Roebroek et al. 1992; Khatib, 
Siegfried et al. 2001; D'Anjou, Routhier et al. 2011).  
Furin was the first identified PC and acts within the constitutive secretory pathway 
(Molloy, Thomas et al. 1994). It processes many cancer-related proteins like IGF1R (Khatib, 
Siegfried et al. 2001), the vascular endothelial growth factor C (VEGF-C) (Siegfried, Basak et 
al. 2003) or the membrane-type 1 matrix metalloprotease 1 (MT1-MMP) (Remacle, Rozanov 
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et al. 2006). Aberrant furin expression is associated with neoplasias like head and neck 
cancer, breast, lung or colon cancers (Schalken, Roebroek et al. 1987; Cheng, Watson et al. 
1997; Bassi, Mahloogi et al. 2001; Scamuffa, Siegfried et al. 2008). Upregulation of furin 
expression and translocation to the plasma membrane under hypoxic conditions are 
considered to favour invasiveness of cancer cells through enhanced proteolytic activation of 
MT1-MMP and TGFβ (McMahon, Grondin et al. 2005; Arsenault, Lucien et al. 2012). Thus, 
furin is a key activator of proproteins involved in cancer progression and represents a 
promising target to improve cancer treatment. Furin is endogenously inhibited by its own 
prodomain that is cleaved in a two-step autocatalytic activation process and the use of the 
prodomain as furin inhibitor has been proposed (Basak, Chen et al. 2010; Scamuffa, Sfaxi et 
al. 2014). Alternative inhibitory approaches are application of polyarginines (Kacprzak, 
Peinado et al. 2004), nanobodies (Zhu, Declercq et al. 2012) or α1-antitrypsin Portland (PDX) 
(Anderson, Thomas et al. 1993). However, most if not all proposed inhibitors lack selectivity 
for furin and are still in early developmental phases. 
We previously identified specific RMS homing peptides that bind to the proprotein 
convertase (PC) furin (Hajdin, D'Alessandro et al. 2010). Here, we investigate in detail the role 
of furin in aRMS progression in vitro and in vivo. We use inducible expression of furin specific 
shRNA to decrease furin expression and activity. Furin silencing resulted in impaired cell 
viability, caspase-dependent apoptosis and regression of tumours. We further found that furin 
is expressed in most patient biopsies. Therefore, we propose the proprotein convertases furin 
as novel target for aRMS therapy.  
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2. Material and methods 
 
Ethics Statement 
All animal experiments were approved and monitored by the veterinary office of the 
Canton of Zurich according to the Swiss Federal Law. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Data are expressed as 
mean ± standard deviation (SD). Statistical significance was tested for multiple comparison 
with analysis of variance (ANOVA). The differences were considered to be significant if 
p<0.05.  
Cell lines and cell culture 
The cell lines Rh4, Rh30 (Peter Houghton, St. Jude Children’s Hospital, Memphis, TN), 
Rh3 (Susan Ragsdale, St. Jude Children’s Hospital, Memphis, TN), CW9019 (Soledad 
Gallego, Hospital Universitari Vall d'Hebron, Barcelona, Spain), MRC5 and HEK293T (ATCC, 
LGC Promochem) were cultured in DMEM (Sigma-Aldrich), supplemented with 100 U/mL 
penicillin/streptomycin, 2 mM L-glutamine, and 10% FBS (Life Technologies) in 5% CO2 at 
37 °C. aRMS cell lines were tested and authenticated by cell line typing analysis (STR 
profiling) on 2011/2014 and positively matched (Hinson, Jones et al. 2013).  
Production of lentiviral particles and transduction of cells 
Third generation lentiviral packaging plasmids and vectors containing shRNA 
(scrambled (scri) or targeted against furin (target sequence shFAi: 
CCTGTCCCTCTAAAGCAATAA; target sequence shFEi: CCACATGACTACTCCGCAGAT)) 
under a U6-tet promoter as well as reporter genes GFP and puromycine resistance under 
PGK promoter were purchased from Cellecta (Cellecta Inc. Mountain View, USA). Lentiviral 
particles were generated by calcium phosphate-based transfection of HEK293T cells. 
Transducing units per mL (TU/mL) were determined through titration of lentiviral particles on 
Rh4 cells and analysis of % GFP positive cells by fluorescent activated cell sorting (FACS) on 
a FACSCanto II (BD Bioscience, Missisagua, Canada) 48h post transduction. TU/mL were 
determined using the formula TU/mL= (F*C*D)/V (F=frequency of GFP positive cells; 
C=number of cells; D=virus dilution; V=volume of inoculum). Cells were transduced with a 
multiplicity of infection (MOI) of 5. Transduction was performed by addition of required amount 
of lentiviral particles in DMEM in the presence of 10 µg/mL polybrene (Sigma-Aldrich) followed 
by centrifugation (32 °C, 1h, 800 g). Medium was replaced with fresh medium 4h post 
transduction start and efficiency of transduction was determined by analysis of GFP-positive 
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cells by FACS 7-10 days post transduction. Transduction efficiency was over 98% for all cell 
lines. 
To generate Rh4 cells with double knock out for BAX and BAK a CRISPR/Cas9-based 
approach was chosen. Vectors based on the LentiCrispr v1 vector (Addgene) were modified to 
carry a TagBFP for selection and delivered packaged in lentiviral particles. Two different 
sgRNAs for each target gene were evaluated individually for their knock down efficiency by 
immunoblot and the two best sequences were then co-delivered to achieve a double knock out 
(Rh4 BAX/BAK; sgRNA BAX: CGAGTGTCTCAAGCGCATCG; sgRNA BAK: 
ACGGCAGCTCGCCATCATCG). A scrambled sgRNA sequence was used as control (Rh4 sc; 
sgRNA sc: GCACTACCAGAGCTAACTCA).     
qRT-PCR 
Total RNA was extracted from cells or tumour tissue using the Qiagen RNeasy Kit 
(Qiagen, Hombrechtikon, Switzerland) and reverse-transcribed using oligo (dT) primers and 
Omniscript reverse transcriptase (Qiagen). qRT-PCR pas performed for furin 
(Hs00965485_g1), PC1 (Hs01026107_m1), PC2 (Hs0015992_m1), PC4 (Hs00399493_m1), 
PC5 (Hs00196400_m1), PACE4 (Hs00159844_m1), PC7 (Hs00237114_m1), S1P 
(Hs00921626_m1) and PCSK9 (Hs00545399_m1) employing TaqMan gene expression 
master mix (all Life Technologies). Cycle threshold (CT) values were normalised to GAPDH 
(Hs02758991_g1) or HMBS (Hs00609296_g1) for cells or tumour tissue, respectively. Relative 
expression levels were calculated using the ΔΔCT method. 
Immunoblot 
Total protein extracts from cells or tumour tissue were separated using 4-12% Bis-Tris 
SDS-PAGE gels (Life Technologies) and transferred to nitrocellulose membranes (PROTAN; 
Schleicher & Schuell). Membranes were blocked with 5% milk powder in TBS/0.05% Tween 
and subsequently incubated with primary antibodies overnight at 4°C. After washing in TBS, 
membranes were incubated with IgG horseradish peroxidase (HRP)-linked secondary 
antibody for 1h at RT. Proteins were detected using ECL detection reagent (Fisher Scientific) 
after washing in TBS. 
IGF1 stimulation 
RMS cells were treated with 25 ng/mL DOX for a total of 48h. After 24h cells were put 
on starvation medium (DMEM, 0.2% FBS). Cells were stimulated for 10 min with 50 ng/mL 
IGF1 (ab73455, Abcam). Cells were washed with ice-cold PBS and snap frozen in liquid 
nitrogen. Whole cell lysates were prepared as described above and IGF1Rβ, Akt, 
phosphorylated Akt, Erk1/2 and phosphorylated Erk1/2 were analysed by immunoblotting. 
Antibodies 
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The following antibodies were used: anti-furin MON-152 (1:750, ALX-803-017-R100, 
Alexis Corporation), anti-IGF1Rβ (9750S, Cell Signaling), anti-caspase-9 (9502, Cell 
Signaling), anti-cleaved caspase-7 (9491, Cell Signaling), anti-PARP (9542, Cell Signaling) 
and anti-α-tubulin (1:5000, A5316, Sigma-Aldrich). All Cell Signaling antibodies were used in a 
dilution of 1:1000.  
Cell proliferation and viability assays 
Cells were seeded in a 96-well format in 100 µL medium. To assess metabolic activity 
10 µL WST-1 reagent (Roche) were added. After 30-60 min incubation at 37°C in the dark 
absorbance was measured and recorded as ΔOD440-640. Background values were subtracted. 
To determine their number, cells were fixed in 4% paraformaldehyde for 10 min at RT and 
stained in 0.05% crystal violet (Sigma-Aldrich) for 20 min at RT. Excess crystal violet was 
removed and cells air dried. Dye was dissolved in 100% methanol and absorbance was 
measured at OD594. Cell proliferation was determined through BrdU incorporation (Cell 
Proliferation ELISA, BrdU (Chemiluminescent), Roche) according to manufacturer’s 
instructions. Cells were labelled with BrdU for 2h at 37°C, fixed and stained for 1h with anti-
BrdU-POD solution. Chemiluminescent substrate was added and luminescence measured. 
Caspase 3/7 activity 
Cells were seeded in a 384-well format in 20 µL medium. At the desired time point, 
10 µL Caspase Glo® 3/7 Substrate (Promega) were added and plates vigorously shaken for 
1 min. After 30 min incubation at RT in the dark luminescence was measured. 
Cell cycle distribution 
One million cells were collected and fixed in ice cold 70% ethanol at -20°C for at least 
2h. Fixed cells were washed in PBS and resuspended in propidium iodide (PI) solution 
(20 µg/mL PI and 200 µg/mL RNase A (Sigma-Aldrich) in PBS/0.1% Triton X-100). PI signal 
was assessed by FACS. Cell cycle distribution was analysed with FlowJo software, version 10 
(TreeStar).   
Immunoprecipitation of active BAX 
For detection of active BAX, cells were lysed in CHAPS lysis buffer (10 mM HEPES 
(pH 7.4), 150 mM NaCl, 1% CHAPS) as previously described (Häcker, Dittrich et al. 2009). 
Briefly, 1000 µg protein were incubated overnight at 4°C with 5 µg5 mouse anti-BAX antibody 
(6A7, Sigma) followed by addition of 10 µL Dynabeads Protein G (Invitrogen) and further 
incubation for 2h at 4°C. Dynabeads were washed with lysis buffer and BAX levels were 
analysed by immunoblotting using rabbit anti-BAX (1:1000; 5023, Cell Signaling). 
Xenograft studies 
To study in vivo growth 2.5x106 Rh30 or 3.25x106 Rh4 cells were engrafted 
subcutaneously in 6-week-old NOD/SCID IL2rg-/- mice (female, 20-25 g; Charles River). In 
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Rh30 xenografts doxycycline (DOX)-supplemented food (SynergyHealth) was given one week 
prior engraftment. DOX administration in Rh4 xenografts was started upon a tumour size of 
200-250 mm3 through intraperitoneal (i.p.) injection of 0.053 mg DOX/g body weight on two 
consecutive days and continuous DOX-supplemented food. Control treated mice were injected 
with PBS. Body weight and tumour growth were monitored over time. Tumour volumes were 
determined by measuring two diameters (d1, d2) in right angles using a digital caliper (V = 
(4/3) π r3; r = (d1 + d2)/4). Upon reaching a tumour size of 1000 mm3 mice were sacrificed, 
tumour tissue was harvested and snap frozen for RNA and protein extraction.  
Immunohistochemistry 
Sections (3 µm thick) of formalin-fixed, paraffin-embedded tissue were mounted on 
glass slides (SuperFrost Plus; Menzel), deparaffinised, rehydrated and stained with 
hematoxylin and eosin (H&E). Immunohistochemistry was performed on Leica BondMax 
instruments using Refine HRP-Kits (Leica DS9800; Leica Microsystems Newcastle, Ltd.). 
Dewaxed and pretreated (Epitop Retrieval Buffer 2, Leica Biosystems, Muttenz, Switzerland; 
60 min, 100°C) paraffin slides were incubated with anti-cleaved caspase-3 antibody (1:500; 
#9661, Cell Signaling).  
Tissue microarray 
A tissue microarray with 248 cores from 124 RMS tumours (17 aRMS with known 
FOXO1 gene rearrangements and 107 eRMS) was constructed. Tumours used were collected 
at the University Hospital Zurich, Switzerland and at the Kiel Paediatric Tumour Registry, 
Germany. Immunohistochemistry was performed essentially as described above. Paraffin 
slides were dewaxed, pretreated (Epitop Retrieval Buffer 2, Leica Biosystems; 10 min, 95°C) 
and incubated with furin antibody (1:3000; Ab28547, Abcam). Overall staining was graded 
according to intensity and assigned to four different groups (no expression, low, intermediate 
or high expression). Tissue microarrays were analysed double-blinded.  
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3. Results 
Validation of inducible furin silencing in alveolar RMS cells 
In order to simulate specific furin inhibition we generated stable aRMS cell lines with 
tetracycline-dependent expression of furin shRNA (shFAi and shFEi) or control shRNA (scri) 
(Figure 1A). Furin silencing was assessed 24-72h after doxycycline (DOX) treatment. Upon 
DOX treatment furin mRNA was reduced to around 15% in Rh30 cells (Figure 1B) and to 6.5-
25% in other aRMS cell lines (Figure S1A).  
 
 
Figure 1. Inducible silencing of 
furin in alveolar RMS cells.  
A) Schematic overview of the pRSI 
vector for inducible shRNA 
expression. Tet repressor, GFP and 
puromycin resistance under control of 
a phosphoglycerate kinase 1 (PGK) 
promoter are constitutively expressed. 
The tetracycline dependent promoter 
(U6Tet) controls expression of 
shRNA. Rh30 cells transduced with 
pRSI coding for control (scri) or furin 
(shFAi, shFEi) shRNAs were treated 
with 25 ng/mL doxycycline (DOX). B) 
Furin mRNA levels were determined 
in Rh30 cells by qRT-PCR at different 
time points after DOX addition. 
Expression levels relative to GAPDH 
and normalized to non-treated control 
(scri) cells are shown. The 
experiments were performed in 
duplicates. C) Protein expression of 
furin and its substrate IGF1Rβ were 
examined in Rh30 cells by 
immunoblotting 24h, 48h and 72h 
post-induction. One representative 
experiment is shown. D) Rh3 cells 
were stimulated for 10 min. with 50 
ng/mL IGF1 48h post induction of 
furin silencing and phosphorylation of 
IGF signalling pathway mediators Akt 
and Erk1/2 was examined by 
immunoblotting. One representative 
experiment is shown.  
 
 
Subsequently, we analysed furin protein levels in Rh30 cells by immunoblotting und 
could confirm that furin protein levels were strongly reduced upon DOX treatment (Figure 1C). 
To monitor furin activity we analysed the maturation of a known furin substrate, IGF1Rβ. 
Decrease of furin led to clear reduction of mature IGF1Rβ, indicating that furin activity is 
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indeed lowered upon silencing of furin (Figure 1C). mRNA levels of other PCs, examined by 
qRT-PCR after 48h of treatment with 25 ng/mL DOX, were unaffected suggesting that furin 
silencing was specific and was not compensated for by increased mRNA expression of other 
PCs (Figure S1B). In conclusion, we generated and validated aRMS cell lines with functional 
furin silencing that is inducible by application of DOX. Furthermore, effects of furin silencing on 
IGF1R processing and downstream Akt activation upon stimulation with IGF1 could be 
demonstrated in Rh3 cells (Figure 1D) and to a lesser extent in Rh4 cells (Figure S1C). This 
suggests that activation of the IGF signalling pathway is furin dependent at least in a subset of 
aRMS cells.  
 
Furin silencing decreases cell viability and proliferation 
Furin processes a variety of substrates, e.g. IGF1R, that support cancer cell viability 
and proliferation. Thus, we induced furin silencing in four different aRMS cell lines, Rh30, Rh4, 
CW9019 and Rh3 and assessed cell viability. Cell viability was clearly decreased, as 
compared to non-treated cells (Figure 2A- Rh30: 27%, Rh4: 7%; Figure S2A- CW9019: 48%, 
Rh3: 19%). The number of viable adherent cells was reduced up to 5-fold compared to non-
treated cells (Figure 2B- Rh30: 23%, Rh4: 20%; Figure S2B- CW9019: 54%, Rh3: 23%). 
Furthermore, proliferation, examined by BrdU incorporation, was much lower in furin silenced 
Rh30 and Rh4 cells than in cells expressing control shRNA and went down to 48% and 15%, 
respectively (Figure 2C). We also noted a slight toxic effect upon expression of the control 
shRNA (scri) in all aRMS cell lines (Figure 2A-C). Since DOX application alone had no effect 
on viability of aRMS wt cells (data not shown), we assume that this slight effect may be due to 
high shRNA expression after DOX treatment. Furthermore, we investigated furin silencing in 
MRC5 fibroblast cells and found that induced silencing of furin had no significant impact on 
viability of MRC5 fibroblast cells (Figures 2D and E). Thus, furin activity seems to be a critical 
factor in viability and proliferation of aRMS cells, whereby a decrease of furin does not alter 
cell viability of normal fibroblasts.    
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Figure 2. Cell viability and proliferation of aRMS cells are decreased upon furin 
silencing. Rh30, Rh4 and MRC5 cells were treated with 25 ng/mL DOX for 96h and analysed. 
A) Cell viability in Rh30 and Rh4 cells was determined with a WST-1 assay. B) The number of 
Rh30 and Rh4 cells was quantified by staining with crystal violet. C) Proliferation in Rh30 and 
Rh4 cells was measured by incorporation of BrdU. D) Cell viability in MRC5 cells was 
determined with a WST-1 assay. E) The number of MRC5 cells was quantified by staining with 
crystal violet. All data represent mean ±SD of three independent experiments. *P<0.05, 
**P<0.01, ***P<0.005, two-way ANOVA. 
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Reduced furin activity results in caspase-dependent cell death involving mitochondria 
In our initial investigation of aRMS cell viability upon furin silencing we observed that 
reduced furin activity not only impaired viability and proliferation of the cells, but also led to 
morphological changes and cell death in Rh4 and Rh3 cells. Therefore, we examined the cell 
cycle distribution of Rh4 and Rh3 cells 72h after DOX treatment and found a clear increase of 
cells in sub-G1 phase (Figure 3A- shFAi: 54-62%, shFEi: 26-32%). As a positive control for 
apoptosis we treated aRMS cells with a combination of 1 µM of the IGF1R-inhibitor AEW451 
(AEW) and 275 nM of the dual PI3K/mTOR inhibitor BEZ235 (BEZ) for 24h, conditions that 
induce apoptosis in aRMS cell lines (Wachtel, Rakic et al. 2014). As expected, treatment with 
BEZ/AEW led to an increase of cells in sub-G1 phase (Figure 3A- Rh4: 22%, Rh3: 18%). To 
assess the contribution of caspases in cell death induction we treated the cells with 100 µM of 
the pan-caspase inhibitor zVAD. Cell cycle profiles of furin silenced or BEZ/AEW treated cells 
were restored in the presence of zVAD similar to non-treated levels, indicating that induced 
cell death is caspase dependent (Figure 3A).  
To further elucidate the mechanism underlying cell death, we analysed cleavage of 
caspase-7 and -9 and PARP by immunoblotting. In Rh4 and Rh3 cells both caspases as well 
as PARP were cleaved upon furin silencing and BEZ/AEW treatment, confirming apoptosis 
induction. Cleavage of the effector caspase-7 and of PARP could be almost completely 
prevented in the presence of zVAD, whereby inhibition of caspase-9 cleavage was incomplete 
(Figure 3B). Caspase activity of the caspases-3 and -7 was elevated 5 to 7-fold upon furin 
silencing in Rh4 and Rh3 (Figure 3C and data not shown), but not in Rh30 or CW9019 cells 
(data not shown). This suggests that in some aRMS cells furin silencing mainly affects 
proliferation and viability, whereas in other aRMS cell lines a decrease in furin activity 
additionally induces caspase-dependent cell death. Furthermore, application of zVAD to Rh4 
cells upon induction of furin silencing only partially rescued cell viability as assessed by 
measuring metabolic activity and number of attached cells (Figure S3A and B). In this case 
caspase inhibition prevented apoptosis, but did not prevent anti-proliferative processes.  
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Figure 3. Cell death induction upon furin silencing is caspase dependent and 
involves mitochondria. A) Caspase inhibition restores normal cell cycle distribution. 
Rh4 and Rh3 cells were treated with 100 ng/mL DOX for 72h in the presence or 
absence of 100 µM zVAD, fixed and stained with propidium iodide and cell cycle 
distribution was studied by FACS. B) Inhibition of caspase activity rescues cleavage of 
caspase-7 and PARP, but not caspase-9 cleavage. Furin silencing was induced in Rh4 
(left panel) and Rh3 (right panel) cells by addition of 100 ng/mL DOX in the presence 
or absence of zVAD, total protein was extracted 72h post induction, and cleavage of 
caspase-9 and -7 and PARP was analysed by immunoblotting. Wt cells were treated 
with 275 nM BEZ235 and 1 µM AEW451 for 24h as positive control (A-B, D). C) 
Effector caspase activation is mitochondria dependent. Rh4 cells with a stable BAX 
and BAK (BAX/BAK) or control (sc) knock out were generated using a lentiviral 
CRISPR/Cas9 based approach. Knock out cells were stably transduced with inducible 
furin silencing constructs. Cells were treated with 100 ng/mL DOX for 48 and 72h and 
caspase-3/7 activity was analysed by a caspase specific luminescent assay. Data 
represent mean ±SD of three independent experiments. D) Apoptosis induction is 
dependent on BAX activation. Rh4 and Rh3 cells were treated with 100 ng/mL DOX for 
48h (scri, shFAi) or 72h (shFEi) and active BAX was immunoprecipitated using a 
conformation-specific antibody.  
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Furin silencing results in remission of Rh4 xenografts in vivo 
Reduced furin activity decreased cell viability and proliferation in Rh4 cells and further 
induced caspase-dependent apoptosis in vitro. To examine the role of furin in Rh4 tumour 
growth we engrafted 3.25 million cells harbouring either inducible furin shRNA (shFAi and 
shFEi) or control shRNA (scri). In order to simulate a potential therapy aiming at abrogating 
furin activity in established tumours, mice were treated with DOX once tumours reached a size 
of 200-300 mm3 (Figure 4A). Mice were sacrificed upon reaching a tumour size of 1000 mm3. 
PBS-treated tumours took on average 16-17 days to attain this size (Figure 4B- scri: 17 days; 
shFAi: 16.6 days; shFEi: 16.5 days). Rh4 scri tumours treated with DOX showed slightly 
decelerated tumour growth and took on average 25 days to reach a size of 1000 mm3. In 
contrast, Rh4 shFAi and shFEi tumours went into full remission after 10-15 days. 4 out of 5 
Rh4 shFAi tumours relapsed 9-20 days later, whereby the last tumour of this group never 
relapsed, not even after DOX withdrawal 60 days post remission. None of the Rh4 shFEi 
DOX-treated mice relapsed (Figure 4B). Assessment of furin mRNA by qRT-PCR revealed 
that only half of Rh4 shFAi DOX-treated relapsed tumours maintained low levels of furin. The 
other two tumours showed higher furin mRNA levels (41% and 75% over control treated Rh4 
shFAi tumours), indicating a possible outgrowth of cells with ineffective furin silencing (Figure 
4C). To further investigate the mechanisms leading to remission of Rh4 shFAi and shFEi 
tumours upon DOX administration, we sacrificed few mice 5 days after initial administration of 
DOX. Decreased furin mRNA levels were confirmed by qRT-PCR (Figure S5- shFAi: around 
30%; shFEi: 15%). Total protein was extracted from tumour tissue and protein levels of 
different cell death markers were examined by immunoblotting. The three tumours with lower 
furin levels displayed elevated levels of cleaved caspase-9 and -7 and cleaved PARP as 
compared to Rh4 scri tumours (Figure 4D). Furthermore, Rh4 shFEi, but especially shFAi 
tumours showed high levels of cleaved caspase-3 after 5 days of DOX treatment (Figure 4D). 
Expression of scri in control tumours did not lead to activation of this effector caspase. 
Thus, we could show that induced silencing of furin leads to full remission of Rh4 
tumours in vivo. This is most likely achieved through initiation of apoptotic processes, as 
shown by activation of key caspases. Beside reactivation of furin expression, other, yet 
undetermined, processes might lead to relapse of tumours and should be further investigated.       
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Figure 4. Induction of furin silencing results in remission of Rh4 tumours in vivo. 
A) Schematic overview of Rh4 xenograft model. 3-5 NOD/SCID mice per group were 
engrafted s.c. with 3.25 million Rh4 cells. Expression of shRNA was induced through 
administration of DOX (i.p. injection of 53 mg/kg DOX on two consecutive days 
combined with DOX-supplemented food) once a tumour size of 250-300 mm3 was 
reached. Mice were sacrificed upon a tumour size of 1000 mm3. B) Tumour growth 
over time as monitored by caliper measurements in Rh4 xenografts. Arrows indicate 
that mice were put back on normal food approximately 60 days post onset of 
remission. C) Furin mRNA levels in Rh4 tumours. Tumour tissue was collected, total 
mRNA isolated and furin mRNA levels analysed by qRT-PCR. D-E) Apoptotic markers 
in Rh4 tumours after 5 days of DOX treatment. D) Caspase-9, cleaved caspase-7 and 
PARP levels were examined by immunoblotting. E) Levels of cleaved caspase-3 were 
analysed by immunohistochemistry. 
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Tumour growth of Rh30 xenografts in vivo is delayed after furin silencing 
Induction of furin silencing diminished proliferation and cell viability of Rh30 cells in 
vitro. To determine the impact of furin activity on Rh30 tumour growth in vivo we engrafted 
2.5 million Rh30 cells with inducible furin shRNA and shRNA expression was induced by 
administration of DOX-supplemented food 7 days prior engraftment of tumour cells (Figure 
5A). Control groups were fed normal food. Tumour growth was monitored over time through 
calliper measurements and mice were sacrificed once tumours reached a size of 1000 mm3. 
Rh30 scri tumour growth was similar with or without DOX supplement and tumours reached a 
size of 300 mm3 after 25 days. Conversely, early tumour growth was clearly delayed in Rh30 
shFAi and shFEi tumours in the presence of DOX and tumours took approximately 50% more 
time to reach 300 mm3 (Figure 5B- shFAi- no DOX: 21 days, DOX: 31days; shFEi- no DOX: 22 
days, DOX: 34 days). To investigate furin silencing efficiency we extracted RNA from tumour 
tissue and evaluated furin mRNA levels by qRT-PCR. Furin mRNA levels of Rh30 shFAi or 
shFEi tumours with DOX as compared to respective tumours without DOX were on average 
15% and 11%, respectively (Figure 5C), confirming effective furin silencing. Despite having 
low furin levels, once furin silenced Rh30 tumours exceeded a size of approximately 300 mm3, 
they grew almost as fast as control tumours. However, a clear delay in early tumour growth 
could be observed, suggesting that furin activity is important in early phases of Rh30 tumour 
growth in vivo. 
 
Figure 5. Decrease of furin activity delays tumour growth of Rh30 xenografts in vivo. A) 
Schematic overview of Rh30 xenograft model. 3-4 NOD/Scid mice per group were fed with or 
without DOX-supplemented food starting 7 days prior engraftment. Mice were then engrafted s.c. 
with 2.5 million Rh30 cells. Tumour growth was monitored over time and mice were sacrificed 
once tumours reached a size of 1000 mm3. B) Absence of furin activity delays initial tumour 
growth. Tumour growth rate was monitored by caliper measurements. Data represent mean 
tumour size of 3-4 mice per group.  C) Furin expression is reduced upon induction of furin 
specific shRNA. Tumour tissue was collected upon sacrifice of mice, total mRNA isolated and 
furin mRNA levels analysed by qRT-PCR. Expression levels relative to HMBS are shown. 
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Most RMS biopsies express furin  
To evaluate the potential of furin targeted therapies in patients we examined furin 
protein expression in 89 RMS biopsies (74 eRMS, 15 aRMS). A TMA was stained for furin and 
expression was graded according to overall intensity of the staining in tumour cells (Figure 
6A). We found that, independent of the subtype, over 86% of RMS tumours expressed low to 
high amounts of furin (Figure 6B), whereby most tumours showed low to intermediate 
expression. A correlation between the level of furin protein in tumours and event-free or overall 
survival of the patients could not be confirmed (data not shown). 
  
 
Figure 6. Furin is expressed in most RMS biopsies. A patient-derived tissue microarray was 
immunohistochemically stained for furin (n=89). Patients were grouped according to no 
expression (n=12), low (n=35), intermediate (n=35) and high (n=7) furin expression. A) 
Representative pictures of biopsies from all four categories. B) Distribution of furin expression 
intensity based on RMS subtype. Furin expression levels were analysed for 74 eRMS and 15 
aRMS biopsies. 
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4. Discussion 
This study establishes for the first time a link between furin activity and 
rhabdomyosarcoma progression both in vitro and in vivo. Silencing of furin led to significantly 
decreased cell viability and induction of caspase-dependent apoptosis in vitro. Furthermore, 
depletion of furin activity in vivo resulted in regression or delayed tumour growth of aRMS 
tumours.  
Furin is known to process many growth factors and their receptors, like IGF-1 and 2, 
IGF1R or transforming growth factor β (TGFβ) (Lehmann, André et al. 1998; Tian, Huang et al. 
2011). Accordingly, silencing of furin led to significant reduction of cell viability and proliferation 
rate in all investigated aRMS cell lines. Furin silencing had no effect on MRC5 fibroblast 
viability, suggesting that aRMS, but not normal cells are dependent on furin activity. A subset 
of the aRMS cell lines tested was particularly sensitive to furin silencing and underwent 
BAX/BAK- and caspase-9-dependent apoptosis. This indicates that furin silencing primarily 
triggers the intrinsic apoptosis pathway. Others have shown that disruption of the IGF1R 
and/or PI3K/mTOR pathways leads to apoptosis in Rh3 and Rh4 cell lines (Scotlandi, Manara 
et al. 2005; Wachtel, Rakic et al. 2014). In this study we found evidence that activation of the 
IGF signalling pathway is dependent on furin activity. We therefore hypothesize that 
incomplete activation of growth factor-dependent pathways is the principal cause of cell death 
induced upon furin silencing in sensitive cell lines. It remains to be investigated which 
proapototic BH3-only proteins are involved, but treatment of Rh3 and Rh4 cells with a 
combination of the IGF1R inhibitor AEW541 and the dual PI3K/mTOR inhibitor BEZ235 results 
in BMF-dependent apoptosis (Wachtel, Rakic et al. 2014). Other proapototic BH3-only 
proteins linked to growth factor deprivation are BAD, BIM and PUMA. For instance, 
phosphorylation of BAD through active protein kinase Akt results in binding and sequestration 
by 14-3-3 scaffold proteins (Zha, Harada et al. 1996; del Peso, Gonzalez-Garcia et al. 1997). 
Thus, lower levels of activated Akt due to decreased IGF signalling upon furin silencing might 
promote release of BAD and mitochondria pore formation. Further investigations will be 
required to elucidate the exact mechanism of cell death after silencing of furin. 
To examine the impact of furin silencing on aRMS tumour growth in vivo we engrafted 
two aRMS cell lines, Rh30 and the sensitive Rh4. In Rh30 xenografts, upon furin silencing, we 
observed delay of early tumour growth, suggesting that furin cleaves one or more precursor 
proteins that are crucial for early steps of aRMS tumour growth after xenotransplantation.  
A signalling pathway likely to be involved is the VEGF signalling axis. Gee et al. 
confirmed expression of VEGF, VEGFR1, which is a transcriptional target of PAX3-FOXO1 
(Barber, Barber et al. 2002), and VEGFR2 in aRMS cell lines and were the first to propose a 
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role of VEGF signalling in RMS growth (Gee, Tsuchida et al. 2005). Processing of precursor 
VEGF-C and VEGF-D through furin allows their binding to VEGFR2 and induction of 
vasculogenesis and angiogenesis (Millauer, Wizigmann-Voos et al. 1993; Joukov, Sorsa et al. 
1997; Siegfried, Basak et al. 2003; McColl, Paavonen et al. 2007). Additionally, only furin-
processed VEGF-C induces tumourigenesis in mice (Siegfried, Basak et al. 2003), highlighting 
the importance of PC activity in the VEGF signalling axis. Therefore, reduced VEGF-C and 
VEGF-D processing upon furin silencing might suppress proper formation of angiogenic and 
lymphangiogenic vessels inside the new tumours and decrease VEGFR2-dependent aRMS 
tumour cell growth.  
When furin was silenced in established Rh4 tumours, regression was observed. 
Apoptosis was induced, as confirmed by activation of caspases-9, -3 and -7 and PARP 
cleavage. Four of the Rh4 shFAi tumours relapsed and furin re-expression was found in two of 
them. Since we used a heterogeneous cell pool, it is likely that outgrowth of a subset of non-
silenced cells caused the relapse. Further investigations will be required to uncover the 
underlying mechanisms of tumour regrowth. 
We found furin expression in over 86% of tested aRMS and eRMS biopsies, but no 
significant correlation could be confirmed between furin expression and event-free or overall 
survival. It is possible that other risk-factors interacted with the analysis of furin influence on 
survival, or that furin expression alone is not a good marker to for its role in cancerogenesis, 
but rather its subcellular localization and activity are. Our results are in line with other studies 
demonstrating the role of furin and other PCs for cancer cell survival (D'Anjou, Routhier et al. 
2011; Scamuffa, Sfaxi et al. 2014; Sfaxi, Scamuffa et al. 2014). Thus, PCs are emerging 
targets for the treatment of cancer and development of specific inhibitors will be of central 
importance. Levesque et al. recently reported the improvement of peptide-based specific 
PACE4 inhibitors for treatment of prostate cancer (Levesque, Fugere et al. 2012; Levesque, 
Couture et al. 2015) and Zhu et al. described the first furin-specific inhibitory nanobodies (Zhu, 
Declercq et al. 2012). Despite their great clinical potential, specific inhibitors of furin and furin-
like PCs are still in early phases of development. Besides, the safety of such inhibitors will 
have to be closely examined as most PCs are widely expressed in human tissues. 
Nevertheless, disruption of furin activity has been used successfully to enhance an anti-
tumour immune response in patients with advanced cancers. Safety and efficient immune 
response of an autologous tumour cell vaccine (FANG) that combines furin shRNA and 
expression of GM-CSF were confirmed and benefits of treatment were observed from phase I 
trials in Ewing sarcoma and hepatocellular carcinoma patients (Senzer, Barve et al. 2012; 
Nemunaitis, Barve et al. 2014; Ghisoli, Barve et al. 2015). Additionally, increased presence of 
furin on the cell surface of tumour cells could be used for targeted delivery of 
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chemotherapeutics, as we could show previously that furin is the target receptor for RMS-
homing peptides (Hajdin, D'Alessandro et al. 2010). In conclusion, our data clearly validate 
furin as a novel target in aRMS and we predict that the majority of paediatric RMS patients 
would benefit from inhibition of furin activity, either alone or in the context of immune therapy. 
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5. Supplementary figures 
 
 
Figure S1. Validation of furin silencing in other cell lines and expression of other PCSKs. A) 
Furin silencing efficiency. Rh4, MRC5, CW9019 and Rh3 cells were treated with 25 ng/mL DOX for 48h, 
total mRNA was isolated and furin mRNA levels were studied by qRT-PCR. Data represent relative furin 
expression over non-treated scri control.  B) Expression of other PCSKs upon furin silencing. Furin 
silencing was induced in Rh30 cells through addition of 25 ng/mL DOX, total mRNA was extracted 48h 
post induction and mRNA levels of other proprotein convertase family members were analysed by qRT-
PCR. C) Rh4 cells were stimulated for 10 min. with 50 ng/mL IGF1 48h post induction of furin silencing 
and phosphorylation of IGF signaling pathway mediators Akt and Erk1/2 was examined by 
immunoblotting. One representative experiment is shown.  
 
 
 
Figure S2. Cell viability in other aRMS cell lines is affected upon loss of furin activity. CW9019, 
Rh3 and MRC5 cells were treated with 25 ng/mL DOX for 96h. A) Metabolic activity was analysed in a 
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WST-1 assay. B) The number of cells was determined by staining with crystal violet. All data represent 
mean ±SD of three independent experiments. *P<0.05, **P<0.01, ***P<0.005, two-way ANOVA. 
 
 
 
 
Figure S3. Caspase inhibition partially rescues cell viability in Rh4 cells. Rh4 cells were treated 
with 100 ng/mL DOX for 72h in the presence or absence of 100 µM zVAD. A) Metabolic activity was 
examined in a WST-1 assay. B) The number of cells was analysed by staining with crystal violet. Data 
represent mean ±SD of three independent experiments. *P<0.05, **P<0.01, ***P<0.005, two-way 
ANOVA.  
 
 
 
Figure S4. Validation of BAX/BAK knock out in Rh4 cells. Total protein of Rh4 wt, sc and BAX/BAK 
cells was extracted and BAX and BAK protein levels were analysed at protein level by immunoblotting.  
 
 
 
Figure S5. Furin silencing in Rh4 xenografts 5 days post induction. NOD/Scid mice were engrafted 
s.c. with 3.25 million Rh4 cells. Expression of shRNA was induced through administration of doxycycline 
(i.p. injection of 53 mg/kg doxycycline on two consecutive days combined with doxycycline 
supplemented food) once a tumour size of 250-300 mm3 was reached. Mice were sacrificed 5 days post 
induction. Total mRNA was extracted from tumour tissue and furin mRNA levels analysed by qRT-PCR. 
Depicted are expression levels over HMBS.  
  
 
 
104 
 
  
 
 
105 
 
 
 
 
 
 
 
 
Chapter 4 
Discussion 
 
 
 
 
Discussion 
 
 
 
106 
1. Furin activity promotes survival and progression of rhabdomyosarcoma  cells 
In this work we investigated in depth the role of the proprotein convertase furin in the 
proliferative and malignant phenotype of RMS cells. We found that furin is a key regulator of 
the malignant phenotype of RMS cells in vitro and in vivo. Using diverse approaches to 
modulate furin activity, we could show that furin activity is required for cell growth and survival, 
and promotes angiogenesis as well as metastatic and invasive properties. All of these 
processes seem to be characterised by furin-mediated processing of cancer-related 
proproteins.  
Lack of furin activity in RMS xenografts resulted in delayed tumour growth and was 
associated with decreased microvessel density, indicating that furin activity is required for 
angiogenesis. Reduced vascularisation of tumours upon furin inhibition has been confirmed by 
others who showed that ectopic expression of the inhibitor PDX or the prosegment of furin 
resulted in significantly decreased microvessel density in colon carcinoma, and head and neck 
carcinoma xenografts, respectively (Khatib, Siegfried et al. 2001; Lopez de Cicco, Bassi et al. 
2005). As in our study, inhibition of furin led to impaired VEGF-C processing, suggesting that a 
lack of active VEGF-C prevents efficient neovascularisation in growing tumours. Additionally, 
initial reports suggested that hypoxia promotes HIF1-dependent enhanced expression of furin 
and relocalisation of furin from the TGN to the cell surface (McMahon, Grondin et al. 2005; 
Arsenault, Lucien et al. 2011), thus potentially facilitating processing of pro-angiogenic factors 
at the cell surface. However, whether this is also the case in RMS tumours remains elusive. 
Nevertheless, it is highly likely that impaired vessel formation, and thus reduced oxygen and 
nutrient supply, are responsible for delayed tumour growth in furin depleted RMS tumours.  
Induction of furin silencing in aRMS cell lines significantly reduced proliferation of the 
cells. Moreover, half of the cell lines reacted in an even more sensitive way: depletion of furin 
in Rh3 and Rh4 cells induced caspase-dependent apoptosis in vitro and resulted in complete 
remission of Rh4 tumour in vivo. Apoptosis induction upon inhibition of furin through ectopic 
expression of the prosegment of furin was also seen in breast and colon carcinoma cell lines 
(Scamuffa, Sfaxi et al. 2014). Interestingly, the protein expression or activity levels of furin 
alone were not enough to predict the extent of the cellular response to furin silencing, as all 
four investigated aRMS cell lines showed similar levels of mature furin, and Rh3, Rh4 and 
Rh30 depicted comparable furin activity levels (see chapter 2, Figure 1). Intriguingly, a similar 
subclassification of sensitivity was reported for treatment of aRMS cells with an anti-IGF1R 
antibody (Cao, Yu et al. 2008). This suggests that the more pronounced dependency on furin 
might be coupled to IGF signalling levels and, potentially, to the downstream anti-apoptotic 
effects of the IGF-PI3K-Akt pathway, a hypothesis that warrants further investigations. 
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Unfortunately, the inducible furin silencing system could not be set up in eRMS cell lines due 
to insufficient expression of the tet repressor part of the construct, leading to leaky shRNA 
expression. Nevertheless, it would be of interest to determine whether a similar gradual 
sensitivity pattern can be detected in eRMS cells. To gain further insights on the sensitivity of 
eRMS and additional aRMS cell lines or, ideally, of patient derived cell lines, to inhibition of 
furin activity, the development and use of furin-specific inhibitors would be invaluable.  
We further evaluated the impact of furin activity on the metastatic behaviour of RMS 
cells and found that furin activity promotes migration as well as invasion. Similar observations 
were made by Sfaxi et al. who investigated the effects of furin inhibition in colon carcinoma 
cells and confirmed decreased cell migration and invasion (Sfaxi, Scamuffa et al. 2014). The 
reduced metastatic potential correlated with reduced MMP2 and MMP9 activity upon ectopic 
expression of the PC inhibitor Spn4 and thus the authors hypothesised that PC inhibitors 
might be used for prevention of frequently occurring liver metastases of colorectal cancers 
(Sfaxi, Scamuffa et al. 2014). Furthermore, application of the pan-PC inhibitor PDX decreased 
the metastatic behaviour in lung adenocarcinoma and osteosarcoma cell lines (Liu, Li et al. 
2014; Ma, Fan et al. 2014). Interestingly, opposing roles of distinct PCs in metastatic 
processes were also reported. Whereas specific inhibition of furin through ectopic expression 
of its prosegment decreased MMP9 activity and thus reduced the metastatic potential of 
breast cancer cells, inhibition of PACE4, also through prosegment expression, enhanced cell 
motility, migration and invasion in the same cells (Lapierre, Siegfried et al. 2007). This study 
shows the necessity of in depth investigations of distinct PCs in the tumour of interest and, 
eventually, the application of specific inhibitors in order to reduce the risk of unwanted side 
effects resulting from inhibition of other PCs.         
2. The role of individual furin substrates  
Many known cancer-related furin substrates are involved in one or more cellular 
functions that we could show to be altered upon modulation of furin activity in RMS cells, 
underscoring that furin promotes the malignant phenotype of RMS via processing of key 
precursor proteins. Deciphering the role of individual furin substrates is a challenging task, as 
mRNA and protein levels alone provide insufficient information. Thus, we decided to 
investigate the maturation status of some furin substrates previously shown to be involved in 
survival, growth, angiogenesis and metastasis of tumour cells.  
IGF1R is a transcriptional target of the PAX3-FOXO1 fusion protein in aRMS (Ayalon, 
Glaser et al. 2001) and overexpression of IGF1R through gene amplification is frequently 
found in all RMS subtypes (Bridge, Liu et al. 2002). Furthermore, biallelic expression of the 
IGF2 gene either through LOH or LOI (Zhan, Shapiro et al. 1994; Smith, Choufani et al. 2007) 
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results in overexpression of this growth factor, which stimulates autocrine IGF1R signalling in 
RMS cells (El-badry, Kohn et al. 1990; Minniti, Tsokos et al. 1994). Accordingly, increased 
levels of the different components of the IGF1R signalling pathway are associated with 
decreased survival of RMS patients (Blandford, Barr et al. 2006), suggesting the potential of 
targeting the IGF signalling pathway for treatment of RMS. To examine the importance of furin 
activity for functionality of this important growth factor pathway in RMS, we investigated IGF1R 
processing and found that active furin is required to mediate maturation of the receptor. 
Moreover, transient silencing of furin significantly impaired phosphorylation of the main 
downstream mediator Akt, highlighting the crucial role of furin activity for IGF signalling in RMS 
cells.  
Similar to the IGF signalling axis, increased transcriptional levels of components of the 
PDGF signalling axis have been associated with negative outcome for RMS patients 
(Blandford, Barr et al. 2006). Hence, PDGFR-α has been proposed as a therapeutic target in 
RMS (Taniguchi, Nishijo et al. 2008). Whereas both PDGF-A and -B appear to undergo furin-
like PC-dependent processing (Siegfried, Khatib et al. 2003; Siegfried, Basak et al. 2005), 
proteolytic cleavage of the other two ligands, PDGF-C and -D, seems to be dependent on the 
urokinase-type plasminogen activator (uPA) (Ustach and Kim 2005; Hurst, Najy et al. 2012). 
Thus, we examined PDGF-B maturation and could confirm that proteolytic processing of 
PDGF-B in RMS cells is indeed furin-dependent. In a recent study it was shown that PDGF 
signalling promotes cell proliferation, vessel density and macrophage infiltration in RMS 
tumours and likely regulates additional processes in vitro, including cancer cell stemness and 
differentiation (Ehnman, Missiaglia et al. 2013). That study was focussed on the more 
abundantly expressed PGDF-C and -D ligands, thus the role of PDGF-A and -B in RMS 
progression remains to be investigated.  
VEGFs, belonging to the same family as PDGFs, are equally known to play a crucial 
role in tumour angiogenesis and lymphangiogenesis (reviewed in (McMahon 2000)). The two 
ligands VEGF-C and -D require processing by furin or related PCs to become fully active 
(Joukov, Sorsa et al. 1997; McColl, Paavonen et al. 2007). As we observed reduced 
microvessel density in RMS tumours with reduced furin activity, we investigated VEGF-C 
maturation and found that cleavage of pro-VEGF-C is dependent on furin activity. Whether 
furin activity has an equal impact on VEGF-D maturation and VEGF-D-dependent 
lymphangiogenesis in RMS tumours remains to be determined. Besides its pro-angiogenic 
function, VEGF signalling has been further implied in promoting tumour cell growth. Gee et al. 
investigated VEGF signalling in RMS cells and found evidence supporting the presence of an 
autocrine VEGF signalling axis promoting cell growth (Gee, Tsuchida et al. 2005). Whether 
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VEGF-C and -D posses a comparable potential of mediating cell growth remains to be 
investigated.  
An additional furin substrate that was associated with angiogenesis is semaphorin-3B. 
In contrast to semaphorin-3F, which was found to act as an anti-angiogenic factor (Kessler, 
Shraga-Heled et al. 2004), the repellent effect of semaphorin-3B on endothelial cells appears 
to be kept low through furin-mediated cleavage and inactivation (Varshavsky, Kessler et al. 
2008). Hence, overexpression of furin or furin-like PCs might promote neovascularisation of 
tumours through activation of angiogenic factors belonging to the VEGF/PDGF family or 
through inactivation of potentially anti-angiogenic factors like semaphorin-3B.   
We also observed a reduced metastatic potential upon inhibition or silencing of furin, 
which was correlated with impaired maturation of the furin substrate MT1-MMP. Similarly, furin 
inhibition affected processing of MT1-MMP in osteosarcoma and lung adenocarcinoma cells 
and correlated with decreased migration and invasion (Liu, Li et al. 2014; Ma, Fan et al. 2014). 
Investigations of MMP expression patterns in RMS tumours have shown that the gelatinases 
MMP2 and MMP9, as well as the collagenase MMP1 are frequently overexpressed in aRMS 
tumours and were therefore hypothesised to contribute to the aggressive phenotype of aRMS 
(Diomedi-Camassei, Boldrini et al. 2004). MMP2 and MMP9 activity was reduced in breast 
cancer cells upon furin inhibition (Lapierre, Siegfried et al. 2007). Whether furin inhibition has a 
similar impact on MMP2 or MMP9 activity in RMS cells remains to be investigated. 
Nevertheless, matrix metalloproteases are furin substrates that are very likely involved in 
promoting the metastatic potential of RMS tumours.  
3. Targeting furin activity for treatment of paediatric sarcomas 
Our findings suggest that furin activity promotes malignancy of RMS cells by regulating 
the processing of cancer-related proproteins involved in growth, survival, angiogenesis and 
metastasis. Thus, we hypothesise that targeting furin activity will be of benefit for treatment of 
paediatric sarcomas. Since inhibition of furin will impair maturation of multiple furin substrates 
at once, we further predict that the application of furin inhibitors might be more potent than 
targeting individual furin substrates. For instance, targeting furin activity will not only abolish 
IGF1R maturation, but will also affect furin-mediated IGF1 and IGF2 processing (Duguay, 
Milewski et al. 1997; Duguay, Jin et al. 1998). Nonetheless, it might be advantageous to 
combine IGF1R and furin targeting strategies in order to increase the therapeutic benefit. 
To our knowledge, the only furin-specific inhibitors that have been reported are 
dromedary heavy-chain-derived nanobodies, which were shown to bind and inhibit exclusively 
furin in a non-competitive manner (Zhu, Declercq et al. 2012). Unfortunately, these furin 
nanobodies have not been released for general use or clinical application, yet. All other 
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reported furin inhibitors are either not suitable for extracellular applications, e.g. the 
prosegment is a potent inhibitor, but has to be introduced through ectopic expression, or will 
also inhibit other PCs of the consecutive secretory pathway. Thus, the question arises of how 
important specificity towards one single PC is for a PC inhibitor. On the one hand, a broad 
acting PC inhibitor might display increased potency in inhibiting processing of substrates that 
can be cleaved by more than one PC. In contrast, potential side effects of unspecific PC 
inhibition in non-target tissue might be avoided through use of a specific furin inhibitor that 
more exclusively targets aberrantly high furin activity in RMS tumours. In the latter case 
redundancy in substrate processing through several PCs could even compensate for lack of 
furin activity in non-target tissue. In any case, tumour-targeted delivery of furin inhibitors will be 
the most promising approach to contain potential side effects caused by inhibition of furin 
activity in other tissues.      
In order to estimate the therapeutic potential of furin targeting compounds several 
considerations should be taken into account prior to administration of the drug. Firstly, the 
endogenous activity of other furin-like PCs, possibly induced by furin inhibition, has to be 
investigated to ensure that furin-specific inhibition will not be compensate for by other PCs 
with redundant substrate processing function. Secondly, it will be crucial to decipher which 
furin substrates are the key mediators of cellular processes influenced by furin activity. 
Identification of key substrates might further serve to establish biomarkers in order to evaluate 
success chances of furin activity targeted therapy in RMS and other tumours.  
Furthermore, we assessed expression levels of all PCs in other paediatric sarcomas 
and found that furin mRNA levels are, compared to the levels of other PCs, also elevated in 
osteosarcoma cell lines, but not in Ewing sarcoma cells. Liu et al. recently examined the 
potential of PC inhibition in osteosarcoma cells and found that application of the pan-PC 
inhibitor PDX diminishes the migration and invasion abilities (Liu, Li et al. 2014). Thus, furin 
and furin-like PC targeted therapy might be of benefit for prevention of osteosarcoma 
metastasis, a hypothesis that requires further investigation. 
4. Immunomodulatory therapy  
In very recent years Senzer et al. described for the first time the development of an 
autologous cancer cell vaccine that is partly based on silencing of furin (Senzer, Barve et al. 
2012). This furin-knockdown and GM-CSF augmented (FANG) cancer vaccine is based on the 
genetic modification of patient-derived cancer cells to induce silencing of furin through 
expression of a bi-functional shRNA and expression of the granulocyte-macrophage colony-
stimulating factor (GM-CSF), with subsequent reinjection into the patient to elicit an anti-
tumoural immune response. Secretion of the cytokine GM-CSF leads to accumulation of 
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dendritic cells at the injection site, which in turn engulf and process injected cancer cells, 
resulting in tumour antigen presentation and mobilisation of tumour-specific T cells (reviewed 
in (Gupta and Emens 2010)). Simultaneous silencing of furin on the other hand helps to 
counteract immunosuppressive functions of TGFβ, which include the inhibition of cytolytic 
gene expression in cytotoxic T cells and natural killer cells (Rook, Kehrl et al. 1986; Thomas 
and Massague 2005). Since TGFβ members strictly require furin activity for proteolytic 
activation, a knockdown of furin eliminates potential TGFβ-mediated immunomodulatory 
properties, as adopted by many cancers to evade immune surveillance, and thereby enhances 
activity of the vaccine.  
Safety of the FANG vaccine and efficacy of the immune response were confirmed and 
benefits of treatment were suggested by phase I trials in patients with advanced cancers 
including Ewing sarcoma and hepatocellular carcinoma (Nemunaitis, Barve et al. 2014; 
Ghisoli, Barve et al. 2015). Since TGFβ expression was confirmed previously in over 70% of 
RMS tumours and we found that most RMS tumours express furin (Wang, Guo et al. 2010), 
application of the FANG vaccine might represent a valuable new option for treatment of 
patients with RMS. Thus, investigations on the relation of TGFβ maturation and furin activity in 
RMS cells and tumours will be of further interest.  
5. Furin-activated probes for imaging and therapy  
Over the last decade, evidence has been gathered showing that cancer-related 
proteases, including MMPs and furin, may serve as powerful tools for conversion of protease-
activatable imaging probes for visualisation and diagnosis of cancer, or for cancer-site specific 
activation of prodrugs.  
Protease-activatable imaging probes are often composed of a fluorophore and 
quencher pair, thus quenching of the fluorophore in the native state keeps the molecule in an 
optically silent state, whereby liberation of the fluorophore from the corresponding quencher 
upon protease-mediated linker cleavage leads to fluorescent signal emission (reviewed in 
(Lee, Xie et al. 2010)). The fluorophores are chosen to operate preferably in the near-infrared 
spectrum, which improves tissue penetration and the signal-to-noise ratio (Weissleder and 
Ntziachristos 2003). The MMP-activatable near-infrared probe MMPsense 680, for instance, 
was applied to demonstrate the specificity of colorectal adenoma identification and was 
subsequently proposed for combined use with colonoscopy to improve early detection of 
colorectal lesions (Clapper, Hensley et al. 2011). As opposed to photochemical mechanisms, 
photoacoustic imaging based probes were described to provide even higher spatial resolution 
(reviewed in (Wang and Hu 2012)). In 2013, a first report emerged that described the design 
of furin-activatable photoacoustic probes and confirmed their specificity for furin activity-
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dependent visualisation of breast cancer xenografts in mice (Dragulescu-Andrasi, Kothapalli et 
al. 2013).  
Similar to imaging probes, protease-activatable prodrugs are inactive in their native 
state and undergo proteolytic cleavage of the inhibitory promoiety, converting the prodrug into 
its active form (reviewed in (Choi, Swierczewska et al. 2012)). Conversion of prodrugs is often 
dependent on overexpression of a certain protease in the target tissue, for instance 
enzymatically cleavable doxorubicin prodrugs were designed to be activated by uPA, a 
protease that is overexpressed in various cancers (Chung and Kratz 2006). Alternatively, 
selective cancer cell targeting may be achieved through coupling of the compound to a 
selective targeting agent such as an antibody recognising overexpressed cell surface 
receptors. These compounds are internalised upon receptor binding and undergo protease-
dependent cleavage in the endosome, leading to subsequent release of the active drug into 
the cytosol. For instance, Wang et al. used HER2-targeted immunoproapototic proteins 
composed of a HER2 single chain antibody, a furin-cleavable linker and different human 
apoptotic molecules including caspase-3 and caspase-6 (Wang, Zhao et al. 2007). These 
immunoproapototic compounds are internalised and activated upon cleavage through 
endosomal furin and their antitumour activity was confirmed in vivo in HER2 positive tumours 
(Wang, Zhao et al. 2007).  
Taken together, we hypothesise that the application of furin-activatable probes could 
be explored for non-invasive imaging of furin-positive tumours such as RMS in order to 
complement diagnostic modalities or to monitor success of therapy. Furthermore, prodrugs 
that are cleaved by cell surface-bound furin or compounds that undergo furin-dependent 
activation upon endocytosis represent promising new treatment strategies for RMS and other 
tumours with elevated furin activity.       
6. Conclusion  
In this work we have identified the PC furin as a novel key regulator of RMS 
malignancy in vitro and in vivo. We could show that furin activity plays an important role in 
diverse cellular processes, including cell proliferation, tumour growth, neovascularisation, 
metastasis and invasion, by regulating maturation of proproteins such as IGF1R, VEGF-C, 
PDGF-B and MT1-MMP. Furthermore, we uncovered a subgroup of aRMS cell lines, including 
Rh3 and Rh4, which are particularly dependent on furin activity and undergo apoptosis in the 
absence of functional furin, resulting in complete tumour remission in vivo. Since we could 
further confirm the presence of furin protein in 86% of the aRMS and eRMS tumour biopsies, 
we hypothesise that furin might be explored for novel targeted therapeutic approaches to treat 
children with RMS. 
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Importantly, distinct expression of furin in tumours offers several different therapy 
options. For instance, furin activity appears to promote many crucial cellular processes in RMS 
cells, suggesting that inhibition of furin through application of a specific furin inhibitor will 
improve the treatment of RMS patients. However, further investigations are required to 
examine the likely interplay of furin and the IGF signalling pathway in order to determine 
whether IGF1R levels are a biomarker to estimate responsiveness towards furin activity 
targeted therapy and to evaluate the potential of combined IGF1R and furin inhibition.  
Furthermore, furin might serve as cell surface target receptor of RMS-homing peptides 
(Hajdin, D'Alessandro et al. 2010) or as protease to activate imaging probes or prodrugs in a 
tumour site specific manner. These approaches might be applied to improve early diagnosis of 
primary tumours or metastases detection, or to establish targeted delivery of drugs in order to 
decrease potential side effects due to action of chemotherapeutics in non-target tissue. 
Finally, a further therapeutic option is the application of autologous cancer cell vaccines like 
FANG, which already showed good results in Ewing sarcoma (Ghisoli, Barve et al. 2015).  
In conclusion, we have demonstrated the importance of furin activity for RMS cells and 
predict that novel treatment options exploring either inhibition of furin activity or furin activity as 
a tool for tumour site specific delivery and activation of drugs and imaging probes might 
complement existing therapeutic options to improve diagnosis and treatment of paediatric 
RMS.  
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